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Post-translational modifications (PTMs) are important for regulating protein 
structure and function. Despite significant progress for PTM analysis using liquid 
chromatography tandem mass spectrometry (LC-MS/MS), opportunities for new method 
development remain. The research presented in this dissertation promotes 193 nm 
ultraviolet photodissociation (UVPD) as an alternative activation technique for PTM 
analysis with specific utility for phosphorylated and sulfated peptides. 
A novel de novo sequencing method with applications for unbiased PTM 
discovery was developed utilizing Lys-N proteolysis, N-terminal imidazolinylation, and 
UVPD to direct fragmentation for the formation of N-terminal ions. The N-terminal a, b, 
and c ions generated by UVPD were differentiated from one another by characteristic 
mass shifts. Sets of triplet peaks were used to distinguish N-terminal ions from 
confounding C-terminal ions and improve the accuracy of de novo sequencing.  
UVPD was evaluated for the analysis of phosphopeptide cations and anions. 
Negative mode analysis was advantageous for the detection of casein peptides in high 
phosphorylation states, while positive mode proved more robust for global 
phosphoproteomic analysis of HeLa and HCC70 cell lysates. Compared to collisional 
 viii 
activation, the depth of coverage was lower using UVPD yet more extensive 
fragmentation and improved phosphate retention on products ions was achieved.  
Phosphorylation mapping by LC-UVPD-MS was carried out in the C-terminal 
domain (CTD) of RNA polymerase II as a function of kinase treatment, ERK2 or TFIIH, 
and organism, yeast or fruit fly. Single phosphorylations on Ser2 or Ser5 in the consensus 
heptad, YSPTSPS, were observed across all experimental conditions. Analysis of the 
non-consensus fruit fly CTD revealed the significance of Tyr1 and Pro residues in the +1 
position relative to Ser for phosphorylation to occur.   
For sulfated peptides, negative mode UVPD yielded a and x ions that largely 
retained the labile sulfate modification which facilitated peptide sequencing and PTM 
localization. With appropriate MS/MS tools established, the next step towards global 
sulfoproteomics was the development of enrichment methods. Weak anion exchange 
(WAX) was applied for this purpose. Following carbamylation to neutralize primary 
amines which otherwise repel the anion exchanger; improved WAX retention was 
observed for sulfopeptides relative to a complex mixture of unmodified bovine serum 
albumin peptides. 
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Chapter 1 
Introduction 
1.1 INTRODUCTION  
Proteomics is the comprehensive study of an organism’s proteins along with their 
related structure and function.
1–3
 Both qualitative and quantitative information is required 
for complete proteome characterization which presents a significant challenge due to the 
high dynamic range and overall number of proteins within the proteome which far 
exceeds the number of protein coding genes based on splice variants, polymorphisms, 
and post-translational modifications (PTMs).
4
 Beyond simply increasing the complexity 
of the proteome, PTMs are critical for regulating nearly all aspects of normal biological 
function from cellular differentiation, protein turnover and localization, protein-protein 
interactions, signaling cascades and DNA repair to protein degradation. Aberrant PTM 
expression has been linked to various diseases, and efforts to identify new biomarkers or 
therapeutic targets are ongoing.
5
  
Liquid chromatography tandem mass spectrometry (LC-MS/MS) based 
techniques have been key for the advancement of modification-specific proteomics, but 
continued method development is required to address the unique challenges of PTM 
analysis.
6–10
 While modified proteins are indeed ubiquitous, with more than 5% of the 
genes in the human genome encoding enzymes that are responsible for adding or 
removing the myriad of known PTMs, they are also transient and in low abundance 
owing to their function for dynamic protein regulation.
11,12
 An added layer of complexity 
arises when specific protein functionality is dependent on the interplay or cross talk 
between multiple PTMs, as is the case for histone modifications.
13–17
 Finally, the diverse 
array of chemical and physical properties that are associated with the ever growing 
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collection of PTMs continues to drive the development of new LC-MS/MS 
methodologies.  
Two PTMs, phosphorylation
18
 and sulfation
19
 which are chief regulators of 
intracellular and extracellular protein-protein interactions, respectively, exemplify the 
need for improved characterization techniques. Both PTMs are labile, and 
phosphorylations are typically removed during tandem mass spectrometry (MS2), while 
the more labile sulfations are stripped upon both MS1 and MS2 analysis.
20,21
 Sulfation 
analysis also suffers from a lack of effective methods for enrichment from biological 
matrices. The research presented in this dissertation aims to advance 193 nm ultraviolet 
photodissociation (UVPD) as an alternative activation method for improved identification 
and localization of PTMs with particular emphasis towards phosphorylation and 
sulfation.  
 
1.2 BOTTOM-UP/SHOTGUN PROTEOMICS 
The most widely used strategy for mass spectrometry-based protein analysis is the 
bottom-up LC-MS/MS method in which proteins are enzymatically digested into smaller 
peptides and chromatographically separated prior to online MS
n
 analysis. During the first 
stage of mass analysis (MS1), a full MS survey spectrum is acquired which shows all 
peptides at a given elution time point. Peptide ions from the MS1 spectrum are 
subsequently selected for MS2 in a data dependent manner, typically from most to least 
abundant, and activated to promote their fragmentation into diagnostic product ions 
which can be used to reconstruct the peptide sequence either by reference to an in silico 
database or by de novo sequencing. Database search is the more common approach, and 
many algorithms have been developed such as SEQUEST,
22
 Mascot,
23
 MassMatrix,
24
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OMSSA,
25
 X!Tandem,
26
 Byonic,
27
 MaxQuant,
28
 and MS Amanda
29
 to automate peptide 
and ultimately protein identifications. Advanced informatics platforms are particularly 
critical for shotgun proteomics applications which profile very complex mixtures of 
proteins collected from crude tissues or whole cell lysates. The general bottom-
up/shotgun proteomics workflow is illustrated in Figure 1.1. 
 
 
Figure 1.1 Workflow for bottom-up/shotgun proteomics 
 
Advances in separation and mass spectrometry instrumentation have also greatly 
facilitated shotgun proteomics, and the identification of thousands of peptides and 
proteins from a single LC-MS/MS run is not only possible but exceedingly routine.
30–32
 
The advent of high resolution accurate mass (HRAM) mass spectrometers, most notably 
the Orbitrap,
33,34
 has been particularly transformative, enabling better distinction between 
co-eluting peptides of similar m/z, better charge state determination, and more accurate 
quantitation.
35
 These benefits of HRAM technologies have lead to significant 
performance gains for database search algorithms in terms of both the search speed and 
the accuracy of peptide identifications by narrowing the number of potential matches to a 
HPLC
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given MS/MS spectrum through the use of tighter mass tolerance settings for precursor 
and/or product ions. The development of faster mass spectrometers with higher MS/MS 
acquisition rates and varying degrees of parallelization such as the Q-Exactive HF,
36
 
Orbitrap Fusion,
37
 and Bruker Impact II Q-TOF,
38
 has also improved the depth of 
coverage that is possible in shotgun proteomics. At an acquisition speed of 20 Hz, 
sampling 19 peptides per second, comprehensive characterization of the relatively simple 
yeast proteome was achieved in just over one hour.
39
 Also, Mann and coworkers recently 
reported the largest breast tumor proteomic data set to date with a total of 10,135 
identified proteins from 40 breast cancer samples in which more than 7,000 proteins were 
identified per sample.
40
  
 
1.2.1 Modification Specific Proteomics 
The general bottom-up/shotgun proteomics workflow described above may also 
be applied for the analysis of PTMs.
6,10
 Because modified peptides are in low 
stoichiometric abundance in biological samples relative to unmodified peptides, 
incorporating an enrichment step prior to LC-MS/MS analysis at either the peptide or 
protein level can improve the depth of coverage for a particular modification of interest. 
Phosphorylation,
41,42,21
 glycosylation,
43,44
 and acetylation
45
 have all benefited from 
enrichment by means of acid-base interactions, metal ion affinity, ion exchange, 
hydrophilic interaction, lectins, or antibodies, leading to the identification of thousands of 
modified peptides. Serial enrichment has also been reported in order to profile multiple 
classes of PTM from a single biological sample.
46
  
Additionally, LC-MS/MS methods can be tailored to address the specific 
physicochemical properties of different modifications. This is especially advantageous 
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for the detection of peptides modified with labile PTMs for which conventional MS/MS 
strategies are less effective. For example, using electron transfer dissociation instead of 
the more commonly employed collisional dissociation results in improved modification 
retention for both phosphorylated
47–51
 and glycosylated peptides.
52,53
 Advanced 
multistage activation or decision tree programs, in which an MS3 event is triggered by 
the detection of MS2 generated characteristic neutral loss or reporter ions, have further 
optimized data dependant acquisition methods for PTM analysis.
54–57
  
Bioinformatics tools have also been developed to specifically aid PTM 
characterization. For example, phosphorylation sites may be scored and localized using a 
variety of programs including Ascore,
58
 SLoMo,
59
 phosphoRS,
60
 and LuciPHOr.
61
  
Software has also been developed that attempts to automate structural characterization of 
complicated N-linked glycopeptides.
62
 There are also algorithms for predicting potential 
modification sites within proteins based on sequence motifs, such as the Sulfinator
63
 and 
PredSulSite
64
 for sulfation, which can provide a framework for selecting potential 
systems of study as well as a means for validating newly identified modification sites.   
 
1.2.2 De novo Sequencing 
For studies that are not directed towards a certain modification, de novo 
sequencing can provide the ultimate flexibility for PTM discovery because peptide 
sequences are derived without reference to a database.
65
 Instead, the MS/MS 
fragmentation pattern is used to determine the peptide sequence based on mass 
differences between product ions that account for sequential cleavages along the peptide 
backbone.
66,67
 In this way, all potential PTMs can be considered and appropriately 
assigned within peptides based on their characteristic mass additions without increasing 
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the search space or search time. Additionally novel or unexpected PTMs may be 
identified by de novo sequencing. A number of programs have been developed for 
automated de novo sequencing including PEAKS,
68
 PepNovo,
69
 NovoHMM,
70
 
MSnovo,
71
 and Vonode,
72
 yet de novo sequencing is less often used compared to database 
search methods. Differentiating confounding product ion series and poorly resolved 
product ions as well as inferring the amino acid composition in regions where sequence 
coverage is lacking present significant challenges for de novo sequencing even with 
advanced bioinformatics programs in place.
73,74
 Isotopic labeling at one terminus of the 
peptide provides an effective means for differentiating product ion series.
75–78
  Other 
methods have been developed to specifically bias fragmentation for a certain ion series in 
order to simplify spectral interpretation.
79–81
 Although many of these strategies have 
improved de novo sequencing efforts, their success for PTM identification hinges on 
modification stability during ion activation and dissociation which is problematic for 
many labile PTMs. Also, without enrichment only the most abundant PTMs present in a 
biological sample will be detected which precludes de novo sequencing from global PTM 
analysis.  
 
1.3 TANDEM MASS SPECTROMETRY NOMENCLATURE 
The success of shotgun proteomics experiments using both de novo and database 
search methods is highly dependent on the ion activation technique that is used for 
peptide fragmentation. This is especially true for peptides that carry PTMs because 
extensive fragmentation is required to accurately pinpoint the modification to a single 
amino acid residue. Additionally for labile PTMs, fragmentation methods must be 
carefully selected to mitigate modification loss from product ions which would otherwise 
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prevent confident site localization. In order to accurately determine a peptide sequence 
from corresponding MS/MS data, the fragmentation pattern must be predicable and 
reproducible. To achieve this goal, dissociation methods have been developed that largely 
restrict fragmentation to specific bonds along the peptide backbone, and nomenclature 
has been established to classify the different types of fragment ions.
82,83
 Figure 1.2 shows 
the fragmentation nomenclature and a representative set of product ions from a 
tetrapeptide in which the amino acid side chains are denoted as R1-R4. 
 
      
Figure 1.2 Peptide/protein fragmentation nomenclature and representative product ions 
b1
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c1
z3
b2
y2
a2
x2x3
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z2
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c3
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c2
x2
y2
z2
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All peptides have the same core structure that is composed of three repeating 
bonds: Cα-C, C-N, and N-Cα (where C refers to the carbonyl carbon), and cleavage of 
these bonds produces complementary pairs of a/x, b/y, and c/z product ions, respectively. 
Ions that contain the N-terminus include a, b, and c ions, while x, y, and z ions contain the 
C-terminus. The number associated with each product ion indicates the number of amino 
acids that are present between the point of cleavage and the peptide terminus. Amino acid 
specific side chains branch off from the peptide backbone at the α-carbon, and thus 
successive cleavages along the backbone can be used to determine both the identity and 
connectivity of the amino acids that make up the peptide based on the characteristic mass 
of each side chain. Different activation techniques promote cleavage at different bonds in 
the peptide backbone.
84
 Cleavage of the C-N amide bond to form b and y ions is the most 
common dissociation pathway. This is because the amide bond is the weakest bond in the 
peptide backbone and may be readily cleaved using slow heating activation methods such 
as collisional dissociation (CID, HCD) or infrared multiphoton dissociation (IRMPD). 
Alternatively, electron-based activation methods, which include electron transfer 
dissociation (ETD)
85
 and electron capture dissociation (ECD),
86–88
 generate c and z ions 
from cleavage at the N-Cα bond. The Cα-C bond may be cleaved using higher energy 
activation methods such as ultraviolet photodissociation, to form a and x type ions.
89
  
Cleavage at more than one bond in the peptide backbone can lead to the formation 
of internal ions which lack both the N- and C-terminus, and these ions are annotated with 
the amino acid letter codes that correspond to the side chains that are included. 
Immonium ions are internal ions that contain only a single amino acid side chain. Other 
dissociation pathways observed for peptide ions include the neutral loss of small 
molecules such as water or ammonia as well as the loss of amino acid side chains which 
give rise to d, w, and v type satellite ions.
90,91
 These amino acid side chain losses, pictured 
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in Figure 1.3, are formed from a and x type ions and can be useful for differentiating 
isobaric leucine and isoleucine.  
 
 
Figure 1.3  Side chain loss ions 
 
1.3.1 Collision Induced Dissociation 
 Collision induced dissociation (CID) is the method of choice for peptide 
sequencing and comes standard on nearly all commercial mass spectrometers. Even as 
new activation methods are developed, CID remains popular for its ease of 
implementation and robust performance. During CID, peptides gain energy through 
multiple collisions with inert neutral gas molecules like helium, nitrogen, or argon until 
enough internal energy is acquired to break peptide bonds and produce b and y ions.
92
  
Extensive mechanistic studies have helped to characterize the CID process, 
ultimately leading to the widely accepted mobile proton model in which backbone 
fragmentation proceeds through a charge site initiated mechanism.
93,94
 Adequate proton 
mobility is key for efficient CID fragmentation and if the number of charge sequestering 
sites exceeds the number of ionizing protons, fragmentation becomes dictated by charge 
remote pathways in which preferential cleavage occurs C-terminal to acidic aspartic and 
glutamic acid residues.
95,96
  Even under conditions of high proton mobility, other 
d2 v2 w2
(a2-R2’’) (x2-CO-R3) (x2-CONH-R3’’)
From a ions: From x ions:
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preferential cleavages are observed using CID, most notably N-terminal to proline 
residues, which can suppress fragmentation at other sites along the peptide backbone and 
lower the overall peptide sequence coverage.
96–98
  
Because cleavage occurs at the most labile bonds using CID, peptides modified 
with labile PTMs such as phosphorylation,
99,100
 glycosylation,
52
 and sulfation
101,102
 
undergo abundant undesirable modification loss from both precursor and product ions. 
CID in ion trap mass spectrometers is also limited by what is called the low mass cutoff 
(LMCO) in which the trajectories of low m/z ions become destabilized at the increased rf 
voltages applied for collisional activation leading to the removal of potentially 
informative product ions. A beam type variant of CID called higher energy collisional 
dissociation (HCD) overcomes the low mass cutoff problem because activation is 
independent of trapping parameters.
103,104
 This feature is particularly advantageous for 
PTMs whose identification is aided by the detection of low mass reporter ions.
56,105
 The 
higher energy deposition of HCD provides added utility for PTM analysis because 
cleavage is possible at bonds other than those that are most labile.
106
  
  
1.3.2 Ultraviolet Photodissociation at 193 nm  
Ultraviolet photodissociation (UVPD) is gaining popularity for peptide 
sequencing, and has been applied using a number of different excitation wavelengths for 
a growing number of proteomic applications.
89
 The peptide backbone directly absorbs 
157 nm and 193 nm photons, making these wavelengths the most widely applicable for 
peptide analysis. Absorption of a 157 nm or 193 nm photon promotes an electron into the 
excited state. Subsequent dissociation from excited electronic states leads to extensive 
fragmentation along the peptide backbone which produces all product ion types including 
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a, b, c, x, y, and z ions. Radial a and x ions (a• and x•) that are 1 Da heavier than 
conventional a and x ions are also observed.
91
 These are formed by homolytic cleavage of 
the Cα-C bond and loss of a radical proton converts these ions to a and x ions as shown in 
Figure 1.4.  
 
 
Figure 1.4  Formation of a+1/x+1 and a/x ions upon 193 and 157 nm UVPD 
 
Because fragmentation is not directed by mobile protons, the efficiency of UVPD 
depends less on the peptide charge state compared to CID and preferential cleavages are 
less abundant. UVPD may also be applied for the analysis of peptide anions, which are 
less effectively characterized using CID.
107,108
  The negative mode sequencing 
capabilities of UVPD have been used to identify and localize sulfation,
109,110
 O-
glycosylation,
111
 and phosphorylation
112
 PTMs which are all more stable in peptide 
anions.  
These advantages of UVPD have prompted its implementation on a growing 
number of high performance mass spectrometers beyond the traditionally used ion trap 
and time of flight (TOF) instruments. Various Orbitrap instruments such as the Orbitrap 
Elite,
113
 Orbitrap Q-Exactive,
114
 and Orbitrap Fusion Tribid
115
 have been equipped for 
a2+1 or a2• a2
-H•
x2+1 or x2• x2
-H•
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193 nm UVPD, and most recently photodissociation has been reported on a 15T FT-ICR 
(Fourier transform-ion cyclotron resonance) mass spectrometer.
116
  
 
1.4 Overview of Chapters 
Despite great strides in many aspects of modification specific proteomics, 
opportunities for continued method development remain particularly in the area of 
tandem mass spectrometry. There is currently no single MS/MS method that is 
universally applicable for sequencing all types of peptides, thus fragmentation must be 
tailored for specific applications. The research presented in this dissertation is aimed at 
improving the characterization of PTMs including phosphorylation and sulfation using 
193 nm UVPD. 
In chapter 3, Lys-N proteolysis, imidazolinylation of the resulting N-terminal 
lysine ε-amine, and UVPD were combined to generate simplified MS/MS spectra for 
improved de novo sequencing. For imidazolinylated Lys-N peptides, positive charges 
were effectively sequestered at the N-terminus which biased fragmentation for enhanced 
formation of N-terminal product ions while suppressing the formation of C-terminal ions. 
Using UVPD, all N-terminal ions were generated including a, b, and c ions, and their 
appearance as sets of regularly spaced triplet peaks further aided the distinction between 
N- and C-terminal ion series, leading to improved accuracy in de novo sequencing.   
 More directed PTM analysis was carried out in chapter 4 in which UVPD was 
evaluated for the analysis of phosphopeptides in both positive and negative ion modes. 
Negative ion mode offered the best phosphate retention; however, low sensitivity limited 
its application to peptides in high phosphorylation states that were otherwise not detected 
using positive mode. Positive UVPD was applied for phosphoproteomic analysis of HeLa 
and HCC70 cell lysates and benchmarked against the more conventional HCD activation. 
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More peptides and proteins were identified using HCD, but better phosphate retention on 
product ions was achieved using UVPD which can facilitate more confident phospho-site 
localization.   
 UVPD was next applied in chapter 5 to map phosphorylation sites within the C-
terminal domain (CTD) of RNA polymerase II. Alternative proteolysis using proteinase 
K or chymotrypsin was required to digest the CTD which is composed of repeating units 
of the seven amino acid consensus sequence: YSPTSPS. Two different CTDs including 
the highly consensus yeast (saccharomyces cerevisiae) and highly divergent fruit fly 
(drosophila melanogaster) were analyzed following treatment with TFIIH and/or ERK2 
kinases. Preferential phosphorylation was detected on Ser5 and Ser2. Deviations from the 
consensus sequence within the fruit fly CTD revealed the importance of certain amino 
acid residues and their relative positions within the heptad sequence, namely Tyr and Pro, 
for regulating phosphorylation events. 
 Sulfated peptides were analyzed using UVPD in chapter 6. Analysis was 
undertaken in the negative ion mode to maximize the stability of the labile sulfate 
modification on precursor and product ions, thus permitting accurate peptide sequencing 
and sulfate localization. The sulfate modification was stable on product ions over a range 
of UVPD conditions (laser energy and number of pulses), but considerable sulfate loss 
was observed from the undissociated precursor ion. This characteristic fragmentation 
behavior was ultimately useful for distinguishing sulfated peptides from similarly 
modified phosphorylated peptides. LC-UVPD-MS was applied for the analysis of bovine 
fibrinogen, a 340 kDa heterohexamer, and the sulfated peptide of interest was positively 
identified.  
 In chapter 7, weak anion exchange chromatography (WAX) was developed as an 
enrichment method for sulfated peptides to extend the negative LC-UVPD-MS strategy 
 14 
established in chapter 6 for sulfoproteomic analysis on a global scale. Sulfopeptides were 
carbamylated to convert primary amines to less basic carbamates and thus improve their 
retention on WAX by the removal of interfering positive charges. Following 
carbamylation the desired shift to longer retention was observed for model sulfopeptides, 
which facilitated their separation from a matrix of unmodified peptides from bovine 
serum albumin. 
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Chapter 2 
Experimental Methods 
2.1 MASS SPECTROMETRY 
 The development of electrospray ionization (ESI) has revolutionized the field of 
proteomics by providing a means for converting large nonvolatile biomolecules into gas 
phase ions.
1
 In the process of ESI, a voltage is applied to an analyte solution which is 
then sprayed from a capillary or emitter tip to form an aerosol of charged droplets 
containing solution phase analyte molecules. As solvent evaporates from the droplets, 
charges become condensed until the columbic repulsion exceeds the Rayleigh limit, 
causing the ejection of gas phase ions. ESI is a soft ionization technique that is rarely 
implicated for peptide fragmentation, and instead intact molecular ions are typically 
observed across multiple charge states in the mass spectrum.  
 ESI is now widely coupled with mass spectrometers, and the research in this 
dissertation was conducted using several different ESI-MS instruments including linear 
ion trap (LIT)
2
 and Orbitrap
3
 mass analyzers. In LITs, ions are confined axially by rf 
fields and radially by DC voltages that are applied at separate ends of the rods. Mass 
selective ion ejection from the trap is achieved by applying appropriate rf voltages to the 
rods. The four rod geometry of LITs enables much greater ion trapping capacity 
compared to 3D quadrupole ion traps. In contrast, Orbitraps are advantageous for their 
high resolution and mass accuracy. During Orbitrap analysis, ions exhibit simultaneous 
orbital and translational motion around/along an inner spindle electrode housed within an 
outer barrel electrode, and the resulting image current is converted to a mass spectrum via 
Fourier transform. The following sections highlight more specifically the instrumentation 
that was used in this dissertation.  
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2.1.1 Thermo Fisher Scientific LTQ XL Linear Ion Trap 
A Thermo Fisher Scientific LTQ XL mass spectrometer (San Jose, CA) equipped 
for electron transfer dissociation and photodissociation
4,5
 was used for the analysis of 
Lys-N peptides. The spray voltage was maintained at 4 kV, the capillary temperature was 
180 °C, and the MS1 automated gain control (AGC) was 3E4.  
 
2.1.2 Thermo Fisher Scientific Velos Pro Dual Linear Ion Trap 
A Velos Pro dual linear ion trap mass spectrometer (Thermo Fisher Scientific, 
San Jose, Ca) with CID, HCD, and UVPD
4,5
 functionality was operated in both positive 
and negative mode for the analysis of CTD and casein peptides eluting from nano LC, 
and also for sulfopeptides from capillary LC. For nano ESI, 1.8-2 kV was applied in 
positive mode and 1.5-1.7 kV was applied in negative mode. The temperature of the 
heated capillary was 275 °C in positive mode and increased to 300-325 °C in negative 
mode to improve desolvation. For negative ESI, the source was operated at 4 kV and 10 
units of sheath gas. An MS1 AGC between 1E4 and 2E4 was used for all experiments. 
 
2.1.3 Oribtrap Elite Mass Spectrometer 
A modified Thermo Fisher Scientific Orbitrap Elite mass spectrometer (Thermo 
Fisher Scientific, Bremen, Germany)
6,7
 was used for the analysis of model sulfopeptides 
and bovine fibrinogen peptides by both positive and negative ESI. In positive mode, the 
ESI source was operated at 3.5 kV with a sheath gas flow of 4 units. In negative mode, 
the heated ESI source (HESI) was used, and the optimal spray parameters were more 
variable with HESI temperatures ranging from 40-60 °C, source voltage 2.3-3 kV, and 
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sheath gas flow between 25-40 units. For both polarities the Orbitrap MS1 AGC target 
was 1E6.  
2.1.4 Orbitrap Fusion Tribrid Mass Spectrometer 
An Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific Instruments, 
Bremen, Germany) modified for UVPD
8
 was used for the analysis of HeLa and HCC70 
lysates and also the fruit fly CTD. Orbitrap detection was used for both MS1 and MS2 
measurements at resolving powers of 60K and 15K (at m/z 200), respectively. The MS1 
AGC target was 2E5 and spectra were collected over m/z 400-1500.  
Intact mass analysis was carried out for the fruit fly CTD at a resolving power of 
240K at m/z 200. The maximum number of informative spectra were averaged together 
prior to Xtract deconvolution at a S/N threshold of 3 to improve the accuracy of the 
deconvolved mass.  
 
2.2 LIQUID CHROMATOGRAPHY 
 The success of shotgun proteomics is also heavily reliant on techniques for 
efficient peptide separation. The subsequent sections describe the reverse phase 
separation methods that were utilized in this dissertation.  
 
2.2.1 Dionex Ultimate 3000 
All separations were carried out on a Dionex Ultimate 3000 LC either at nano (0.3 
µL/min) or capillary (4 µL/min) flow rates. Positive mode analysis was exclusively 
undertaken using nano LC (nLC) in which mobile phase A (MP A) was 0.1% formic acid 
in water, and mobile phase B (MP B) was 0.1% formic acid in acetonitrile (ACN). Nano 
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and capillary flow rates were used for negative mode MS analysis, and various different 
mobile phase systems were employed which will be described in section 2.2.1.2.  
Initial nLC separations were carried out by direct injection onto a 15 cm x 75 µm 
Acclaim PepMap RSLC nano column packed with 2 µm C18. Using this set-up, bovine 
serum albumin (BSA) Lys-N peptides were separated by a gradient of 5-50% B over 55 
min. Reproducibility, robustness, and throughput were increased by implementing a 
preconcentration nLC set-up in which peptides were loaded onto a short trap column at 
microliter flow rates and subsequently separated by switching the analytical column in 
line with the trap and applying a gradient. In-house column packing was adopted for both 
trap and analytical columns using 100 µm integrafrit and 75 µm integrated emitter 
picofrit capillaries (New Objective, Woburn, MA), respectively. Traps were packed to 
~3.5 cm with 5 µm Michrom magic C18, and analytical columns were packed to 15-20 
cm with either 3 µm Michrom magic C18 or 3.5 µm Waters Xbridge BEH C18 (Milford, 
MA). UPLC columns containing 1.8 µm, 120 Å UChrom C18 (nanoLCMS Solutions, 
Gold River, CA) were also fabricated specifically for cell lysate applications. 
 
2.2.1.1 Positive Mode LC-MS/MS Analysis 
Yeast CTD peptide separations were carried out using the trap and elute set-up 
described above. Peptides were loaded onto the trap column for 5 min at 5 µL/min in 
aqueous loading solvent containing 2% ACN, and 0.1% formic acid. A multi-step 
gradient was applied for separation in which the percent B was increased from 2-15% 
during the first 15 min and further increased to 35% during the last 5 min. The LC 
conditions for fruit fly CTD separations were analogous to those described for the yeast 
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CTD, except that peptides were loaded directly onto the C18 analytical column and 
separated over 60 min using a gradient from 2-40% B. 
The separation of HeLa and HCC70 cell lysates was carried out by direct 
injection onto a 30 cm UPLC column heated to 60 °C inside a custom column oven.
9
 
HeLa was separated by an 80 min gradient in which the percentage of MP B was 
increased from 2-25% B during the first 65 min and from 25-40% B during the final 15 
min. The same gradient steps were used for HCC70 but the increase from 2-25% B was 
carried out more gradually over 118 min. 
 
2.2.1.2 Negative Mode LC-MS/MS Analysis 
Fruit fly CTD peptides were analyzed by nLC in negative mode. Methanol 
(MeOH) was used instead of ACN for mobile phase B and 0.1% trifluoroethanol (TFE) 
was added to all mobile phases instead of formic acid. Peptides were loaded for 3 min at 
5 µL/min in water containing 2% MeOH and 0.1% TFE. A 50 min linear gradient from 
2-90% B was used for separations. For negative nLC-MS analysis of alpha and beta 
casein phosphopeptides ammonium acetate (NH4OAc) containing mobile phases were 
used. MP A was 5 mM NH4OAc in water, and MP B was 5 mM NH4OAc in 90% MeOH. 
The pH of MP A was adjusted to eight using ammonium hydroxide. Following 4 min 
loading at 5 µL/min, separation proceeded over a 45 min linear gradient from 2-45% B.  
Performing separations at capillary flow rates and directing the LC eluent through 
the ESI source provided improved negative mode spray stability (but with some loss in 
sensitivity). Sulfopeptides were separated by capillary LC using a 3 x 150 mm Agilent 
Zorbax Extend-C18 column packed with 3.5 µm particles (Santa Clara, CA). MP A was 5 
mM NH4OAc in water, and MP B was 5 mM NH4OAc in 90% MeOH. Steeper gradients 
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were often required using MeOH due to its weaker eluting strength relative to ACN, but a 
fast gradient from 25-60% B over 15 min proved effective for separating a mixture of 
sulfopeptides. Alternatively, ACN was used instead of MeOH along with the NH4OAc 
mobile phase modifiers for sulfopeptide separations following carbamylation reaction 
and WAX fractionation. In this case, MP A was 5 mM NH4OAc in water (pH 8) and MP 
B was 5 mM NH4OAc in 85% acetonitrile. Separations were carried out on the Zorbax 
column using a linear gradient from 5-45% B over 45 min.  
 
2.3 ION ACTIVATION 
CID, HCD and UVPD were applied for peptide activation and dissociation. The 
MS2 AGC targets were set to 1E4 on the LTQ and Velos Pro ion trap instruments; 1E4 
(positive mode) and 5E4 (negative mode) on the Orbitrap Elite; and 1E5 using the 
Orbitrap Fusion. Typical MS2 isolation widths ranged from 3 Da down to 1.6 Da using 
quadrupole isolation on the Orbitrap Fusion. 
For protein digests analyzed by LC-MS, data dependant acquisition (DDA) was 
used to systematically select and dissociate peptides. Using this method, an MS1 
spectrum was first collected to survey the available peptides at a given time in the 
separation, followed by a series of MS2 events for ions selected in order of abundance 
(beginning with the most abundant). After acquiring a user defined number of MS2 
spectra, the DDA cycle is repeated. For most experiments the MS1 spectrum covered m/z 
400-2000. Exceptions were for cell lysate analysis on the Orbitrap Fusion which used a 
narrower range from m/z 400-1500 and yeast CTD analysis on the Velos Pro which used 
a wider range from m/z 300-2000. The number of MS2 spectra acquired between each 
MS1 spectrum was both sample and instrument dependant. For complex peptide mixtures 
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derived from large proteins such as fibrinogen and BSA, ten MS2 were acquired. For 
simpler mixtures from casein or CTD protein digests, MS2 was acquired for the top eight 
or five ions, respectively. Using the Orbitrap Fusion, DDA was performed in a top speed 
mode in which the maximum number of MS2 spectra are acquired during a 3s cycle time.  
 
2.3.1 Collisional Activation 
For CID and HCD, normalized collision energies (NCE) between 30-35% were 
most often applied for peptide fragmentation, although greater NCE values up to 55% 
were used specifically for sulfopeptides in an effort to generate fragmentation beyond the 
neutral loss of SO3. For CID on the LTQ, 30 ms of activation using a q value of 0.25 was 
necessary for optimal fragmentation. Faster CID (10 ms) was possible on the Orbitrap 
instruments, but HCD provided far superior speed based on sub millisecond activation 
times (0.1 ms on the Orbitrap Elite) and also alleviated the low mass cut off problem.    
 
2.3.1 Photodissociation at 193 nm 
All mass spectrometers mentioned in the preceding sections were coupled with a 
Coherent ExciStar XS excimer laser (Santa Clara, Ca) operated at 193 nm and 500 Hz to 
generate one pulse every 2 ms.
4–8
 On the LIT instruments, UVPD was triggered by 
setting the CID NCE to zero. Since UVPD functions independently of activation q, the q 
value was decreased to 0.1 in order to improve the detection of low m/z ions. UVPD on 
the Orbitrap Elite was performed in the HCD cell, and thus a voltage must be applied to 
direct ions into the cell for UVPD fragmentation. Using 1% NCE, efficient ion transfer 
was achieved without sufficient energy deposition to cause unwanted 
activation/dissociation prior to UVPD. On the Orbitrap Fusion the UVPD controls were 
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built into the instrument software for more streamlined analysis. In initial UVPD studies 
of Lys-N peptides, a single 8 mJ laser pulse was used for activation. In all subsequent 
studies, 1-2 pulses at 2-3 mJ were effective for peptide fragmentation using UVPD. 
 
2.4 CHEMICALS 
Peptides KLVFFAEDVGS, KYGVSVQDI, KPLLIIAEDVEGEY, 
KLVANNTRL, KVPRNQDWL, KMVELVHFL, and KTMTESSFYSNMLA were 
purchased from AnaSpec (Fremont, CA); KGAIIGLM, GDFEEIPEEsYLQ, and 
NsYsYGWMDF-NH2 were from Sigma (St. Louis, MO); GlpQDsYTGWMDF-NH2, 
RDsYTGWNleDF-NH2, Ac-DpYVPML-NH2, RRLIEDAEpYAARG-NH2, Ac-
IpYGEF-NH2, and TSTEPQpYQPGENL were from American Peptide Company 
(Sunnyvale, Ca); and sYGGFL was from Phoenix Pharmaceuticals (Burlingame, Ca).  
The proteins BSA, alpha casein, and beta casein were obtained from Sigma, while bovine 
fibrinogen was obtained from Calbiochem.  
 The proteases metalloendopeptidase Lys-N, from Grifola frondasa, was 
purchased from Associates of Cape Code (E. Falmouth, MA); Lys-C and chymotrypsin 
were from Promega (Madison, WI); and trypsin was obtained from Promega, Sigma, or 
Thermo Fisher Scientific (Grand Island, NY). All other solvents, chemicals, and reagents 
were obtained from Sigma, Thermo Fisher Scientific, or EMD Millipore (Temecula, CA).  
 
2.5  SAMPLE PREPARATION 
2.5.1 Cell Culture 
 HeLa and HCC70 stable shRNA scramble cells were cultured in accordance with 
ATCC guidelines and maintained at 37 °C and 5% CO2. Dulbecco’s Modified Eagle 
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Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) was used for HeLa 
cells. RPMI media supplemented with 10% FBS, 2 mM glutamine, 1% 
antibiotic/antimycotic (10 U/mL penicillin, 10 µg/mL streptomycin, 0.025 µg/mL 
amphotericin B), and 1 µg/mL puromycin was used for HCC70. HeLa cells were lysed 
by sonication for 30 s with 1 s alternating on and off cycles at 20% amplitude in buffer 
containing 50 mM ammonium bicarbonate (pH 8), 8 M urea, 1 mM sodium 
orthovanadate, 100 mM sodium fluoride, 10 mM sodium pyrophosphatase, 1 µM 
microcystin-LR, 100 nM calyculin A, complete EDTA-free protease inhibitor mix 
(Roche), and phosSTOP phosphatase inhibitor mix (Roche). HCC70 cells were lysed by 
freezing and thawing in the same lysis buffer described for HeLa. Protein concentration 
was measured by Bradford assay. 
 
2.5.2 Protein Processing 
 For proteins with disulfide linkages, reduction and alkylation were carried out 
prior to enzymatic digestion. Disulfide bonds were reduced using 5 mM dithiothreitol 
(DTT) at 55 °C for 30-45 min. The resulting free thiols were then capped by alkylation 
using 15 mM iodoacetamide (IAM) at room temperature in the dark for 30-45 min after 
which an additional aliquot of DTT was added to quench the reaction.  
For trypsin digestion, protein solutions were buffered at pH 7.5-8 using 50-100 
mM ammonium bicarbonate or Tris HCl. The ratio of trypsin to protein (w/w) ranged 
from 1:20 to 1:50, and digestion proceeded overnight at 37 C.  
For HeLa and HCC70 cell lysates, Lys-C digestion was first applied directly in 
the cell lysis buffer in order to preserve phosphorylations during protein processing. A 
1:200 ratio of Lys-C to protein was used for digestion, and after 2-4 hrs of incubation at 
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37 °C the urea concentration was diluted to 1.5 M by addition of 50 mM Tris HCl, 5 mM 
CaCl2. Trypsin was then added in a 1:50 ratio and digestion continued overnight at 37 °C.  
Serial digestion by trypsin and proteinase K was applied to the yeast GST-CTD.   
The first stage of digestion using trypsin occurred overnight at 37 °C in 50 mM 
ammonium bicarbonate and 1.6 M urea using a 1:50 ratio of enzyme to protein.  The 
digest solution was then passed through a 10 KDa molecular weight cutoff (MWCO) 
filter to isolate and buffer exchange the CTD 26mer into 50 mM Tris HCl containing 10 
mM CaCl2 (pH 8). Proteinase K was added to the CTD solution in a 1:100 ratio and 
digestion proceeded overnight at 37 °C.  
Chymotrypsin was used in a 1:50 enzyme to protein ratio to digest the fruit fly 
GST-CTD. The digest buffer was 100 mM Tris HCl containing 10 mM CaCl2 (pH 8). 
After overnight digestion at room temperature, proteolysis was quenched by the addition 
of 0.5% trifluoroacetic acid. 
 
2.5.3 Peptide Derivatization 
Imidazolinylation of the lysine ε-amine of Lys-N peptides was carried out by 
diluting 10 µg of peptide into 30 µL of 1M Na2CO3 and 45 µL of 1M 2-methylthio-2-
imidazoline hydroiodide followed by incubation at 55°C for 12 hours.  Reactions were 
desalted using Thermo Pepclean C18 spin columns and reconstituted to10 µM for model 
peptides and 1 µM for protein digests.   
Carbamylation was applied to sulfated peptides to convert all available primary 
amines to carbamates. Urea was added directly to peptide solutions to a concentration of 
8 M and the samples were incubated at 80 °C for 4 hours. No sample clean-up was 
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carried out after carbamylation and instead reaction solutions were diluted to 500 µL in 
50 mM ammonium chloride in preparation for weak anion exchange.  
 
2.6 ENRICHMENT 
2.6.1 Immobilized Metal Affinity Chromatography 
Phosphopeptide enrichment from whole cell lysates was achieved by immobilized 
metal affinity chromatography (IMAC) using Ni-nitrilotriacetic acid (Ni-NTA) magnetic 
agarose beads (Qiagen, Germantown, MD).
10
 The beads were prepared for IMAC by 1 hr 
of shaking in 40 mM EDTA (pH 7.5) to remove metal ions by chelation, followed by 
thorough washing with water. Next Fe
3+
 was incorporated onto the surface of the beads 
by shaking for 1 hr in 100 mM FeCl3. Washing with IMAC loading buffer composed of 
80% ACN, 0.15% TFA removed excess FeCl3 and conditioned the beads for sample 
loading. Protein digests were added to the beads in IMAC loading buffer and shaking 
proceeded for 1 hr to bind phosphopeptides. Three washes in loading buffer were 
performed to removed non-phosphorylated peptides, and phosphopeptides were 
subsequently eluted by vortex shaking for 1 min and 15 sec in 100 µL of 50% ACN, 
0.7% NH4OH (pH ~11). The solution of IMAC enriched phosphopeptides was 
immediately neutralized by addition of 50 µL of 4% formic acid. 
 
2.6.2 Hydroxyapatite 
Phosphopeptides from alpha and beta casein were enriched using ceramic 
hydroxyapatite (HAP) type I, 20 µm resin (Bio Rad, Hercules, CA). Digested peptides in 
50 mM Tris HCl were mixed with HAP resin in a 1:5 (w/w) ratio in a fritted centrifuge 
column. Phosphopeptide binding to HAP occurred for 1 hr at room temperature with 
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shaking. To remove unmodified peptides, the loading/binding solution was removed by 
centrifugation at 1200 rcf, and the resin was washed using 200 µL aliquots of 50 mM Tris 
HCl containing 20% ACN. To elute bound phosphopeptides, the HAP resin was exposed 
to 1 M KH2PO4 (pH 7.8) for 15 min with shaking. Desalting on either C18 or graphite 
solid phase extraction columns followed. 
 
2.6.3 Weak Anion Exchange 
Weak anion exchange (WAX) using diethylaminoethyl (DEAE)-Sephadex A-25 
(Sigma, St. Louis, MO) resin was applied for sulfopeptide enrichment. WAX columns 
were prepared by adding 20 µg of pre-swollen DEAE-Sephadex suspended in 50 mM 
ammonium chloride (NH4Cl) to a fritted SPE column. A second frit was added to secure 
the resin bed. Several milliliters of 50 mM NH4Cl loading buffer were used to condition 
the column followed by sample loading in the same buffer. For peptide fractionation, 500 
µL aliquots of increasing NH4Cl concentration were passed through the WAX column 
and separately collected. Samples were desalted on C18 stage tips constructed according 
to published protocols using Empore C18 extraction disks (3M, Minneapolis, MN).
11
  
 
2.7 AUTOMATED PEPTIDE SEQUENCING 
 Several programs were used to interpret the results of bottom up LC-MS/MS 
experiments. Certain search parameters, such as those related to enzymes, were applied 
independent of search algorithm. For both trypsin and chymotrypsin, three missed 
cleavages were allowed and the P-rule, which prohibits cleavage N-terminal to Pro, was 
applied. Cleavage C-terminal to Lys and Arg was specified for trypsin and C-terminal to 
Phe, Tyr, Trp, Leu, and Met for chymotrypsin. The minimum peptide length was set to 5 
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amino acids. Advanced search settings for each program are described in the sections that 
follow.  
 
2.7.1 PEAKS 
PEAKS Studio 5.3 was used to de novo sequence tryptic BSA peptides that were 
analyzed by LC-MS-CID. Prior to de novo sequencing, separate MS/MS scans were 
merged when precursor ion m/z values and chromatographic retention times agreed 
within tolerance limits of 1 Da and 5 min, respectively. The range of allowed precursor 
charge states was +1 to +3. Peak centroiding, charge deconvolution, and deisotoping 
were used for all MS/MS spectra. For de novo sequencing, the mass error tolerances for 
parent and fragment ions were both set to 0.5 Da. Carbamidomethylation of cysteine was 
a fixed modification. Scoring thresholds of total local confidence (TLC) ≥ 5 and average 
local confidence (ALC) (%) ≥ 50 were used to filter de novo peptide sequences. 
 
2.7.2 Proteome Discoverer 
Proteome Discoverer 1.3 was used for positive mode UVPD and HCD analysis of 
IMAC enriched tryptic peptides from HeLa and HCC70 lysates. A non-fragment filter 
was applied in UVPD searches to remove precursor peaks from MS2 spectra within a 1 
Da mass window prior to Sequest database search against the forward and reverse uniprot 
human database. For UVPD, a, b, c, x, y, and z ions were used for spectrum matching 
while only a, b, and y ions were used for HCD. For both UVPD and HCD neutral losses 
from a, b, and y ions were considered. Other database search parameters used for both 
UVPD and HCD were: 10 ppm precursor mass tolerance; 0.02 Da fragment mass 
tolerance; N-terminal acetylation, methionine oxidation, and serine/threonine/tyrosine 
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phosphorylation dynamic modifications; carbamidomethyl cysteine static modifications. 
PSM (peptide spectral match) validation was carried out using Percolator, and 
phosphoRS 3.0 was used for phosphosite localization. Filters were applied post search to 
select only rank 1, high confidence PSMs and an isoform probability of 75% was 
required for phosphosite localization.  
Proteome Discoverer 2.0 was used to interpret the results from positive UVPD 
analysis of the fruit fly CTD. Sequest database search was performed as described for 
HeLa and HCC70 with the exception of the enzyme which was chymotrypsin and the 
FASTA database which was comprised of fruit fly CTD sequences. Instead of using 
Percolator, matches were filtered based on a maximum Delta Cn of 0.05 using the fixed 
value PSM validator. Strict and relaxed target FDR settings were 0.01 and 0.05 
respectively for both PSMs and peptides. Phospho-site localization was performed using 
ptmRS, which is analogous to phosphoRS but with added utility for localizing any PTM. 
Isoform confidence probabilities of 99% from ptmRS were required for phospho-site 
localization. 
 
2.7.3 MassMatrix 
The MassMatrix database search algorithm (version MassMatrix Xtreme 
3.0.10.16) was used to interpret the UVPD fragmentation of peptide anions.
12–15
 Searches 
were performed against forward and reverse FASTA databases which contained only the 
relevant protein sequences for each study, and peptide matching was based on a, x, c, z, 
and y type product ions.  
For HRAM Orbitrap analysis of bovine fibrinogen, the peptide mass tolerance 
was 20 ppm and the fragment mass tolerance was ±0.02 Da. Sulfated tyrosine and 
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pyroglutamate from glutamate were variable modifications and iodoacetamide 
derivatization of cysteine was a fixed modification. Score thresholds for pp and pptag 
were defined as 5.0 and 1.3, respectively.  
For low resolution ion trap UVPD analysis of phosphopeptides from alpha casein, 
beta casein, and fruit fly CTD the peptide mass and fragment mass tolerances were set to 
±1.00 Da and ±0.80 Da, respectively. Variable modifications were phosphorylation of 
serine, threonine, and tyrosine residues. The minimum pp and pptag scores were 4.0 and 
1.0 respectively for casein peptides and 6.0 and 3.0 respectively for fruit fly CTD 
peptides. 
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Chapter 3 
193 nm Ultraviolet Photodissociation of Imidazolinylated Lys-N 
Peptides for De Novo Sequencing1 
 
3.1 OVERVIEW 
The goal of many MS/MS de novo sequencing strategies is to generate a single 
product ion series that can be used to determine the precursor ion sequence. Most 
methods fall short of achieving such simplified spectra, and the presence of additional ion 
series impede peptide identification. The present study aims to solve the problem of 
confounding ion series by enhancing the formation of “golden” sets of a, b, and c ions for 
sequencing. Taking advantage of the characteristic mass differences between the golden 
ions allows N-terminal fragments to be readily identified while other ion series are 
excluded. By combining the use of Lys-N, an alternate protease, to produce peptides with 
lysine residues at each N-terminus with subsequent imidazolinylation of the ε-amino 
group of each lysine, peptides with highly basic sites localized at each N-terminus are 
generated. Subsequent MS/MS analysis by using 193 nm ultraviolet photodissociation 
(UVPD) results in enhanced formation of the diagnostic golden pairs and golden triplets 
that are ideal for de novo sequencing.  
 
 
                                                 
1 Robinson, M. R.; Madsen, J. A.; Brodbelt, J. S. 193 nm Ultraviolet Photodissociation of Imidazolinylated 
Lys-N Peptides for De Novo Sequencing. Analytical Chemistry. 2012, 84, 2433–2439. 
JAM and JSB provided mentorship and reviewed the manuscript prior to publication.  
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3.2 INTRODUCTION 
The development of mass spectrometry techniques for analyzing biological 
samples, in particular tandem MS using collisional induced dissociation (CID), has 
played a vital role in establishing modern day proteomics.
1
  Despite ongoing 
advancement in instrumentation and a flurry of new activation methods, CID of 
chromatographically-separated tryptic peptides followed by in silico database searching 
remains the gold standard for bottom-up analysis. While this method has proven useful 
for routine protein analysis, it cannot be applied to proteins from organisms having 
unsequenced genomes. Additionally a general decrease in performance occurs as samples 
become more complex. For example, confident identification of proteins having post-
translational modifications remains difficult by in silico algorithms,
2
 especially if 
specialized software and the highest performing (and most expensive) mass 
spectrometers are not available.
3
       
These limitations of in silico database searching have prompted the development 
of de novo sequencing algorithms, which attempt to reconstruct peptide sequences based 
on MS/MS data without reference to a database. Several de novo programs have been 
developed to analyze CID data including Lutefisk,
4
 PEAKS,
5
 DACSIM,
6
 NovoHMM,
7
 
PepNovo,
8
 EigenMS,
9
 and MSNovo
10
.  Because these algorithms identify amino acids 
based on the difference between consecutive product ions of a given series, complete 
backbone fragmentation is ideal for unambiguous identification.  However, full sequence 
coverage is often not obtained, especially when using CID which exhibits dominant loss 
of labile groups as well as preferential cleavage at proline and acidic residues.
11–13
 
By using alternative activation methods instead of conventional CID, a greater 
degree of backbone fragmentation can be achieved. Photon-based activation methods are 
becoming increasingly well established
14–17
 and promote greater diversity in the 
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fragmentation pathways compared to the predominant b/y ions exhibited up on CID. 
Ultraviolet photodissociation (UVPD) at 193 nm in a linear ion trap has particular merit 
because of the extensive backbone fragmentation that results in the formation of a, b, c, x, 
y, and z ions.
18
 The formation of d, v, and w ions from side-chain losses is also useful for 
differentiating isobaric or near isobaric amino acids.   
While more extensive fragmentation providing a larger array of product ions 
helps to ensure a complete series for de novo sequencing, the presence of multiple ion 
series can complicate spectral interpretation. Several strategies for differentiating 
complementary ion series have been reported, such as those entailing sample 
fractionation and selective labeling at the N- or C-terminus of only one fraction .
19–23
 
Fragments that include the modified terminus are easily identified based on the mass shift 
between peaks in the spectra of the unmodified versus modified fractions. An alternative 
approach involves collection of separate MS/MS spectra using different activation 
methods that yield inherently different results, i.e. production of b and y ions for CID 
compared to c and z ions for electron based dissociation and a and x ions for UVPD at 
157 nm. Through comparison of complementary spectra, “golden pairs” of ions, defined 
as a/b, b/c, a/c, or x/y, y/z, x/z pairs, 
24
 can be identified based on characteristic mass 
differences.
24,25
   
An alternative to differentiating ion series that originate from opposite termini is 
to eliminate ion series derived from one terminus of the peptide altogether. Addition of 
negatively charged modifications at the peptide N-terminus neutralizes the positive 
charge to effectively produce spectra consisting of predominantly C-terminal ions.
26–28
 
Conversely, the N-terminal series can be enhanced through modification of the N-
terminus with moieties having high proton affinity.
29
 Careful tuning of the proton affinity 
at the N-terminus is necessary so that the ionizing proton is free to move along the 
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peptide backbone but is ultimately captured at the N-terminus to form b ions upon CID. 
A similar strategy involves the use of an alternate protease, Lys-N, which produces 
peptides with lysines at the N-termini.
30
 When a single basic residue resides at the N-
terminus of a peptide, the proton is effectively sequestered, and simplified spectra 
comprised of mostly b ions for CID and c ions for electron transfer dissociation (ETD) 
are produced.
31
 Further enhancement of N-terminal ions can be achieved following 
guanidination or imidazolinylation to increase the basicity of the lysine’s ε-amino 
group,
32,33
 thus ensuring immobilization of the proton.   
In the present study, 193 nm UVPD is applied to imidazolinylated Lys-N peptides 
to generate clean spectra consisting of “golden triplet” sets of a, b, and c ions and/or 
“golden pair” sets of a and b ions that are well-suited for de novo sequencing. The richer 
diversity of diagnostic ions afforded by 193 nm UVPD allows the three N-terminal ion 
series to be readily identified based on characteristic mass differences to the exclusion of 
other fragment ions. Unlike other “golden pair” techniques, the complete N-terminal ion 
series can be generated in a single spectrum, thus eliminating the need for multiple 
activation events and cross spectral comparison. 
 
3.3 EXPERIMENTAL 
3.3.1 Materials 
Model peptides were obtained from AnaSpec (Fremont, CA) with the exception 
of KGAIIGLM, which was purchased from Sigma-Aldrich (St. Louis, MO). Bovine 
serum albumin (BSA), proteomics grade trypsin, dithiothreitol, iodoacetamide, and 2-
methylthio-2-imidazoline hydroiodide were also acquired from Sigma-Aldrich.  
Metalloendopeptidase Lys-N, isolated from Grifola frondasa, was purchased from 
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Associates of Cape Code (E. Falmouth, MA). Sodium carbonate was purchased from 
EMD Chemicals (Gibbstown, NJ) and all other reagents and solvents were obtained from 
Fisher Scientific (Fairlawn, NJ).   
 
3.3.2 Sample Preparation 
For disulfide bond reduction 5 µL of a 200 mM solution of dithiothreitol (DDT) 
in 100 mM NH4HCO3 was added to 20 µg of BSA, and the mixture was incubated at 55 
°C for 45 min. Subsequent alkylation was performed by addition of 4 µL of 1M 
iodoacetamide. Following reaction for 30 min at room temperature in the dark, 20 µL of 
DTT was added to quench the reaction. For digestion with trypsin, 1 µg of trypsin was 
added to the reduced and alkylated BSA, and the mixture was incubated at 37 °C 
overnight. Protein digestion with Lys-N was performed using a 25:1 protein to enzyme 
ratio in 100 mM NH4HCO3. The reaction mixture was incubated overnight at 37 °C. For 
imidazolinylation of the lysine amine groups, 10 µg of protein digest or model peptide 
was diluted in 30 µL of 1M Na2CO3 and allowed to react with 45 µL of 1M 2-
methylthio-2-imidazoline hydroiodide at 55°C for 12 hours. Prior to analysis, reaction 
mixtures were cleaned up using Thermo Pepclean C18 spin columns and diluted to the 
appropriate concentrations, 10 µM for model peptides and 1 µM for protein digests.   
 
3.3.3 MS, UVPD, and LC 
Model peptides were analyzed by direct infusion ESI-MS using a Thermo Fisher 
Scientific LTQ XL mass spectrometer (San Jose, CA). The spray voltage and capillary 
temperature settings were kept constant at 4 V and 180 °C respectively for all mass 
spectrometry experiments. The automated gain control (AGC) remained at 3.0×10
4
 for 
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MS and 1×10
4
 for MS
n
 scans. For UVPD, a Coherent ExiStar XS ArF excimer laser 
(Santa Clara, Ca) was coupled to the LTQ as previously described,
18,34
 and 193 nm 
photons were delivered at a frequency of 500 Hz. The pulse duration was 5 ns with an 
energy of 8 mJ. A single pulse during an activation period of 30 µs with q=0.1 induced 
fragmentation. For CID experiments, the activation q was increased to 0.25 and 
normalized collision energy was chosen such that the precursor ion remained at about 10 
percent relative abundance in the MS/MS spectrum (to facilitate identification of the 
precursor ion). 
Protein digests were separated on a Dionex Ultimate 3000 RSLCnano system 
using an Acclaim PepMap RSLC nano column of length 15 cm and inner diameter 75 µm 
packed with 2 µm C18 stationary phase. The system was operated at a flow rate of 0.3 
µL/min using mobile phases A and B consisting of water and acetonitrile respectively, 
each containing 0.1% formic acid. The following LC program, lasting 70 minutes for 
each sample, was used for all separations. After 5 minutes running at 5% B, the percent 
of mobile phase B increased linearly to 50% over 55 minutes.  At the end of the gradient, 
the %B was increased to 80% for 5 minutes and subsequently decreased to 5% for the 
final five minutes in preparation for the next run. Data dependent UVPD and CID scans 
were performed by first collecting a full mass spectrum of the m/z range 400-2000. Next, 
UVPD or CID was performed on the top ten most abundant peaks from the full mass 
spectrum. The same UVPD parameters used for direct infusion ESI-MS of model 
peptides were also used for LC-MS-UVPD experiments. For CID, a normalized collision 
energy of 35 was applied during a 30 ms activation period.  
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3.3.4 De Novo Sequencing of Protein Digest 
  De novo sequencing was performed on the results from LC-MS-CID analysis of 
the tryptic digest of BSA using PEAKS Studio 5.3. Prior to de novo sequencing, MS/MS 
data refinement was performed as follows: (1) Separate MS/MS scans were merged when 
the precursor m/z values agreed within an error tolerance of 1 Da and fell within a 5 min 
retention time window (defined as the maximum difference of retention time between 
two spectra to be merged). (2) The minimum and maximum precursor charge states were 
fixed at 1+ and 3+ respectively. (3) Peak centroiding, charge deconvolution, and 
deisotoping functions were applied to all MS/MS scans.    
For de novo sequencing, the parent and fragment mass error tolerances were both 
set to 0.5 Da. Carbamidomethylation of cysteine was selected as a fixed modification. De 
novo peptide candidates were filtered based on amino acid total local confidence (TLC) 
and average local confidence (ALC). The TLC is the sum of the local confidence scores 
which define the likelihood that a particular amino acid is present at a particular position 
in a de novo peptide. Local confidence scores are determined based on several factors 
including the peak abundance, mass errors, and coexistence of other supporting peaks. 
ALC is calculated by dividing the TLC by the total peptide length. Only peptide 
sequences having TLC ≥ 5 and ALC (%) ≥ 50 were kept and cross-checked against 
known tryptic BSA peptides to either confirm identifications or reject false positives. 
  
3.4 RESULTS AND DISCUSSION 
 Via a combination of imidazolinylation of the N-terminus and using UVPD as an 
alternative to conventional CID, our goal was to enhance the formation of triplet a, b, c 
ions from peptides. In theory, the presence of low abundances of C-terminal ions should 
not affect the identification and utilization of the triplet N-terminal (a,b,c) series for de 
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novo strategies, as the latter ions are identified based on characteristic mass differences.  
Thus, as long as the N-terminal triplet sets are present, all other ions can be 
systematically excluded from use in de novo sequencing algorithms. All the same, there 
are several reasons that suppression of the formation of C-terminal series is more ideal.  
Simplified spectra that solely show triplet a, b, c sets lend themselves to more rapid 
manual data interpretation without the need for more tedious manual exclusion of C-
terminal ions. Additionally, spectral overlap can be more problematic for N- and C-
terminal ions that have similar m/z values, especially when high mass accuracy 
measurements are not feasible. Finally, the total product ion abundance that is split three 
ways to yield a, b, and c ions should be greater in the absence of C-terminal ions because 
the ion current will not be further sub-divided among additional fragmentation channels.   
These benefits of generating golden triplets also hold true for golden pairs (when the 
triplet series is not present). In the following sections, the impact of imidazolinylation on 
the enhancement of golden triplets and pairs by UVPD is discussed, as well as the 
distributions of a, b, and c ions and the influence of charge state of the peptide.     
 
3.4.1 Imidazolinylation of N-terminal Lysine Peptides 
Eight model peptides, all having lysine at their N-termini, were modified through 
an imidazolinylation reaction shown schematically in Figure 3.1.  
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Figure 3.1 Imidazolinylation reaction 
 
The mass spectra of the model peptides following derivatization show both one and two 
successive additions of 68 Da, the latter suggesting the double addition of imidazole with 
the second imidazole presumably attached at the N-terminus. Following incubation, all 
peptides were converted to either the singly or doubly imidazolinylated products with no 
unreacted peptides detected in the full mass spectra. Activation of the singly and doubly 
modified peptides by UVPD promoted the same types of fragmentation pathways, 
however with each N-terminal product ion shifted by 68 Da for the ions arising from the 
doubly modified peptides relative to the singly modified peptides. This consistent and 
uniform mass shift confirmed the location of the second imidazole at the N-terminus. 
While a mixture of modified peptides resulted from the imidazolinylation reaction (and 
even occasionally triply-modified peptides of very low abundance), the single addition at 
the lysine was the far more dominant of the products (typically 70% singly modified and 
20% doubly modified based on the peak intensities of these two major products) and is 
the primary product of interest for the remainder of the study.     
 
+
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3.4.2 CID versus UVPD for Formation of N-terminal Triplets  
The eight model peptides as both their protonated imidazolinylated and 
underivatized forms were subjected to CID and UVPD. Representative spectra obtained 
upon CID and UVPD of singly charged underivatized and imidazolinylated 
KLVFFAEDVGS are shown in Figure 3.2. Companion bar graphs to the right of each 
spectrum display the distributions of a, b, and c fragment ions relative to their amino acid 
position in the sequence.   
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Figure 3.2 MS/MS spectra of 1+ KLVFFAEDVGS: (A) CID of underivatized, (B) 
CID of imidazolinylated, (C) UVPD of underivatized, and (D) UVPD of 
imidazolinylated. Peaks labeled with a “°” sign denote loss of H2O or 
NH3.  Companion bar graphs displaying distribution of N-terminal ion 
abundances are shown beside each spectrum with y-axis normalized to 1.    
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Upon conventional CID, b ions dominated the spectrum (Figure 3.2A), and the other two 
N-terminal series of fragment ions (a, c) were poorly represented with only a few a ions 
of low abundance and no c ions observed. After imidazolinylation, CID again produced a 
nearly complete set of b ions, and their relative abundances differed greatly from those 
observed for the underivatized peptide (Figure 3.2B). The product ion distribution bar 
graphs in Figures 3.2A-B show that for underivatized KLVFFAEDVGS the b9 ion was 
the most abundant, but following imidazolinylation the b8 product corresponding to 
cleavage C-terminal to aspartic acid was clearly favored. This type of preferential 
cleavage is observed when CID is applied to peptides in which the number of highly 
basic sites exceeds the number of ionizing protons, thus restricting proton mobility and 
promoting alternative charge remote fragmentation.
12,35,33,29
 Therefore, the presence of 
the abundant b8 ion in Figure 3.2B indicates that the imidazole moiety effectively 
sequesters the ionizing proton to such an extent that other CID pathways are substantially 
reduced. Evidence for this is seen in the supporting ion series, which include a nearly 
complete set of a ions as well as several c ions having isotopic distributions characteristic 
of radical c + 1 ions, all of which have abundances of less than 5% relative to the 
dominant b8 ion.   
UVPD at 193 nm provided a far greater array of a, b, and c ions (Figures 3.2C-
D). Imidazolinylated KLVFFAEDVGS yielded a particularly unique UVPD spectrum 
(Figure 3.2D) showing complete sets of a, b, and c ions along with some additional d 
ions that arise from side-chain losses from a ions. Some preference for b8 formation is 
observed as was seen in the CID spectrum of imidazolinylated KLVFFAEDVGS, but the 
far greater array and abundances of a ions reflects the different mechanism of high 
energy UVPD. The UVPD spectrum of underivatized KLVFFAEDVGS also shows a 
prominent series of N-terminal ions; however, the appearance of y ions, y7 to y10, indicates 
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that unmodified lysine is not sufficiently basic to suppress the formation of C-terminal 
ions, the latter which are not observed for the imidazolinylated peptide (Figure 3.2D).     
The triplet series of N-terminal fragment ions was readily identified based on the 
characteristic 28 Da separation between consecutive a and b ions and the 17 Da 
separation between consecutive b and c ions. The bar graph distribution shown in Figure 
3.2D illustrates the increase in a and c ion abundances relative to the analogous bar graph 
for the underivatized peptide in Figure 3.2C. Moreover, differences in the relative 
abundances of a and b ions were also evident upon comparison of the N-terminal ion 
distribution graphs in Figure 3.2C-D which show a consistent shift from dominant b ions 
for underivatized KLVFFAEDVGS to dominant a ions for imidazolinylated 
KLVFFAEDVGS upon UVPD.   
   
3.4.3 Assessment of Imidazolinylation/UVPD Strategy 
UVPD alone is capable of generating the entire array of peptide fragment ions 
which includes the key a, b, and c ions, but further enhancement of the N-terminal series 
can be achieved by placing a highly basic site at the peptide N-terminus through Lys-N 
digestion and imidazonlinylation. In general, UVPD of the underivatized peptides 
showed similar but in many cases less complete sets of N-terminal ions relative to UVPD 
of the corresponding imidazolinylated peptides. Table 3.1 compares the percent sequence 
coverage afforded by each a, b, and c ion series for the eight model peptides, for which 
percent sequence coverage (adapted from 
36
) is defined by: 
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A) Underivatized 1+ Imidazolinylated 1+ 
  a b c a b c 
KGAIIGLM 100 100 83 100 100 100 
KLVFFAEDVGS 100 100 78 100 100 100 
KYGVSVQDI 86 86 86 100 100 100 
KPLLIIAEDVEGEY 92 100 92 100 100 92 
KLVANNTRL 86 86 57 100 100 100 
KVPRNQDWL 71 86 86 100 86 86 
KMVELVHFL 86 100 86 100 100 100 
KTMTESSFYSNMLA 75 100 58 100 100 92 
 
 B) Underivatized 2+ Imidazolinylated 2+ 
  a b c a b c 
KGAIIGLM 100 100 33 100 100 83 
KLVFFAEDVGS 89 100 67 100 100 67 
KYGVSVQDI 71 100 43 86 100 100 
KPLLIIAEDVEGEY 83 100 75 92 100 50 
KLVANNTRL 57 57 14 86 100 86 
KVPRNQDWL 71 57 43 57 43 14 
KMVELVHFL 71 86 57 71 86 71 
KTMTESSFYSNMLA 50 83 42 92 92 82 
 
Table 3.1 Percent sequence coverage provided by a, b, and c fragment ion sets for 
UVPD of imidazolinylated and underivatized peptides in (A) 1+ and (B) 
2+ charge states. Numbers reported in bold font indicate omission of 
fragment ions due to an inability to distinguish between different ions with 
similar m/z. 100% sequence coverage is defined as a complete set of 
fragment ions ranging from a2 (b2, c2) to an (bn, cn), where n is the total 
number of possible fragment ions. Gray cells highlight sequence 
coverages of less than 100%. 
 
The first N-terminal product ions corresponding to a1, b1, or c1 were not included 
in the calculation of percent sequence coverage (i.e. subtraction of 1 in the denominator) 
because lysine is exclusively the first amino acid for each peptide created using the Lys-
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N protease, and thus the N-terminal residue is already known. Overall, the sequence 
coverage obtained upon UVPD improved for all three series of fragment ions following 
imidazolinylation (an average improvement of 13%, 4% and 18% for a, b, and c ions 
respectively), with the increase in percent sequence coverage being most dramatic for the 
c ion series.  The precursor ion charge state also plays a significant role in the formation 
and distributions of the N-terminal product ions. For both imidazolinylated and 
underivatized peptides, the best sequence coverage for golden a, b, and c ions obtained 
upon UVPD is observed for singly charged peptides, with golden pairs of a and b ions 
more typically observed for higher charge states (see example in Figures 3.3 and 3.4).  
 
 
 
Figure 3.3 MS/MS showing UVPD of (A) underivatized and (B) imidazolinylated 
KGAIIGLM 2+. Peaks labeled with a “°” sign denote loss of H2O or NH3.  
Companion bar graphs displaying distribution of N-terminal ion 
abundances are shown beside each spectrum with y-axis normalized to 1.    
x10 x10 x10
b7
b5
b6b7
2+
a7
c6a5
a6
a4b3
b4
d5
y3y2 y7b7°a7°
d7b6°a6°
y4
c3
MH2+
MH2+°
UVPD KGAIIGLM 2+
250 300 350 400 450 500 550 600 650 700 750 800
m/z
0
20
40
60
80
100
R
e
la
ti
ve
 A
b
u
n
d
a
n
c
e
0
0.2
0.4
0.6
0.8
1
2 3 4 5 6 7
N
o
rm
al
iz
ed
 A
b
u
n
d
an
ce
Fragment Ions
a
b
c
b7
b5 b6
b7
2+
a7
250 300 350 400 450 500 550 600 650 700 750 800 850
m/z
0
20
40
60
80
100
R
e
la
ti
ve
 A
b
u
n
d
a
n
c
e
x10 x5
a2 c5
a5 a6
a3 a4b2
b4
d5
MH2+
a6
2+ a7
2+
b6
2+
b3
y3
y2
UVPD  imid-KGAIIGLM 2+
c4 c6 c7
MH2+°
0
0.2
0.4
0.6
0.8
1
2 3 4 5 6 7
N
o
rm
al
iz
ed
 A
b
u
n
d
an
ce
Fragment Ions
a
b
c
A)
B)
 51 
Table 3.1B shows that the b ions maintain relatively high sequence coverage even 
for the higher charge states due to an increase in proton mobility which facilitates b ion 
formation,
37
 but the higher proton mobility does not enhance a ions nor c ions, the latter 
formed by an alternative route.
38
 Interestingly, for the 2+ peptides, increases in sequence 
coverage are achieved following imidazolinylation due to the increase in basicity of the 
N-terminus, thus causing at least one proton to be more strongly retained at the N-
terminus. The high a/b sequence coverage of over 85% for six out of eight 
imidazolinylated 2+ peptides allows successful de novo sequencing of doubly charged 
precursor ions. The incidence of spectral overlap (i.e. inability to distinguish between 
different fragment ions having similar m/z values), shown by bold values in Table 3.1, 
also increases for the doubly charged peptides because a greater number of product ions 
are observed for precursors of higher charge state. 
UVPD of triply charged ions, as exemplified in Figure 3.4 for KLVANNTRL, 
results in the same trends reported for doubly charged ions but with more notable 
decreases in the a/b sequence coverage as a result of the additional mobile proton (which 
allow greater opportunities for formation of fragment ions containing the C-terminus). 
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Figure 3.4 MS/MS spectra showing (a) UVPD of underivatized KLVANNTRL 3+, 
and (b) UVPD of imidazolinylated KLVANNTRL 3+. Peaks labeled with 
a “°” sign denote loss of H2O or NH3.  Companion bar graphs displaying 
distribution of N-terminal ion abundances are shown beside each spectrum 
with y-axis normalized to 1.    
 
To further illustrate the shifts in a and b ion abundances following 
imidazolinylation, the ratios of the normalized average abundances of a and b ions for 
each of the eight peptides upon UVPD were calculated and plotted in Figure 3.5. Ratios 
greater than 1.0 or less than 1.0 indicate dominant a ion or dominant b ion series, 
respectively. For seven out of the eight singly protonated peptides, the a ions increased in 
abundance relative to the b ions after derivatization (Figure 3.5A). The one exception, 
KLVANNTRL, shows the opposite trend, and this is attributed to the formation of a 
single unusually abundant b ion (b5). If this anomalously abundant product ion is 
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excluded, the a/b ratio increases to 1.12. The shift in the dominance of a versus b ions is 
attributed to a decrease in proton mobility that is experienced upon imidazolinylation.
37
  
When the proton mobility is lost, other fragmentation channels are increasingly 
competitive. With UVPD, the bond between the carbonyl-carbon and the α-carbon is 
photolytically cleaved to form a and x ions,
39
 with a ions being the major product 
normally observed for Lys-N peptides. Moreover, addition of a second proton 
substantially enhances the formation of b ions along with the complementary y ions. For 
this reason, b ions remain dominant compared to other N-terminal ions. This outcome is 
illustrated in Figure 3.5B for doubly charged peptides by the a/b ratio that never exceeds 
1.0 regardless of the lysine modification. In short, the abundance of the a ions increased 
relative to the b ions after imidazolinylation, but the a ions never gain dominance as 
observed for the singly charged peptides. 
 
 
 
Figure 3.5 Comparison of a and b ion abundances for UVPD of (A) 1+ and (B) 2+ 
imidazolinylated and underivatized peptides. Ion abundances are 
normalized to the most abundant a, b, or c ion. Normalized abundances 
are averaged across all a ions (b ions) for each peptide and then ratios are 
calculated. 
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Figure 3.6 compares the total product ion distribution of N- and C-terminal ions 
in terms of the summed percentage of N-terminal versus C-terminal ions for the singly 
and doubly protonated peptides upon UVPD. For the underivatized peptides, a greater 
percentage of the product ions arise from the C-terminus (on average 27%). The 
percentage of C-terminal ions decreased to less than 3% for six of the peptides following 
imidazolinylation. The other two peptides, KLVANNTRL and KKVPRNQDWL, showed 
greater portions of C-terminal ions, 8% and 13% respectively, likely because each of 
these peptides contains a basic arginine residue that is able to compete with the 
imidazolinylated lysine for retention of a proton. The C-terminal series is less effectively 
suppressed upon UVPD of doubly charged peptides, as summarized in Figure 3.6B.  
With the addition of more charges to the peptide backbone, the likelihood of a proton 
residing on the C-terminal side of the cleavage site in the peptide backbone is greater. 
   
   
 
Figure 3.6 Total fragment ion distribution in terms of percentage of N- and C-
terminal ions for UVPD of (A) 1+ and (B) 2+ underivatized and 
imidazolinylated peptides 
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3.4.4 LC-MS/MS Analysis of Lys-N Digested BSA 
Based on the consistent formation of a, b, and c triplets or a and b pairs upon 
UVPD of the series of imidazolinylated model peptides, the strategy was extended for an 
LC-MS/MS proteomic workflow - in this case demonstrated for bovine serum albumin in 
conjunction with Lys-N digestion.    
           
Peptides Charge State a b c 
KPLLE 1+ 100 100 100 
KAFDE 1+ 100 100 100 
KLVTDLT 1+ 100 100 100 
KAEFVEVT 1+/2+ 100/100 100/100 67/33 
KDLGEEHF 1+/2+ 100/67 100/83 83/17 
KQTALVELL 1+ 100 71 86 
KGACLLP 1+ 80 60 40 
KFGERAL 1+ 60 60 20 
KIETMRE 1+ 20 40 40 
KTVMENFVAFVD 2+ 100 100 10 
KEYEATLEECCA 2+ 80 90 10 
KYICDNQDTISS 2+ 60 100 0 
KATEEQL 2+ 80 80 20 
KLVVSTQTALA 2+ 78 89 11 
KLVNELTEFA 2+ 88 88 38 
KSEIAHRF 2+ 83 83 33 
KSLHTLFGDELC 2+ 70 80 40 
KTCVADESHAGCE 2+ 45 64 27 
KLGEYGFQNALIVRYTR 2+ 47 40 7 
KYNGVFQECCQAED 2+ 42 58 8 
KDDSPDLPKL 2+ 11 33 22 
KVPQVSTPTLVEVSRSLG 3+ 50 81 13 
KVASLRETYGDMADCCE 3+ 40 73 20 
KGLVLIAFSQYLQQCPFDEHV 3+ 32 47 16 
KECCHGDLLECADDRADLA 3+ 47 47 6 
KQEPERNECFLSH 3+ 35 64 0 
 
Table 3.2  Peptides identified by UVPD from a BSA Lys-N digest with 
corresponding charge state and a, b, c sequence coverage (%)    
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Table 3.2 lists the peptides identified in the digest along with their charge states 
and a, b, and c sequence coverages. In total 26 peptides accounting for 289 amino acids 
(out of 607) were identified to give a sequence coverage of approximately 50%. As 
expected based on the model peptide experiments described above, the most complete 
triplet sets of a, b, c ions are achieved for singly charged peptides with several of the Lys-
N peptides yielding a complete or nearly complete golden set. Among these peptides is 
singly charged KAEFVEVT, shown in Figure 3.7, that only lacks two N-terminal c ions 
(c5, c7) but for which the entire series of a and b ions is detected. While the singly 
charged peptides show the cleanest golden triplet sets, they only account for about one 
third of the total peptide population, and the doubly charged peptides are also heavily 
relied upon for de novo sequencing. Many of these peptides maintain high sequence 
coverage of a and b ions, but the abundances of c ions are diminished. The a and b series 
constitute a golden pair, and complementary c ions are useful to validate the pairs but are 
not necessarily needed for de novo sequencing.   
  
 
 
Figure 3.7  UVPD of singly charged imidazolinylated Lys-N peptide KAEVFVEVT 
from BSA   
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The percentages of golden triplets and pairs as well as single (or absent) product 
ions are shown for the Lys-N BSA peptides in Figure 3.8.   
 
 
 
Figure 3.8  Percentages of golden ion triplets, golden ion pairs, and singlet/absent ions 
for BSA lys-N peptides obtained by UVPD after imidazolinylation of the 
digest.  Singly, doubly, and triply charged peptides are grouped in the top, 
middle, and bottom portions of the graph.    
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Singly and doubly charged peptides show a large percentage of product ions that 
are part of golden sets. Exceptions occur for peptides that have internal basic residues 
presumably because these basic sites sequester the ionizing proton away from the N-
terminal lysine. All of the observed triply charged peptides contain a second basic site, 
and consequently individual product ions (i.e. a or b ions but not both) are more common 
than golden sets, the latter which account for less than 50% of the total product ion 
population. Furthermore, the triply charged peptides generally exhibit poor sequence 
coverage for all N-terminal ions including b ions. The increased length of the triply 
charged peptides, many of which contain missed cleavages, may account for the 
diminished sequence coverages. Missed cleavages that result in an internal 
imidazolinylated lysine produce results in an erosion in the formation of the golden series 
similar to that observed for peptides containing arginine, thus reinforcing the importance 
of the proteolytic efficiency in generating Lys-N terminated peptides. 
 As a comparison to our UVPD/imidazolinylation strategy for de novo 
sequencing, a tryptic BSA digest was analyzed by LC-MS/MS (using conventional CID 
as the activation method) followed by de novo sequencing using PEAKS Studio 5.3. De 
novo sequencing based on CID data derived from non-derivatized tryptic peptides is 
representative of the universal standard, and therefore these results provide a benchmark 
for assessing improvements to de novo sequencing based on the novel Lys-
N/imidazolinylation/UVPD protocol. PEAKS was chosen instead of other de novo 
sequencing software based on its superior performance in terms of the number of 
accurate peptide identifications and ease of use.
40
 After applying filters based on the total 
local confidence (TLC) and average local confidence (ALC) of amino acid assignments, 
a total of 105 de novo peptides were identified, listed in Table 3.3.  
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Sequence TLC ALC (%) z Local Confidence (%) 
KQTALVELLK 9.1 91 2 74 84 92 93 96 95 95 97 98 82 
LVNELTEFAK 9.1 91 2 94 94 95 96 96 97 96 92 93 53 
WPVSVLLR 7.1 88 2 84 91 92 87 88 95 98 69 
MQTALVELLK 8.7 87 2 92 87 91 93 93 94 91 88 89 52 
*LVNELTEFAK 8.6 86 2 86 85 90 94 95 95 88 85 87 45 
GFAVSVLLR 7.7 85 2 74 73 84 91 86 88 95 98 72 
LVTDLTK 5.8 83 1 75 72 74 92 95 96 72 
EVCTEDYLSLLLNR 11.5 82 2 
61 56 73 96 97 98 86 98 97 97 99 72 
72 43 
MTCAEDYLSLLLNR 11.5 82 2 
69 64 79 94 95 97 80 97 96 97 95 69 
69 39 
TLYLVQDLMETDLYK 12.2 81 2 
57 55 84 89 91 84 86 87 96 95 95 80 
78 87 49 
TATVSLPR 6.5 81 2 91 90 74 71 84 80 90 65 
APLMTYAVSVLLR 10.5 81 3 
36 40 40 80 96 92 92 95 94 96 97 99 
84 
CCTESLVNR 7.2 80 2 9 96 76 96 96 96 89 89 69 
EPCTEDYLSLLLNR 11.1 80 2 
62 53 69 92 95 95 75 96 97 97 96 70 
70 38 
RQTALVELLK 7.9 79 2 49 49 96 93 93 96 93 83 86 47 
TVMENFVAFVDK 9.5 79 2 43 42 63 95 92 96 97 97 97 81 83 54 
WFLGSFLYEYSR 9.3 78 2 50 86 28 98 97 97 98 85 85 60 85 56 
**QTALVELLK 7 77 2 25 27 82 91 94 93 96 98 86 
HAQENFVAFVGK 9.2 77 2 57 55 80 86 85 92 92 94 97 73 74 31 
LCVLHEQTPVSTR 9.8 76 3 
88 88 98 97 92 92 85 95 68 54 46 49 
25 
YLCDNQDTLSSK 9.1 76 2 41 73 45 96 73 78 96 95 96 98 99 9 
HLVDESCNLLK 8.2 75 2 90 89 98 98 86 61 57 32 63 84 58 
CLYELAR 5.2 74 2 79 79 46 68 66 95 83 
LWYGFQNELLVR 8.9 74 2 0 0 92 98 98 70 63 91 97 98 98 78 
FQDLGEEHFK 7.3 73 2 52 48 98 98 78 78 96 77 53 42 
DWYGFQNALLVR 8.6 72 2 57 41 23 26 91 85 86 94 96 96 97 66 
CHGGGTFK 5.7 72 2 84 83 71 52 50 67 94 68 
FLALGSFLYEYSR 9.2 71 2 
32 31 70 95 97 95 95 97 76 75 44 72 
40 
CVVGGPLR 5.7 71 2 51 51 77 80 81 81 82 60 
 
Table 3.3 PEAKS de novo peptides assigned from LC-MS-CID of tryptic BSA   
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Table 3.3 Continued 
QDMADDKEACFAVEGPK 12 71 2 
33 27 29 82 83 81 59 96 97 93 92 93 
94 91 64 67 9 
AEFVEVTK 5.6 70 2 63 61 92 80 49 48 88 72 
MFVSVLLR 5.5 69 2 45 43 86 89 85 82 85 34 
FQDLGEEHFK 6.8 68 3 70 40 44 51 88 91 96 83 63 49 
RHPEHPVSVLLR 8.1 68 2 91 97 97 96 40 38 35 45 47 80 89 49 
SMEVEVTQLVTDLTK 10 67 2 
22 16 17 89 38 37 93 89 97 96 96 93 
80 82 49 
RPPELLYYANK 7.3 66 2 69 72 74 74 75 92 74 39 60 62 34 
KLHLVDEPKNLLK 8.6 66 2 
32 36 92 98 99 99 94 50 34 32 52 87 
53 
CTVADESHAGCEK 8.5 65 2 
26 25 95 95 94 97 95 96 94 58 26 26 
17 
FETSVLLR 5.2 65 2 53 40 43 72 72 91 94 53 
RALLAGNR 5.2 65 2 79 35 35 63 73 71 74 87 
TSEAWSVAR 5.8 64 2 35 34 89 91 26 85 76 83 52 
NYVLHEKTWVVR 7.7 64 2 30 32 69 97 97 96 81 84 14 54 67 40 
SSLSSVVGR 5.7 64 2 74 58 51 67 68 72 69 73 36 
QAAVSVLLR 5.7 63 2 35 35 37 87 92 91 81 81 23 
LVHVTTTRR 5.7 63 2 93 93 95 83 44 24 25 47 59 
LCVLHEQTPVSEK 8.2 63 2 
15 15 18 97 98 98 91 97 88 86 39 45 
24 
KEYFADYEER 6.3 63 2 74 87 28 56 66 64 83 40 46 81 
FSALTPEDDTFPK 8.1 63 2 
27 26 86 96 98 89 22 21 39 54 79 96 
75 
FTGTSEEYLSLLLNR 9.4 63 2 
75 53 24 24 64 77 65 52 59 97 97 97 
57 57 33 
LYGDALLVR 5.6 62 2 77 76 53 29 30 58 91 91 51 
KPQGGGMYTLK 6.8 62 2 70 60 41 72 82 92 95 69 33 38 24 
MRVTEEYLSLLLNR 8.7 62 2 
20 20 24 86 94 88 63 61 94 95 94 47 
47 27 
KPEEGFAHASSK 7.4 62 2 59 21 21 37 73 54 51 69 85 85 85 94 
GCNELTEFAK 6.2 62 2 51 51 70 54 91 95 78 50 51 19 
DCVLHEQTAFSTR 8 62 2 
80 80 91 93 94 91 60 58 69 25 17 19 
18 
SLHTLFGDELCK 7.4 61 1 32 27 72 91 97 97 95 92 66 18 29 14 
MRDSEEYLSLLLNR 8.6 61 2 
27 20 14 28 91 95 63 66 97 97 97 62 
62 33 
FCLMSTFNLCK 6.7 61 2 76 67 33 35 89 88 88 76 43 43 24 
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Table 3.3 Continued 
MCLSMDYLSLLLNR 8.4 60 2 
20 20 15 40 58 94 79 95 94 98 97 48 
48 29 
RGKVDNQDTLSSK 7.6 59 2 13 11 11 46 53 70 85 93 94 89 89 93 9 
KKTYSLALLK 5.8 58 2 60 82 94 33 24 32 45 81 86 40 
GFHTLFGDELCK 7 58 2 13 13 15 84 98 97 92 89 65 55 31 38 
KLECCDPKLLEK 6.9 58 2 67 70 88 59 60 63 63 23 29 61 65 38 
KVPKVSTPTLVEVSR 8.6 58 2 
70 85 92 64 92 93 86 27 16 17 75 59 
30 31 19 
QELRETYTAMADCCAK 9.2 58 2 
40 31 30 38 93 96 80 35 35 95 96 97 
68 22 36 19 
WLYGFQKGLLVR 6.9 57 2 16 17 14 96 97 58 11 15 90 98 98 75 
CSVDEAARGPLK 6.8 57 2 76 66 68 80 70 67 33 22 24 33 51 89 
VPAANGSFLYEHNR 8 57 2 
20 20 27 77 71 92 89 89 95 68 53 24 
42 23 
SPCTGAATR 5.1 57 2 77 77 76 41 27 30 38 44 95 
AEFVEVNDLVTHLTK 8.5 57 2 
79 78 86 90 96 84 0 34 67 36 35 61 38 
40 20 
MEAYYLLPEAYFYPFK 9 56 2 
58 54 72 96 96 77 65 33 32 80 78 70 
20 18 18 27 
FADEQLAPAR 5.6 56 2 60 58 96 73 45 76 71 34 23 26 
ALQADSSVAR 5.6 56 2 84 83 87 83 51 50 23 22 40 37 
GNYNLVGGRCK 6.2 56 2 83 65 66 47 85 94 65 28 28 28 23 
YLCHNKDTLSSK 6.7 56 2 75 84 53 38 14 19 22 80 84 92 95 9 
AFEVDDLDLVTDLTK 8.3 56 3 
54 46 34 34 67 65 73 93 89 83 84 48 
21 21 14 
FWLGSFLYEYTR 6.6 55 2 25 18 15 97 98 97 97 79 53 26 40 13 
*LVNELTEFAK 5.5 55 1 64 63 80 87 89 80 22 21 21 18 
WVSTPTLPMWR 6 55 2 63 81 89 80 68 67 78 36 22 0 16 
LVNELTGYVR 5.5 55 2 72 63 41 46 76 78 67 39 42 19 
GVEATPGNLEVTK 7 54 3 
41 37 64 63 33 32 33 50 52 93 78 80 
44 
GSTLTNNAVSVLLR 7.6 54 3 
22 25 38 90 50 14 15 21 78 89 89 89 
91 42 
ALYGTVEVSR 5.4 54 2 18 15 17 54 74 85 91 67 70 42 
MMPAELKTVMENFVAFWR 9.7 54 2 
26 21 29 30 52 63 67 68 70 88 70 44 
82 87 93 29 23 17 
CDKFSLVNSPPDR 6.9 53 2 
89 76 14 18 85 92 90 67 47 39 25 28 
11 
TAVVEQAAVDALLR 7.4 53 3 
42 25 24 25 36 30 46 87 91 54 48 80 
92 52 
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Table 3.3 Continued 
DRHADLCTLPGQCK 7.3 52 2 
16 15 13 87 59 56 80 66 70 83 65 40 
53 25 
RPVDKSGFAEPK 6.3 52 2 79 87 86 83 75 47 43 26 26 21 30 16 
NNHLEALLNR 5.2 52 2 26 16 16 36 64 71 93 76 76 45 
FWLGSPGLGLEYTR 7.3 52 2 
24 0 88 96 72 70 71 73 29 30 87 27 43 
13 
GYTEAVNEHMENFVAFKR 9.3 52 3 
60 56 63 65 32 32 73 48 50 71 81 80 
61 23 23 39 45 23 
WKTGGRKVQLLVR 6.7 52 3 
48 40 14 31 35 20 20 27 71 94 96 97 
73 
KLFLLSLLLNR 5.7 52 3 63 79 24 24 24 29 43 89 73 74 43 
VTFKGFQATALLVR 7.2 52 2 
45 24 22 27 72 51 50 29 28 32 86 95 
96 62 
HVSSRSCHGDLLECWDR 8.8 52 3 
67 60 30 30 20 20 14 23 87 93 98 97 
95 53 25 25 35 
KLECCHQPLLEK 6.2 51 2 82 90 89 61 14 14 14 67 63 42 43 29 
MNFPLQTQPLLTR 6.7 51 2 
77 70 40 21 22 66 93 78 75 66 18 18 
16 
LPDTLVHAAVPK 6.1 51 2 30 29 24 46 60 68 41 40 49 66 82 73 
GSEDLGGGALDTR 6.6 51 2 
35 35 62 85 81 71 51 38 36 53 30 47 
29 
CPQDQFEQLGEYGFQNALVLR 10.7 51 2 
11 11 11 22 23 87 30 62 94 86 88 97 
96 93 79 55 33 27 18 20 12 
RGYLDAHFTFLQHMR 7.6 51 2 
41 38 39 77 57 54 56 62 92 88 78 0 25 
25 18 
YNTFARSCMENFVAFVDK 9.1 50 3 
12 12 14 49 15 15 27 20 85 44 71 92 
97 97 90 61 62 34 
KSSMTMTYFEEK 6 50 2 68 76 58 56 68 60 60 60 26 18 17 29 
AQFASVEVSR 5 50 2 49 21 21 40 52 75 77 60 64 36 
TTKEVAVPSPRR 6 50 2 48 38 37 46 85 96 78 54 27 27 34 25 
 
Table 3.3 PEAKS de novo peptides assigned from LC-MS-CID of tryptic BSA. TLC 
and ALC are listed along with the peptide charge and local percent 
confidence scores of amino acid assignments. Peptide confidence scales 
with ACL as follows: 90% is very high confidence, >80% is high, 60%-
80% is medium, and <60% is low. Rows highlighted in gray show 
sequences that match to BSA tryptic peptides. Sequences marked with an 
asterisk denote a repetitive identification while sequences marked with a 
double asterisk denote redundant sequence information (i.e. a peptide that 
is encompassed by another larger peptide having missed cleavages)   
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From this list ten peptides corresponded to BSA peptides, while the rest were 
false positives. Included in this set of ten peptides were three peptides which provided 
redundant protein sequence information based on repeat identifications of the same 
peptide and overlapping amino acid sequences in peptides having different numbers of 
missed cleavages, for example QTALVELLK and KQTALVELLK. Further manual 
inspection of the CID spectra and assessment of the PEAKS-assigned peptides in a 
manner similar to that undertaken for interpretation of the UVPD spectra reveals 11 
additional peptides, listed in Table 3.4, having sequences that closely agree with BSA 
peptides except for mis-assigned isobaric or nearly isobaric amino acids that cannot 
reliably be distinguished using low mass accuracy data. After manually-assisted de novo 
sequencing, 208 different amino acids were identified accounting for 35% of the total 
BSA sequence. 
 
PEAKS de novo peptide Actual BSA peptide %correct Miss assignments 
EV(228.111)CTEDYLSLLLNR MP(228.093)CTEDYLSLILNR 86 I/L + missed pair 
W(186.079FLGSFLYEYSR DA(186.064)FLGSFLYEYSR 85 missed pair 
LCVLHEQTPVSTR(257.149) LCVLHEKTPVSEK(257.138) 85 Q/K + missed pair 
YLCDNQDTLSSK YICDNQDTISSK 92 I/L  
FQDLGEEHFK FKDLGEEHFK 90 Q/K  
DW(301.106)YGFQNALLVR LGE(299.1482)YGFQNALIVR 77 
I/L + missed 
consecutive three 
RHPEHP(234.112)VSVLLR RHPEYA(234.100)VSVLLR 83 missed pair 
KLHLVDEPKNLLK LKHLVDEPQNLIK 85 Q/K + I/L + flip-flop 
CTVADESHAGCEK TCVADESHAGCEK 85 flip-flop 
KLECCDPKLLEK LKECCDKPLLEK 83 flip-flop 
KVPKVSTPTLVEVSR KVPQVSTPTLVEVSR 93 Q/K 
 
Table 3.4  Manually assisted PEAKS de novo sequencing. Amino acids in bold and 
underlined denote incorrect assignments with the molecular weight listed 
in parentheses. I/L and Q/K denote mis-assignment of Ile and Leu or Gln 
and Lys residues. “Flip-flop” under the mis-assignment column denotes 
correct amino acids that are assigned the wrong location in the sequence.  
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 3.5 CONCLUSION 
The present study demonstrates the ability to generate golden sets of a, b, and c 
ions through 193 nm UVPD activation of imidazolinylated Lys-N peptides. UVPD of 
unmodified Lys-N peptides can provide a similar set of N-terminal ions; however, a 
greater number of C-terminal ions are formed and the N-terminal ion distribution is 
skewed in favor of the b ion series. Following imidazolinylation, the a and c ion series 
increase in abundance with the a ions gaining dominance for singly charged peptides. 
The quality of the golden triplet series decreases with increasing precursor ion charge 
state because a second proton makes additional fragmentation channels more accessible 
due to greater charge mobility. In conjunction with the Lys-N protease, this methodology 
was applied to a BSA digest for which 50% sequence coverage was achieved. A high 
percentage of the total product ion population was comprised of golden sets for the singly 
and doubly charged peptides upon UVPD, making them amenable to the proposed de 
novo sequencing strategy. We anticipate that using a customized de novo algorithm that 
caters more specifically to the type of fragment ions generated upon UPVD of 
imidazolinylated lys-N peptides could result in even more accurate de novo sequencing 
results. We are currently investigating new automated spectral interpretation strategies 
that can utilize the unique peptide fragmentation chemistry defined in this study.     
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Chapter 4 
193 nm Ultraviolet Photodissociation Mass Spectrometry for 
Phosphopeptide Characterization in the Positive and Negative Ion 
Modes 
 
4.1 OVERVIEW 
 Advances in liquid chromatography tandem mass spectrometry (LC-MS/MS) 
have permitted phosphoproteomic analysis on a grand scale, but ongoing challenges 
specifically associated with confident phosphate localization continue to motivate the 
development of new fragmentation techniques. In the present study, ultraviolet 
photodissociation (UVPD) at 193 nm is evaluated for the characterization of 
phosphopeptides in both positive and negative ion modes. Compared to the more 
standard higher energy collisional dissociation (HCD), UVPD provided more extensive 
fragmentation with improved phosphate retention on product ions. Negative mode UVPD 
showed particular merit for detecting and sequencing highly acidic phosphopeptides from 
alpha and beta casein, but was not as robust for larger scale analysis due to lower 
ionization efficiencies in the negative mode. HeLa and HCC70 cell lysates were analyzed 
by both UVPD and HCD. While HCD identified more phosphopeptides and proteins 
compared to UVPD, the unique matches from UVPD analysis could be combined with 
the HCD data set to improve the overall depth of coverage compared to either method 
alone.   
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4.2 INTRODUCTION 
Post-translational modifications (PTMs) direct a variety of biological activities, 
many of which are critical for sustaining normal cellular function. Phosphorylation is 
known to modulate enzymatic activity, alter protein folding, and inhibit or promote 
interactions with other proteins. Abnormalities in phosphorylation pathways have been 
associated with various diseases, a factor that has stimulated interest in kinases and 
phosphatases as therapeutic targets and their substrates as potential diagnostic 
biomarkers.
1,2
  The tremendous impact of phosphorylation has inspired the development 
of extremely powerful mass spectrometry strategies to map the dynamic 
phosphoproteome and quantify variations in phosphorylation as a function of cell state. 
The majority of these strategies are based on bottom-up workflows that rely on the ability 
to identify phosphorylation sites of proteins via MS/MS characterization of diagnostic 
proteolytic peptides.
3
 Due to significant inroads in enrichment methods, chromatographic 
capabilities, and performance metrics of mass spectrometers, there have been reports of 
grand scale phosphoproteomics.
4–7
 For example, identification of thousands of 
phosphopeptides, corresponding to 18,055 phosphosites and 4,708 phosphoproteins, was 
achieved using 1 mg of material via a 2D enrichment/fractionation strategy combining 
immobilized metal affinity chromatography (IMAC), hydrophilic interaction liquid 
chromatography (HILIC) and reversed phase LC.
4
 Yet even with these advances, there 
continue to be major efforts to improve depth of coverage, sensitivity of phosphopeptide 
detection, and confidence in phosphosite localization. 
The choice of MS/MS technique can significantly impact the outcome of a PTM 
mapping experiment, and thus a variety of fragmentation methods have been evaluated 
for phosphopeptide analysis.  Collision induced dissociation (CID) remains popular for 
peptide sequencing based on the ease of implementation, robust performance, and the 
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multitude of available data analysis tools.
8
 Because CID promotes cleavage at the most 
labile bonds, phosphorylated peptides readily undergo loss of neutral phosphate groups 
while more informative backbone fragmentation is suppressed, making it difficult to both 
sequence the peptide and localize the modification.
9,10
 Higher energy collisional 
dissociation (HCD) is a beam type variation of CID that results in greater energy 
deposition. This facilitates cleavage of bonds other than those that are the weakest, and 
the phosphate neutral loss problem is largely mitigated although not entirely overcome.
11
 
Phosphate neutral loss can be eliminated nearly entirely using electron-based activation 
methods, including electron transfer dissociation (ETD) and electron capture dissociation 
(ECD) for which cleavage occurs at the N-Cα bond to form c and z type ions while PTMs 
are preserved.
12–16
 Both ETD and ECD exhibit a significant charge state dependence, and 
peptides with insufficient charge density typically do not fragment efficiently. Charge 
density limitations are particularly problematic for phosphopeptides because the 
negatively charged phosphate decreases the overall positive charge, thus offsetting the 
effectiveness of ETD and ECD for phosphopeptide analysis.  
Photodissociation has been explored as an alternative to collision- or electron-
based dissociation methods. Infrared multiphoton dissociation (IRMPD) has been the 
most widely adopted, but because fragmentation occurs through the slow heating of 
vibrational modes, many of the same limitations that are observed for CID of 
phosphopeptides also apply for IRMPD.
17
 At the same time, IRMPD can provide an 
effective means for screening complex peptide mixtures for phosphorylation based on the 
superior IR absorbance of phosphopeptides compared to nonphosphorylated peptides, 
causing the former to dissociate while the later are left intact.
18–21
 
In the near IR regime, femtosecond laser-induced ionization/dissociation (fs-LID) 
uses ultrafast laser pulses to induce electron loss through tunneling followed by peptide 
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bond cleavage to form a, b, c, x, y, and z ions.
22,23
 Because dissociation is initiated by 
electron abstraction, fs-LID is most effective for singly protonated peptides based on 
their lower ionization potentials compared to more highly charged ions, a trend that is 
opposite to CID/HCD and ETD/ECD fragmentation. Along with superior sequence 
coverage, singly charged phosphopeptides exhibited the greatest phosphate retention on 
product ions. No phosphate neutral loss was detected from c/z or a/x ions with the 
exception of potentially diagnostic a+1-98 ions observed C-terminal to the site of 
phosphorylation. FsLID has also been applied in negative ion mode for the analysis of 
multiply deprotonated phosphopeptide anions, where phosphate retaining a/x ions 
facilitate sequencing and modification localization.
24
 Long activation times and narrow 
charge state restrictions ultimately have limited the adoption of fsLID for large-scale 
analysis. 
Ultraviolet photodissociation has also been applied for the analysis of 
phosphopeptides. For phospho-serine containing peptides, 220 nm UVPD resulted in the 
dominant neutral loss of tyrosine side-chains via homolytic bond cleavage while other 
fragmentation channels including peptide backbone cleavage and phosphate loss were 
suppressed.
25
 In contrast, 266 nm UVPD yielded mostly b and y ions with only minor a 
and x ions.
26
 Likewise, phosphate neutral loss patterns were similar between 266 nm 
UVPD and CID even for phospho-tyrosine peptides for which the site of phosphorylation 
coincides with the site of photon absorption.
26
 Photodissociation using 157 and 193 nm 
photons is also widely applicable for proteomics applications because photons are 
absorbed efficiently by the peptide backbone. High energy fragmentation channels are 
accessible upon 157 and 193 nm photoexcitation to yield a/x, c/z, and d/v/w side chain 
loss ions in addition to more conventional b/y ions.
17,27,28
 Both 157 nm and 193 nm 
UVPD have been used for various proteomics applications 
27,29–32
, ranging from single 
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protein analysis to more complex whole cell lysates in both positive and negative 
modes.
33–36
 To date, PTM analysis has been primarily conducted in negative mode based 
on the improved retention of labile modifications including sulfation, O-glycosylation, 
and phosphorylation; however, larger scale analysis in the negative mode has been 
significantly hindered by poor ionization efficiency.
35,37–40
 Both 157 nm UVPD and 193 
nm UVPD have been used to characterize phosphopeptides.
35,41–44
 For example, the 
fragmentation behavior of singly protonated phosphopeptides with C-terminal arginine 
residues was explored using 157 nm UVPD, showing that the loss of the phosphate group 
was time-dependent and varied based on whether the phosphate group was appended to 
tyrosine, serine, or threonine.
42
 193 nm UVPD of singly protonated phosphopeptides that 
had N-terminal basic residues resulted in prominent a+1-98 ions observed C-terminal to 
sites of phosphorylation, thus providing a signature for the site of phosphorylation.
41
 
Product ions that are diagnostic for phosphorylation have also been observed in the 193 
nm UVPD spectra of phosphopeptide anions where formation of y-H3PO4-NH3 ions was 
observed N-terminal to the site of phosphorylation in addition to an array of phosphate 
retaining sequence ions.
35
 Unique phosphorylation sites in the protein TrpM7 were 
identified using ET-UVPD in which hydrogen rich radical peptide ions generated from 
electron transfer without dissociation (ETnoD) were activated and dissociated using 193 
nm UVPD, resulting in a rich array of product ions for which z ions were most 
abundant.
43
 The most recent study compared 193 nm UVPD and HCD for the analysis of 
phosphopeptides from a HeLa digest and found improved modification retention using 
UVPD.
44
  
The present study expands upon UVPD-based phosphoproteomics via analysis of 
phosphopeptides enriched from casein proteins in addition to HeLa and HCC70 primary 
ductal carcinoma cell lysates. UVPD is implemented on an Orbitrap Fusion Tribrid mass 
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spectrometer, and both polarities are evaluated for phosphopeptide characterization. The 
overall depth of coverage is compared between UVPD and HCD as well as differences in 
the identified phosphopeptides such as length, charge state, and number of 
phosphorylations. The extent of phosphate neutral loss also is also explored. 
 
4.3 EXPERIMENTAL 
4.3.1 Cell Culture and Sample Preparation 
HeLa and HCC70 stable shRNA scramble cells were maintained at 37 °C and 5% 
CO2 and cultured in accordance with ATCC guidelines. HeLa was grown in Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 
and HCC70 was grown in RPMI media supplemented with 10% FBS, 2 mM glutamine, 
1% antibiotic/antimycotic (10 U/mL penicillin, 10 µg/mL streptomycin, 0.025 µg/mL 
amphotericin B), and 1 µg/mL puromycin. Cells were lysed in buffer containing 50 mM 
ammonium bicarbonate (pH 8), 8 M urea, 1 mM sodium orthovanadate, 100 mM sodium 
fluoride, 10 mM sodium pyrophosphate, 1 µM microcystin-LR, 100 nM calyculin A, 
complete EDTA-free protease inhibitor mix (Roche), and phosSTOP phosphatase 
inhibitor mix (Roche). Protein concentration was measured by Bradford assay and lysates 
were stored at -80°C prior to digestion.  
Protein disulfide bonds were reduced by 30 minute incubation with 5 mM 
dithiothreitol at 56 °C then alkylated by 30 minute incubation with 15 mM iodoacetamide 
at room temperature in the dark. Lysates were then digested with Lys-C (Promega, 
Madison, WI) in a 1:200 enzyme to protein ratio for 2-4 hours at 37 °C. The urea 
concentration was then diluted to 1.5 M by addition of 50 mM Tris HCl, 5 mM CaCl2 and 
trypsin (Thermo Fisher Scientific, Grand Island, NY) was added in a 1:50 enzyme to 
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protein ratio for overnight digestion at 37 °C. Digests were desalted using Waters tC18 
Sep-Pak cartridges and dried by speed vac. Immobilized metal affinity chromatography 
(IMAC) was used for phosphopeptide enrichment .
45
 Briefly, Ni-NTA magnetic agarose 
beads (Qiagen, Germantown, MD) were prepared for IMAC by shaking in 40 mM EDTA 
(pH 7.5) for 1 hour followed by thorough washing with water and shaking in 100 mM 
FeCl3 for 1 hour. Protein digests were resuspended in IMAC loading buffer composed of 
80% ACN containing 0.15% TFA and added to the IMAC beads following the removal 
of FeCl3 solution. Phosphopeptide binding was carried out over 1 hour of shaking 
followed by three washes in loading buffer to remove non-phosphorylated peptides. 
Phosphopeptides were recovered from the beads by vortexing for 1 min and 15 sec in 100 
µL of 50% ACN, 0.7% NH4OH (pH ~11) and the eluent was immediately neutralized in 
50 µL of 4% formic acid and dried completely. IMAC enriched HeLa samples from 500 
µg of starting material were resuspended in 20 µL of 0.2% formic acid prior to LCMS 
analysis.  
An equimolar mixture of alpha s1 casein, alpha s2 casein, and beta casein from 
bovine were digested in 50 mM Tris HCl (pH 7.5) with trypsin in a 1:50 enzyme to 
protein ratio overnight at 37°C. Digested peptides were directly added to a 5x excess 
(w/w) of ceramic hydroxyapatite type I, 20 µm beads (Bio Rad, Hercules, Ca) suspended 
in 50 mM Tris HCl. Phosphopeptide binding to HAP occurred for 1 hour at room 
temperature with shaking. Unmodified peptides were washed away using 50 mM Tris 
HCl containing 20% ACN. Bound phosphopeptides were recovered from the HAP resin 
by 15 minutes of shaking in 1 M KH2PO4 (pH 7.8). The eluent was split and desalted 
using both C18 and graphite solid phase extraction (SPE) to avoid the loss of very 
hydrophilic phosphopeptides. Desalted samples were dried and resuspended in water for 
LCMS analysis. 
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4.3.2 LC-MS/MS Analysis 
Cell lysate separations were carried out on a Dionex Ultimate 3000 nano LC 
equipped with water as mobile phase A and acetonitrile (ACN) as mobile phase B, each 
containing 0.1% formic acid. For LCMS analysis 4 µL of IMAC-enriched HeLa was 
directly injected onto a 30 cm x 75 µm UPLC column with integrated emitter (New 
Objective, Woburn, MA), packed in house using 1.8 µm, 120 Å UChrom C18 
(nanoLCMS Solutions, Gold River, CA). The column was heated to 60 °C inside a 
custom built column oven that was fabricated similarly to that described by Coon and 
coworkers.
46
 For HeLa phosphopeptides, separation occurred over an 80 minute gradient 
in which the percentage of mobile phase B was increased from 2-25% B during the first 
65 minutes and further increased from 25-40% B during the final 15 minutes. For HCC 
phosphopeptides, the same gradient steps were used, but the increase from 2-25% B was 
carried out more gradually over 118 minutes. Eluting peptides were analyzed using an 
Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific Instruments, Bremen, 
Germany) equipped with a 193 nm Coherent ExciStar XS excimer laser (Santa Clara, 
CA) for ultraviolet photodissociation.
47
 Orbitrap detection was used for both MS1 and 
MS2 measurements at resolving powers of 60K and 15K (at m/z 200), respectively. Data 
dependent MS/MS analysis was performed in top speed mode with a 3 s cycle time 
during which precursors detected within the range of m/z 400-1500 were selected for 
activation in order of abundance. Quadrupole isolation with a 1.6 Da isolation window 
was used and dynamic exclusion was enabled for 45 s. AGC targets were 2E5 for MS1 
and 1E5 for MS2, with 50 ms and 100 ms maximum injection times, respectively. The 
signal intensity threshold for MS2 was 5E4. HCD was performed using 30% normalized 
collision energy and for UVPD, 2 pulses at 2.5 mJ were used. For triplicate HCD and 
triplicate UVPD LCMS runs, one microscan was used for MS
1
 and two microscans were 
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used for MS2. The number of MS2 microscans was decreased to one for the HCC lysate 
in order to maximize the depth of coverage. Alternating activation experiments were also 
performed for HeLa in which the same precursor ion was selected for consecutive 
activation using UVPD and HCD. For these experiments, the MS/MS parameters listed 
above were used for run one, the MS2 signal intensity threshold was increased to 5E6 for 
run two, and the maximum MS2 injection time was increased to 300 ms for run three.  
Negative mode LCMS analysis of phosphopeptides from alpha and beta casein 
proteins was carried out on a Thermo Scientific Instruments Velos Pro dual linear ion 
trap mass spectrometer equipped with a 193 nm Coherent ExciStar XS excimer laser 
(Santa Clara, CA) as previously described for UVPD.
27,48
 A Dionex ultimate 3000 nano 
LC was used for separations in which mobile phase A was 5 mM ammonium acetate in 
water and mobile phase B was 5 mM ammonium acetate in 90% methanol. Peptides were 
loaded for 4 minutes at 5 µL/min onto a 3 cm x 100 µm trap column (New Objective, 
Woburn, MA) packed with 5 µm Michrom magic C18. The analytical column was 20 cm 
long x 75 µm OD with an integrated emitter tip (New Objective, Woburn, MA) packed 
with Waters Xbridge BEH C18 (Milford, MA). Separation occurred over a 45 minute 
linear gradient from 2-45% B. MS1 survey scans were acquired from m/z 400-2000 and 
data dependant UVPD using a single 2 mJ pulse was carried out on the top five most 
abundant precursor ions.  
 
4.3.3 Data Analysis 
 Proteome Discoverer 1.3 was used for positive mode UVPD and HCD analysis of 
the IMAC enriched cell lysates. For UVPD, a non-fragment filter was applied to MS2 
spectra to remove precursor peaks within a 1 Da mass window offset prior to database 
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search using Sequest and a human database obtained from Uniprot. All product ions 
including a, b, c, x, y, and z were used for spectrum matching for UVPD while only a, b, 
and y ions were used for HCD. Neutral losses from a, b, and y ions were considered for 
both UVPD and HCD. The following additional database search parameters were 
consistent between UVPD and HCD experiments: 10 ppm precursor mass tolerance; 0.02 
Da fragment mass tolerance; N-terminal acetylation, methionine oxidation, and 
serine/threonine/tyrosine phosphorylation dynamic modifications; carbamidomethyl 
cysteine static modifications. Percolator was used for PSM validation and phosphoRS 3.0 
was used for phosphosite localization. Only rank 1, high confidence PSMs were 
considered and an isoform probability of 75% was required for phosphosite localization.  
 Negative mode UVPD results for alpha and beta casein phosphopeptides were 
interpreted using MassMatrix Xtreme 3.0.10.16, which is programmed to search for a, x, 
c, z, and y type product ions. Peptide mass and fragment mass tolerances were ±1.00 Da 
and ±0.80 Da, respectively, and the minimum pp score was 4 while the minimum pptag 
score was 1.  
 
4.4 RESULTS AND DISCUSSION 
4.4.1 UVPD and HCD Analysis of Alpha and Beta Casein Phosphopeptides 
UVPD and HCD were initially evaluated for phosphopeptide analysis in the 
positive mode using phosphopeptides generated from trypsin digestion of bovine 
phosphoproteins alpha S1 casein, alpha S2 casein, and beta casein. Eight singly 
phosphorylated peptides including DIGpSESTEDQAMDIK, EKVNELpSK, 
EQLSTpSEENSK, FQpSEEQQQTEDELQD, NMAINPpSK, TVDMEpSTEVFTK, 
VPQLEIVPNpSAEER, and YKVPQLEIVPNpSAEER as well as three doubly 
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phosphorylated peptides including DIGpSEpSTEDQAMEDIK, EQLpSTpSEENSK, and 
EQLpSTpSEENSKK were identified in LC-MS runs by both UVPD and HCD. All 
peptides were detected in the 2+ charge state and three peptides, 
FQpSEEQQQTEDELQDK, VPQLEIVPNpSAEER, and YKVPQLEIVPNpSAEER, 
were detected in both 2+ and 3+ charge states. HCD and UVPD spectra for 
TVDMEpSTEVFTK are displayed in Figure 1A-B.  
                            
 
 
Figure 4.1 MS/MS analysis of doubly charged TVDMEpSTEVFTK (m/z 733.8 in 
positive mode and m/z 731.8 in negative mode) from alpha S2 casein 
using (A) positive mode HCD, (B) positive mode UVPD, and (C) negative 
UVPD. Two laser pulses of 2.5 mJ were used for UVPD, and 30 NCE was 
applied for HCD. Each spectrum is the average of five scans. 
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For both activation methods, the dominant product ions series are b and y ions; 
however, UVPD also yields numerous a, x, c, and z ions, which contribute to an overall 
richer MS/MS spectrum. The additional product ions generated by UVPD have the 
potential to facilitate more confident peptide identifications when using database search 
programs as previously demonstrated for unmodified peptides.
27
 Significantly higher 
Sequest Xcorr scores for UVPD compared to HCD for seven out of the eleven peptides 
examined (Figure 4.2 and 4.3) are a direct indication of more confident sequence 
assignments.  
 
 
Figure 4.2  Xcorr scores for phosphopeptides in the 2+ charge state identified from 
alpha and beta casein using UVPD (red) and HCD (blue).   
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Figure 4.3  Xcorr scores for phosphopeptides in the 2+ charge state identified from 
alpha and beta casein using UVPD (red) and HCD (blue).   
 
Even small increases in Xcorr can help to distinguish the correct peptide sequence from 
false matches as demonstrated by the commonly used ΔCn threshold of just 0.1, where 
ΔCn represents the difference in Xcorr between the highest scoring candidate and each 
lower scoring candidate.
49
  
For peptides that carry PTMs, retention of modifications on product ions is 
critical in order to facilitate accurate localization within the peptide sequence. For 
TVDMEpSTEVFTK, phosphate neutral losses from y7, y8, y9, and y10 are among the 
most abundant product ions in the HCD spectrum (Figure 4.1A), and the abundances of 
these ions exceed those of their phosphate-retaining counterparts. In contrast, the 
abundances of the phosphate-retaining y7, y8, y9, and y10 ions produced upon UVPD of 
TVDMEpSTEVFTK are greater compared to the same y-ions, which undergo phosphate 
neutral loss (Figure 4.1B). Greater phosphate retention using UVPD is consistent with 
recent reports and is believed to be a result of the fast and high energy deposition upon 
absorption of 193 nm photons (6.4 eV per photon) compared to lower energy, step-wise 
collisional activation methods such as CID and HCD.
44
 When the abundances of 
phosphate-retaining product ions were compared to the abundances of phosphate neutral 
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loss product ions, all eleven casein phosphopeptides exhibited improved phosphate 
retention when subjected to UVPD compared to HCD. In Figure 4.4 and 4.5, the 
abundance of phosphate-retaining product ions is plotted for each peptide as a percentage 
of the total abundance of product ions that include the site of phosphorylation. All ions 
series were considered for UVPD, while a, b, and y ions were considered for HCD.  An 
average increase in phosphate retention of 20% for doubly charged peptides and 25% for 
triply charged peptides was observed using UVPD.  
 
 
 
Figure 4.4  Percent phosphate retention on product ions for 2+ phosphopeptides 
identified from alpha and beta casein using UVPD (red) and HCD (blue).   
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Figure 4.5  Percent phosphate retention on product ions for 2+ phosphopeptides 
identified from alpha and beta casein using UVPD (red) and HCD (blue).   
 
Photodissociation of deprotonated phosphopeptides yielded significantly different 
fragmentation patterns compared to the UVPD spectra of protonated phosphopeptides. 
For UVPD of doubly deprotonated TVDMEpSTEVFTK, a and x ions accounted for full 
sequence coverage (Figure 4.1C). The phosphate neutral loss behavior also differed, with 
very few product ions exhibiting phosphate neutral loss for the deprotonated 
phosphopeptides. This is in stark contrast to both UVPD and HCD of doubly protonated 
TVDMEpSTEVFTK (Figure 4.1A-B) for which nearly every product ion that included 
the phosphorylated residue experienced some degree of phosphate loss. Despite superior 
phosphate retention of deprotonated peptides, the ionization efficiency in the negative 
mode is lower than the positive mode for phosphopeptides and most classes of peptides, 
making it challenging to adopt negative polarity UVPD-MS for large scale analysis.
50
   
Only the most highly phosphorylated peptides with the greatest net negative 
charge, ionized more efficiently in negative mode compared to positive mode.  
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These peptides included:  
 QMEAEpSIpSpSpSEEIVPNpSVEQK  
 NTMEHVpSpSpSEESIIpSQETYK 
 ELEELNVPGEIVEpSLpSpSpSEESITR 
 RELEELNVPGEIVEpSLpSpSpSEESITR  
 
To aid in the detection of these peptides, hydroxyapatite (HAP) enrichment was used 
based on the previously demonstrated propensity for isolation of phosphopeptides with 
higher phosphorylation states as well as acidic sequence motifs.
51,52
 Following HAP 
enrichment, phosphopeptides were desalted using either graphite SPE or C18 SPE to 
ensure recovery of both hydrophilic and hydrophobic peptides. In Figure 4.6A-B, LC-
MS base peak chromatograms are displayed for positive mode and negative mode ESI-
MS analysis of the same HAP-enriched casein protein digest. Chromatographic peaks 
shaded in blue represent peptides recovered from C18 SPE and peaks shaded in purple 
represent peptides recovered using graphite SPE. The most hydrophilic peptides, 
QMEAEpSIpSpSpSEEIVPNpSVEQK and NTMEHVpSpSpSEESIIpSQETYK, were 
only detected following desalting on graphite while all other peptides were effectively 
recovered after desalting on C18. In positive mode (Figure 4.6A), singly and doubly 
phosphorylated peptides were preferentially detected while the most highly 
phosphorylated peptides from alpha and beta casein were not detected. These peptides, 
each modified with at least four and up to five negatively charged phosphates, ionized 
more efficiently in negative mode while at the same time ionization was suppressed for 
peptides in lower phosphorylation states (Figure 4.6B). UVPD was applied for 
characterization of these multiply phosphorylated peptides. Regardless of the peptide 
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length and number of phosphorylations, the sequence coverage afforded by UVPD 
remained high with no significant phosphate neutral losses observed as demonstrated for 
UVPD of quadruply deprotonated QMEAEpSIpSpSpSEEIVPNpSVEQK shown in 
Figure 4.6C. While UVPD in the negative ion mode has shown merit for phosphopeptide 
characterization, especially for peptides in high phosphorylation states, improvements in 
ionization efficiency are required before negative UVPD can be routinely implemented 
on a larger scale. Thus UVPD analysis in the positive mode will be the focus of the 
remainder of the study. 
 
 
 
 
Figure 4.6  Based peak MS1 chromatograms for (A) positive mode and (B) negative 
LC-MS analysis of alpha S1, alpha S2, and beta casein phosphopeptides 
enriched on hydroxyapatite beads. Chromatographic peaks shaded in blue 
are recovered following C18 SPE and those shaded in purple are 
recovered using graphite SPE. (C) UVPD mass spectrum for 
phosphopeptide, QMEAEpSIpSpSpSEEIVPNpSVEQK (4-, m/z 679.61), 
from alpha S1 casein using two 2 mJ pulses.  Five UVPD spectra were 
averaged over retention time 10.98-11.96 min.  
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4.4.2 UVPD and HCD Analysis of HeLa Phosphopeptides 
To evaluate the performance of UVPD for phosphopeptide analysis on a more 
global scale, phosphopeptides were enriched from a HeLa cell lysate using Fe(III)-
IMAC. UVPD and HCD analyses of the IMAC-enriched HeLa digests were carried out in 
triplicate using an Orbitrap Fusion mass spectrometer using high resolution/high accuracy 
analysis for both precursor ions and fragment ions.  This dual high accuracy mode 
improves the accuracy of peptide identifications, especially for UVPD which uses a 
greater search space to account for all possible product ion series.  
 
 
 
Figure 4.7 Comparison of UVPD and HCD for HeLa phosphoproteome analysis: (A) 
overlap between UVPD- identified and HCD-identified phosphopeptides 
and phosphoproteins, (B) phosphorylation site localization performance, 
(C) phosphate retention on product ions, (D) phosphopeptide charge state 
distribution, and (E) phosphopeptide length distribution. All results are 
based on three replicate UVPD and HCD LC-MS runs.  
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Greater depth of coverage was achieved using HCD for which 6,565 phosphopeptides 
and 2,027 phosphoproteins where identified compared to 3,945 phosphopeptides and 
1,500 phosphoproteins for UVPD (Figure 4.7A-B), consistent with recent results 
reported in another study.
44
 Not all UVPD identifications were encompassed by the larger 
HCD dataset as shown in the Venn diagrams in Figure 4.7A; 231 phosphopeptides, 
corresponding to 49 phosphoproteins, were uniquely identified using UVPD.  
When the overlap between replicate runs acquired using the same activation mode 
was evaluated, a significant amount of variation was observed as well. On average 63% 
of the peptides from each individual run were also identified in the other two replicate 
runs (Figure 4.8A). The overlap in protein identifications was greater with 77% of 
proteins from each run detected in all three replicates (Figure 4.8B). 
 
               
 
Figure 4.8  Overlap in (A) peptide and (B) protein identifications from IMAC-
enriched HeLa analyzed in triplicate using UVPD and HCD. 
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The variations in peptide and protein identifications between replicate runs are a 
reflection of the sample complexity, which results in selection of different precursor ions 
for MS/MS analysis in each LC-MS run. Comparing UVPD and HCD based on the 
collective results from triplicate analysis improves the likelihood that differences in 
observed peptide and protein identifications are specifically related to the activation 
method and not due to random sampling or under-sampling in the MS/MS workflow.  
In addition to the number of peptide and protein identifications, other properties 
of the phosphopeptides identified by UVPD and HCD were explored and compared. 
Consistent with the results for alpha and beta casein, the average Xcorr score of UVPD-
identified peptides (4.3) was greater than the average Xcorr score of HCD-identified 
peptides (3.6) (Figure 4.7B). Despite higher Xcorr scores that are indicative of more 
extensive fragmentation, phosphate localization using phosphoRS was slightly less 
successful for UVPD (localization rate of 74%) compared to HCD (81%) based on the 
lower number of peptides with a phosphoRS isoform probability greater than 75% 
(Figure 4.7B). This result was unexpected given the trend of greater phosphate retention 
on UVPD-generated product ions that was observed for phosphopeptides from alpha and 
beta casein. Thus, the percent phosphate retention on UVPD versus HCD product ions 
was also evaluated for the HeLa dataset. For all peptides in the same charge state and 
considering only the product ions that contained the site of phosphorylation and therefore 
could undergo neutral loss, the ion abundances for phosphate-retaining ions and the 
corresponding phosphate loss ions were summed. Using these values, the percent 
phosphate retention was calculated by the following equation: 
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The results for peptides in the 2+, 3+, and ≥4+ charge states are plotted in Figure 4.7C. 
For all charge states, UVPD product ions exhibited greater phosphate retention compared 
to HCD. The improvement using UVPD compared to HCD is greatest for peptides in 
lower charge states for which the lower overall proton mobility leads to increased 
phosphate rearrangement and loss upon collisional activation.
53,54
 For doubly charged 
peptides an 18% increase in phosphate retention was achieved using UVPD relative to 
HCD, and for a 22% increase was achieved for triply charged peptides. These results 
suggest that UVPD should perform as well if not better than HCD for phosphorylation 
site assignment. Consequently, lower UVPD localization rates are likely the result of 
using non-optimal localization parameters associated with the phophoRS algorithm. With 
the current photodissociation set-up on the Orbitrap Fusion, UVPD spectra are designated 
as CID events at zero normalized collision energy. Thus UVPD data is processed by 
phosphoRS localization software analogous to CID data, and only singly and doubly 
charged b and y ions are considered for localization.
55
 While b and y ions do constitute 
the majority of the UVPD product ion current, other ion types also contribute as shown in 
the bar graphs in Figure 4.9A-B which display the distribution of a, b, c, x, y, and z ions 
based on the total number of ions (4.9A) as well as the abundances of each ion type 
(4.9B). Further, the UVPD product ion distributions appears to be charge state dependent 
with the ratio of y ions to other product ion types decreasing as the peptide charge 
increases, indicating a shift toward more uniform product ion distribution for peptides in 
higher charge states. When these and other characteristic UVPD fragmentation trends are 
incorporated into phosphorylation localization software, the accuracy of phosphorylation 
site assignment will likely improve and better reflect the improvements in phosphate 
retention and extent of fragmentation that is observed for UVPD. 
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Figure 4.9  Distribution of a, b, c, x, y, and z product ions observed for 
phosphopeptides from IMAC enriched HeLa displayed as percentages of 
(A) total ion counts and (B) ion abundances. 
 
In addition to scoring and localization results, several more general characteristics 
of HeLa phosphopeptides were compared to further distinguish the performance metrics 
of UVPD and HCD. In Figure 4.7D, the distributions of 2+, 3+, and more highly charged 
(>3+) peptides identified by UVPD and HCD are displayed. Singly charged 
phosphopeptides are not included in this comparison because only a handful of singly 
protonated phosphopeptides were identified, thus prohibiting adequate statistical 
comparisons.  While the charge state distributions for UVPD and HCD were similar, a 
larger percentage of phosphopeptides specifically identified by UVPD were doubly 
charged compared to HCD, the latter, which identified a larger percentage of more highly 
charged phosphopeptides. Although subtle, this trend reinforces previous results 
demonstrating successful UVPD even for peptides with low proton mobility.
33,34
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UVPD versus HCD (Figure 4.7E), and UVPD appeared to outperform HCD for the 
detection of short peptides containing fewer than 12 amino acids. Because shorter 
peptides are likely to carry fewer charges, the UVPD length distribution correlates well 
with the UVPD charge state distribution. Finally, differences in the overall 
phosphorylation state as well as differences in the individual frequencies of phospho-
serine, phospho-threonine, and phospho-tyrosine were explored for UVPD and HCD 
phosphopeptides (Table 4.1). Singly phosphorylated peptides were most commonly 
observed using both UVPD and HCD for which only 5% and 10% of peptides were 
detected with more than one phosphorylation, respectively. The distributions of 
phosphorylation sites found on serine, threonine, and tyrosine residues was almost 
identical between the two activation methods, in addition to closely agreeing with 
previously reported distributions for human cell lines, lending additional validity to both 
datasets.
56
   
 
 
 
Table 4.1 Distribution of phosphorylation observed for IMAC enriched HeLa 
analyzed by UVPD and HCD. The percentage of singly, doubly, and 
multiply (3 or greater phosphorylations) phosphorylated peptides are 
displayed along with the frequency of occurrence on serine, threonine, and 
tyrosine. 
 
% Single 
phospho
% Double 
phospho
% Multi
phospho
% pSer % pThr % pTyr
UVPD 95% 5% <1% 84% 16% 1%
HCD 89% 10% <1% 85% 15% 1%
Phosphorylation distribution in IMAC enriched HeLa
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4.4.3 Alternating Activation of HeLa Phosphopeptides 
To this point, no significant differences related to UV photoactivation could 
account for the disparity in the number of peptide and protein identifications compared to 
HCD. A series of experiments in which HCD and UVPD were implemented in back-to-
back alternating scans were carried out to further investigate the basis for the lower 
number of UVPD identifications.  
 
 
 
Figure 4.10  Overlap in peptide identifications from IMAC-enriched HeLa analyzed 
using UVPD and HCD applied in (A) separate LCMS runs or (B-D) 
alternated for each precursor selected within the same LC-MS run. For 
alternating UVPD/HCD runs, 100 ms and 300 ms maximum ion injection 
times were applied with a 5E4 MS2 threshold in B and C, respectively.  
The threshold for MS2 selection was increased to 5E6 with a 100 ms 
maximum injection time in D.  
 
First separate UVPD-only and HCD-only analyses were performed to provide a 
baseline for comparison (Figure 4.10A). The number of scans averaged was reduced 
from two to one for this experiment to minimize the time penalty for UVPD which 
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requires 2 ms per laser pulse used for activation in contrast to the faster sub-millisecond 
HCD activation period. In subsequent LC-MS runs, UVPD and HCD were carried out 
within the same analysis as consecutive, alternating activation events, ensuring identical 
precursor selection and number of MS/MS acquisitions for each activation method. Based 
on the data sets acquired using the alternating MS/MS scan mode, the difference in the 
number of UVPD and HCD peptide identifications dramatically decreased; however, 
there were still 1022 unique HCD peptides (Figure 4.10B) indicating an additional 
handicap associated with UVPD.  
Sensitivity is also a concern for UVPD because UVPD results in a greater array of 
fragment ions, thus sub-dividing ion current into more channels.  The overall lower ion 
load for a phosphoproteomics sample relative to a complete proteome exacerbates this 
problem.
44
 To evaluate differences in MS/MS sensitivity between UVPD and HCD, two 
additional alternating LC-MS/MS experiments were conducted in which low abundance 
precursor ions were either excluded from activation by raising the threshold for MS2 
selection, or their abundances were boosted by increasing the maximum ion injection 
time. When the maximum ion injection time was increased from 100 ms to 300 ms 
(Figure 4.10C), the overlap in peptide identifications substantially improved while the 
number of unique peptides was reduced to 71 for UVPD and 319 for HCD.  The best 
overlap between activation techniques was achieved when MS/MS activation was 
restricted to precursor ions with abundances greater than or equal to 5E6 (Figure 4.10D), 
suggesting that UVPD can approach the same depth of protein identifications when 
existing sensitivity and speed limitations are further improved.  
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4.4.4 HCC70 Lysate Analysis 
 The HCC70 cell line is a primary ductal carcinoma that is classified as triple 
negative because the cells lack the genes for estrogen receptor, progesterone receptor, and 
human epidermal growth factor receptor 2.
57–59
 Because these receptors are the primary 
targets of current chemotherapies, triple negative breast cancers are more difficult to treat 
and have a poorer prognosis, thus representing an important area of research.
60
 Two 
HCC70 lysates, one maintained in full serum and the other serum-starved for 6 hrs prior 
to lysis, were analyzed by UVPD and HCD. Consistent with HeLa results, HCD 
identified more peptides and proteins than UVPD, but similar trends between serum-fed 
and serum-starved cells were observed using both activation methods (Figure 4.11). For 
both HCD and UVPD analyses, a greater number of phosphopeptides and 
phosphoproteins were observed in the serum-starved sample (Figure 4.11A-B) for which 
phosphorylation is expected to be more homogenous based on cell synchronization in G0 
phase. Collectively, for both serum-fed and serum-starved cells using UVPD and HCD, 
9324 total phosphorylation sites were identified from 13417 phosphopeptides which 
accounted for 3134 phosphoproteins. Compared to HCD alone, integration of the UVPD 
and HCD data sets resulted in 207 additional phosphopeptides and 24 additional 
phosphoproteins (Figure 4.11C), thus showing the gains in using UVPD and HCD as 
complementary methods to extend phosphoprotein analysis. 
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Figure 4.11 HCC70 phosphoproteomics results from UVPD and HCD analysis. (A) 
Overlap in peptide for cells maintained in full serum (fed) compared to 
cells that were serum-starved prior to lysis. (B) Number of 
phosphoproteins and unique phosphosites identified in serum-fed and 
serum-starved samples using UVPD and HCD. (C) Overlap in total UVPD 
and HCD peptides and proteins from both serum-fed and serum-starved 
cells.  
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4.5 CONCLUSION 
 Photodissociation at 193 nm offers several promising benefits compared to other 
activation methods for the analysis of phosphopeptides. The functionality of UVPD for 
sequencing both peptide cations and anions enabled phosphopeptide characterization 
across a wider range of phosphorylation states spanning from monophosphorylated 
peptides up to pentaphosphorylated peptides. The most highly phosphorylated peptides 
required negative mode analysis for detection, while peptides in lower phosphorylation 
states were effectively detected in the positive ion mode. Compared to HCD, UVPD 
facilitated more confident phosphosite determination based on both the greater array of 
product ions that were generated and the improved phosphate retention on those product 
ions. For the analysis of phosphopeptides from a HeLa cell lysate, no significant 
differences in the phosphopeptide populations were observed between UVPD and HCD 
data sets, but the overall number of identifications was lower for UVPD based on lower 
speed and sensitivity compared to HCD. While the speed of UVPD is ultimately limited 
by the repetition rate of the laser, improvements in sensitivity are anticipated with further 
development and optimization of UVPD-MS instrumentation. In its current state, UVPD 
remains a complementary technique to HCD for phosphopeptide characterization and can 
be used strategically to increase the overall depth of coverage for phosphoproteomics 
experiments.  
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Chapter 5 
Phosphorylation Mapping the C-terminal Domain of RNA Polymerase 
II using Ultraviolet Photodissociation Mass Spectrometry 
 
5.1 OVERVIEW 
Phosphorylation in the C-terminal domain (CTD) of RNA polymerase II plays a 
critical role in regulating transcription. A novel method for phosphorylation mapping in 
wild type CTD from yeast (Saccharomyces cerevisiae) and fruit fly (Drosophila 
melanogaster) is presented which combines alternative proteolysis using proteinase K or 
chymotrypsin and ultraviolet photodissociation tandem mass spectrometry to attain 
residue resolved phosphorylation information. Two kinases, Erk2 and TFIIH, were used 
to phosphorylated the CTD. For yeast CTD, single phosphorylations on Ser2 or Ser5 in 
the consensus heptad, YSPTSPS, were observed across all experimental conditions. 
Phosphorylation also occurred preferentially at Ser2 and Ser5 in the fruit fly CTD, and 
the phosphorylation marks in divergent heptads revealed the significance of Tyr and Pro 
residues for phosphorylation to occur. 
 
5.2 INTRODUCTION 
The “CTD Code” refers to the collection of post-translational modifications that 
are reversibly added to the C-terminal domain (CTD) of RNA polymerase II (RNAP II), 
a eukaryotic protein complex involved in transcription, as well as their associated protein 
factors.
1–5
 A species-specific number of repeats of the consensus amino acid heptad, 
Tyr1-Ser2-Pro3-Thr4-Ser5-Pro6-Ser7, make up the CTD.
6
 Phosphorylation may occur at 
Tyr1, Ser2, Thr4, Ser5, and Ser7, leading to many potential phosphorylation patterns 
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which act to coordinate the recruitment of protein factors that influence transcription at 
different stages and promote RNA processing, gene regulation, and accurate initiation 
and termination of transcription.
7
 Historically, phosphorylation in the CTD has been 
studied using specific monoclonal antibodies against modifications of the consensus 
heptad, but these methods suffer from several inherent limitations. Because antibodies are 
raised against consensus CTD, heptads that diverge from the consensus sequence will not 
be recognized which precludes confident phosphorylation characterization in these 
regions. The similarity of phosphate accepting motifs (i.e. YS2P vs. TS5P vs. PS7Y) also 
presents the opportunity for potential antibody cross-reactivity across multiple 
phosphorylation sites. Finally, antibodies cannot identify the location of phosphorylation 
marks in the context of the full length CTD sequence.  
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) can provide 
more detailed information for peptide and protein sequencing; however, MS/MS methods 
for phosphorylation analysis are hindered by several shortcomings. Phosphate neutral 
loss is the dominant product of collision induced dissociation (CID) methods which 
promote cleavage of the most labile bonds.
8,9
 To address this problem, a beam type CID 
configuration termed higher energy collisional dissociation (HCD) has been adopted to 
impart higher energy to peptide ions, thus improving backbone fragmentation.
10
 While 
HCD offers an improved method for phosphopeptide characterization, not all peptides 
fragment equally well and those in low charge states frequently display limited sequence 
coverage and/or loss of the modifications which impedes their localization. 
Electron transfer dissociation (ETD) and electron capture dissociation (ECD) are 
peptide sequencing methods that are considered complementary to collision based 
methods, although fragmentation efficiency remains largely dictated by peptide charge 
state.
11
 Peptide cations must have at least two charges to avoid neutralization upon 
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electron capture or transfer, and three or more charges are needed for optimal 
dissociation. For phosphopeptides that meet these criteria, unparalleled modification 
retention is observed on both precursor and product ions leading to highly confident 
phosphorylation site assignment.
12–16
  For this reason, ETD and ECD remain attractive 
alternatives to CID and HCD for phosphopeptide analysis despite any inherent 
difficulties for achieving sufficient positive charge density on peptides that carry acidic 
modifications.  
Ultraviolet photodissociation (UVPD) using 193 nm photons is an alternative to 
collision and electron based activation methods that offers several advantages for 
phosphorylation mapping in the CTD. Charge state bias is largely overcome using 
UVPD, and high sequence coverage has been demonstrated even for singly charged 
precursor ions.
17–21
 The high energy deposition (6.4 eV) that is achieved upon absorption 
of a 193 nm photon permits access to fragmentation pathways that are not available using 
traditional methods leading to the formation of a, b, c, x, y, and z ions which account for 
cleavage of each bond in the peptide backbone.
22
 The greater number of product ions 
obtained using UVPD increases the confidence of peptide sequencing results while also 
improving the ability to pinpoint the sites of potential modifications. Another merit of 
UVPD is the ability to generate diagnostic product ions from peptide anions.
23–26
  
Although peptide analysis is generally undertaken in the positive ion mode based on 
greater sensitivity and number of applicable MS/MS techniques, the negative mode offers 
unique benefits for certain types of peptides. This is especially true for characterization of 
labile PTMs including phosphorylation, sulfation, and O-glycosylation, all of which 
exhibit superior retention using negative mode UVPD.
23,27–30
 Alternating between 
positive and negative electrospray ionization modes is easily done, even within a single 
LCMS run, thus further increasing the versatility of UVPD-MS.   
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The unique structure of the CTD adds another layer of complexity to an already 
challenging phosphoproteomics problem. A significant portion of the CTD is comprised 
of serine, threonine, and tyrosine residues while lysine and arginine, basic residues that 
facilitate trypsin proteolysis and subsequent protonation of peptides, represent only a 
minor component of the protein sequence, if present at all. To determine the correct 
phosphorylation pattern when there are many putative sites for modification, complete 
sequence coverage is critical but difficult to achieve for CTD peptides that lack the basic 
character required to fragment well using conventional activation methods. To 
circumvent the lack of tryptic cleavage sites in wild type CTD, Lys and Arg were 
incorporated into yeast
31
 and human
32
 CTDs to permit digestion and facilitate 
phosphorylation localization. CID analysis of the mutant constructs revealed that 
phosphorylation is evenly dispersed throughout the length of CTD; significantly more 
abundant on Ser2 and Ser5 compared to other sites; and significantly less dense than once 
thought, with the most heptads only accepting a single phosphate.
31,32
 In the present 
study, alternative proteolysis using proteinase K and chymotrypsin was employed to 
digest wild type CTD from yeast (Saccharomyces cerevisiae) and fruit fly (Drosophila 
melanogaster). UVPD was used to its full advantage in both positive and negative modes 
to elucidate the phosphorylation patterns following treatment with two kinases, Erk2 and 
TFIIH. 
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5.3 EXPERIMENTAL 
5.3.1 Materials 
Sequencing grade chymotrypsin was obtained from Promega (Madison, WI) and 
MS grade Pierce trypsin was obtained from Thermo Fisher Scientific (Grand Island, NY). 
LC-MS grade solvents were obtained from EMD Millipore (Temecula, CA). Other 
reagents were obtained from Sigma (St. Louis, MO). Integrafrit columns (360 µm O.D. x 
100 µm I.D.) and picofrit columns (360 µm O.D. x 75 µm I.D. x 30 µm emitter tip I.D.) 
were purchased from New Objective (Woburn, MA). 
 
5.3.2 Sample Preparation 
Yeast GST-CTD samples were prepared for bottom-up analysis using a two step 
proteolysis method. First, overnight digestion at 37 °C with trypsin was carried out using 
a 1:50 enzyme to substrate ratio to cleave within the GST portion of the protein while 
leaving the Lys-free/Arg-free 26mer yeast CTD intact. The resulting digest was passed 
through a 10 KDa molecular weight cutoff (MWCO) filter to both remove tryptic GST 
peptides and buffer exchange the retained 26mer into 50 mM Tris HCl containing 10 mM 
CaCl2 (pH 8) in preparation for subsequent proteinase K digestion. Proteinase K was 
added in a 1:100 ratio and digestion proceeded overnight at 37 °C. Samples were diluted 
to 1 µM in 0.2% formic acid for LC-MS analysis.  
Fruit fly GST-CTD samples were reduced for 30 minutes at 55 °C using 5 mM 
dithiothreitol followed by alkylation of reduced cysteines for 30 minutes at room 
temperature in the dark using 15 mM iodoacetamide. Samples were then diluted into 100 
mM Tris HCl containing 10 mM CaCl2 (pH 8) and digested overnight at room 
temperature with chymotrypsin using a 1:50 enzyme to substrate ratio. Digests were 
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quenched by the addition of 0.5% trifluoroacetic acid and desalted on C18 spin columns. 
Samples were resuspended to 1 µM in 0.1% formic acid for bottom-up LC-MS analysis. 
 For top down analysis, fruit fly CTD5 constructs were buffer exchanged into 
0.1% formic acid using a 7 KDa MWCO Zeba size exclusion spin column (Thermo 
Fisher Scientific). Samples were concentrated to a volume of 1 mg/mL prior to analysis.   
 
5.3.3 MS, LC, and UVPD 
 Bottom-up analysis of the yeast CTD was performed on a Velos Pro dual linear 
ion trap mass spectrometer (Thermo Fisher Scientific, San Jose, Ca) equipped with a 
Coherent ExciStar XS excimer laser (Santa Clara, Ca) operated at 193 nm and 500 Hz as 
previously described for UVPD.
18,33
 Two pulses at 2 mJ were used for photodissociation. 
Separations were carried out on a Dionex Ultimate 3000 nano liquid chromatograph 
configured for preconcentration. Integrafrit trap columns were packed to 3.5 cm using 5 
µm Michrom Magic C18 while picofrit analytical columns were packed to 20 cm using 
3.5 µm Waters Xbridge BEH C18 (Milford, MA). Mobile phase A was water and B was 
acetonitrile, each containing 0.1% formic acid. Peptides were loaded onto the trap 
column for 5 minutes in aqueous solvent containing 2% acetonitrile and 0.1% formic acid 
at a flow rate of 5 µL/min. Separations occurred over a 20 minute linear gradient in 
which the percent B was increased from 2-15% during the first 15 minutes and further 
increased to 35% during the last 5 minutes. The flow rate was maintained at 0.3 µL/min 
during the separation. A top seven data dependent acquisition method was first used to 
identify the main phosphorylated species. A targeted analysis followed in which m/z 818, 
corresponding to the singly phosphorylated heptad peptide, was continually selected for 
UVPD activation (between MS
1
 acquisitions that occurred after every five MS/MS 
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events) in order to better resolve partially co-eluting phospho-isomers. The resulting 
UVPD spectra were manually interpreted.  
Fruit fly CTD peptides were analyzed by LC-MS in both positive and negative 
modes. Negative mode analysis was performed on the Velos Pro mass spectrometer and 
Dionex nano LC equipped with C18 columns as described above. To facilitate the 
formation of peptide anions, methanol was used in place of acetonitrile in mobile phase 
B, and 0.1% trifluoroethanol (TFE) was added to all mobile phases in place of formic 
acid. The loading solvent consisted of 98% water, 2% methanol, and 0.1% TFE. 
Following sample loading at 5 µL/min for 3 minutes, a 50 minute linear gradient from 2-
90% B at a flow rate of 0.25 µL/min was used for separations. MS
1
 spectra were acquired 
from m/z 400-2000 and the top eight most abundant ions were selected for UVPD using a 
single 2 mJ pulse. Dynamic exclusion was enabled with an exclusion duration of 8.00 
seconds. MassMatrix database search engine was used to interpret the negative mode 
UVPD spectra.  
An Orbitrap Fusion Tribrid mass spectrometer (Thermo Fischer Scientific, 
Bremen, Germany) equipped with a Coherent ExciStar XS excimer laser operated at 193 
nm was used for positive mode LC-MS analysis of the fruit fly CTD. The Fusion mass 
spectrometer was modified for UVPD as described earlier.
34
 Nano LC conditions were 
analogous to those described for separations of the yeast CTD, except that peptides were 
loaded directly onto the C18 analytical column and separated over 60 minutes using a 
gradient from 2-40% B. Photoactivation was achieved using 2 pulses at 2 mJ in a 3 ms 
top speed data-dependent method. All data was acquired in the orbitrap where MS
1
 and 
MS
2 
spectra were collected at resolving powers of 60K and 15K (at m/z 200), 
respectively. Data analysis was performed using Proteome Discoverer 2.0. 
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Top down LC-MS analysis of intact CTD5 constructs was carried out on the 
Orbitrap Fusion Tribrid mass spectrometer. The nano LC was set up with a 3 cm 
preconcentration column and a 25 cm analytical column containing PLRP-S resin (5 µm, 
1000 Å) and operated under acidic conditions as described for positive mode bottom-up 
analysis. Each construct was preconcentrated online followed by separation using a fast 
ramp from 2-23% B over 5 minutes followed by a shallower gradient from 23-50 %B 
over 25 minutes. All MS
1
 data was collected at a resolving power of 240K at m/z 200. To 
improve spectral signal-to-noise prior to deconvolution, the maximum number of 
informative spectra were averaged together and subsequently Xtracted at S/N threshold 
of 3 to obtained the deconvolved mass of each construct.  
 
5.3.4 Data Analysis 
 Database search was used to interpret the results from both negative and positive 
mode UVPD analysis of the fruit fly CTD. Regardless of the program used, all data was 
searched against a forward and reverse FASTA database containing only fruit fly and 
yeast GST-CTD sequences. Phosphorylation of serine, threonine, and tyrosine was set as 
a variable modification in all searches and carbamidomethyl was a fixed modification of 
cysteines in only the positive mode searches (reduction and alkylation was not carried out 
prior to negative mode analysis). MassMatrix Xtreme 3.0.10.16, which is programmed to 
search for a, x, c, z, and y type product ions, was used to interpret the negative UVPD 
results. Peptide mass and fragment mass tolerances were ±1.00 Da and ±0.80 Da, 
respectively, and the minimum pp score was 6.0 while the minimum pptag score was 3.0. 
All sites of phosphorylation reported by MassMatrix were manually verified due to the 
lack of companion PTM localization software for negative mode fragmentation results.  
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 Positive UVPD data was analyzed in Proteome Discoverer 2.0 using Sequest HT 
database search and ptmRS site localization software. Prior to database search, a non-
fragment filter was applied to remove precursor peaks from MS/MS spectra within a 1 Da 
window offset. The precursor mass tolerance was 10 ppm, and the fragment mass 
tolerance was 0.02 Da. All possible product ions including a, b, c, x, y, and z ions were 
considered for spectrum matching.  PSMs were validated using a fixed value PSM 
validator which filters matches based on a maximum Delta Cn of 0.05. Strict and relaxed 
target FDR settings were 0.01 and 0.05 respectively for both PSMs and peptides. 
Phosphorylation site localization was achieved using ptmRS operating in PhosphoRS 
mode. Only sites with greater than 99% isoform confidence probability were considered 
localized without further manual inspection. 
 
5.4 RESULTS AND DISCUSSION 
5.4.1 Yeast CTD Analysis 
Phosphorylation mapping of the C-terminal domain of RNA polymerase II was 
initially carried out for the highly consensus yeast CTD based on using a GST-tagged 
version of recombinant CTD. The unique sequence of the yeast GST-CTD required the 
development of a novel proteolytic workflow in order to facilitate characterization of the 
phosphorylation pattern of CTD via bottom-up LC-MS/MS analysis (Figure 5.1A). The 
first step involved removal and separation of the CTD from the GST tag used for protein 
purification. Digestion with trypsin provided an efficient means for this aim based on the 
lack of trypsin cleavage sites in the CTD compared to the GST tag. Passing the digest 
through a 10 KDa molecular weight cut off filter following overnight incubation of GST-
CTD with trypsin allowed retention and efficient recovery of the large CTD peptide, 
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whereas the GST peptides were washed through the filter. Proteinase K, which exhibits 
broad cleavage specify, was subsequently used to digest the purified CTD, resulting in 
the formation of two peptides with sequences YSPTSPS and SPSYSPT. Each peptide 
constituted a complete heptad repeat and thus the sample complexity for the entire GST-
CTD was effectively reduced to two peptides (including all potential phosphoforms) 
generated following kinase treatment.  
 
 
 
Figure 5.1 Analytical workflow for yeast GST-CTD (A) and the resulting LC-MS 
base peak full MS chromatogram (B)  
 
The clean chromatographic traces that are obtained for the yeast CTD following 
trypsin and proteinase K digestion are shown in Figure 5.1B, where the heptad peptides 
are the dominant species in the base peak full MS chromatogram Ultraviolet 
photodissociation at 193 nm and CID were evaluated for sequencing the heptads 
generated by proteinase K digestion. Using UVPD more extensive fragmentation 
including the production of a and x-type sequence ions was achieved (Figure 5.2A-B) 
while the abundance of less informative water loss ions was decreased relative to CID 
(Figure 5.2C-D). Additionally, improved phosphate retention on product ions has been 
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demonstrated for UVPD, making it ultimately better suited for CTD phosphorylation 
analysis following kinase treatment.
35
 
 
 
 
Figure 5.2  UVPD and CID analysis in positive ion mode for singly charged heptad 
peptides YSPTSPS (top, A and C), SPSYSPT (bottom, B and D). Tyr side 
chain losses generated by UVPD are denoted m1 and m4 for YSPTSPS 
and SPSYSPT, respectively.  
 
 Two kinases were used to phosphorylate the yeast CTD including TFIIH and 
Erk2. TFIIH is a multi-protein complex that is necessary for the phosphorylation of Ser 5 
of the CTD during the initiation of RNAP II transcription.
36,37
 Erk2 phosphorylation of 
poised RNAP II has been shown to occur at developmentally important genes.
38
 When 
the yeast GST-CTD was treated with TFIIH kinase, a singly charged ion of m/z 818 
corresponding to the mass of the consensus heptad plus one phosphorylation was 
observed in the LC-MS chromatogram (Figure 5.3A) in addition to the two previously 
detected unmodified heptad peptides of m/z 738 corresponding to YSPTSPS and 
SPSYSPT (Figure 5.1B). The MS/MS spectra acquired during the elution of the 
phospho-heptad showed distinctive variations at different elution time-points, thus 
revealing the presence of two isomers (Figure 5.3C-D).  
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Figure 5.3  LC-MS/UVPD analysis of TFIIH and Erk2 treated yeast GST-CTD 
digested with trypsin and proteinase K. Two singly phosphorylated 
heptads, m/z 818.3, are partially resolved in the base peak MS1 
chromatogram (A,E). In subsequent LC-MS analysis, m/z 818.3 was 
targeted for activation during the course of elution and extracted ion 
chromatograms (XICs) for distinguishing product ions, a4 from 
SPSYpSPT and x5 from YSPTpSPS, were generated to track the isomeric 
peptides (B,F). UVPD using two 2 mJ pulses was used to sequence the 
heptad peptides and localize the sites of phosphorylation (C-D,G-H). Ions 
that have undergone phosphate neutral loss are denoted with “-P”. Tyr side 
chain losses generated by UVPD are denoted m1 and m4 for YSPTSPS 
and SPSYSPT, respectively.  
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Targeted LC-UVPD-MS runs allowed better characterization of the two isomers. Two 
abundant UVPD product ions which were unique to the early (m/z 407, a4 from 
SPSYpSPT) and late (m/z 594, x5 from YSPTpSPS) portions of the elution profile were 
identified. Extracted ion chromatograms (Figure 5.3B) revealed that the two ions 
matched to different heptad peptides with phosphorylation at different positions as 
defined by the consensus sequence (YSPTSPS). The UVPD mass spectra confirmed the 
sequences as SPSYpSPT with phosphorylation on Ser2 (Figure 5.3C) and YSPTpSPS 
with phosphorylation on Ser5 (Figure 5.3D). In addition to the unique a4 (SPSYpSPT) 
and x5 (YSPTpSPS) ions, other diagnostic ions that confidently differentiated each of the 
two phosphopeptides were y2 and a2 and the presence or absence of y6.  
The LC-UVPD-MS results obtained for yeast GST-CTD treated with Erk2 kinase 
mirrored those observed following TFIIH reaction in terms of the detection and 
differentiation of the same two phosphorylated heptads (Figure 5.3E-F). Again, 
phosphorylation was confirmed at Ser2 and Ser5 upon Erk2 treatment of CTD based on 
the UVPD mass spectra (Figure 5.3G-H), but never at both sites within the same heptad 
thus providing further evidence that phosphorylation in the CTD is non-saturating and 
may only occur once per heptad.
31,32
 Phosphorylation was not detected at Ser7, Thr4, or 
Tyr1, meaning that these species were either not present or not abundant enough to be 
detected without phospho-enrichment.  
 
5.4.2 Fruit Fly CTD Analysis 
The high degree of divergence from the consensus sequence within the fruit fly 
CTD (only 2 out of 45 heptads adhere to the consensus sequence) allows 
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phosphorylations to be mapped not only within individual heptads but also in the greater 
context of the protein sequence. Moreover, the role that specific neighboring residues 
play in modulating phosphorylation within each heptad can be explored. In order to fully 
characterize the fruit fly CTD and its phosphorylation pattern, a different digestion 
protocol was implemented to account for the deviations from the consensus sequence. 
The presence of lysine and arginine residues throughout the fruit fly CTD sequence 
precluded the use of trypsin for selective digestion and removal of the GST-tag as was 
undertaken for the yeast CTD. In addition, the low frequency of cleavage sites throughout 
the fruit fly CTD prohibited tryptic digestion into appropriately sized peptides for bottom 
up LC-MS analysis, and alternative proteases were evaluated. Proteinase K was rejected 
for its poorly defined cleavage specificity and tendency to cleave at multiple sites within 
each heptad as demonstrated for the yeast CTD in which cleavage occurred C-terminal to 
both Thr4 and Ser7 rather than as expected C-terminal to tyrosine.
39
 Deviation from the 
consensus sequence makes the cleavage specificity of proteinase K even more difficult to 
predict within the fruit fly CTD. More importantly, because the fruit fly CTD is 
composed of mostly unique heptads instead of many repeating consensus units, 
competing cleavage channels would lower the abundance of each individual peptide 
while also increasing the sample complexity of an already more complicated digest.  
As an alternative approach, chymotrypsin, which cleaves more consistently C-
terminal to aromatic residues and to a lesser extent Met, Leu, and His, was ultimately 
used to achieve a more optimal degree of proteolysis within the fruit fly CTD. Missed 
cleavages were common and the majority of peptides spanned two or more heptads. To 
account for the possibility of di- and tri-phosphorylated species arising from 
phosphorylation in neighboring heptads of multi-heptad long peptides, the fruit fly CTD 
was analyzed by UVPD in both positive and negative ion modes (i.e. analysis of 
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protonated and deprotonated phosphopeptides, respectively). The negative mode UVPD-
MS analysis ensured the detection of multiply phosphorylated peptides which ionize 
more readily as anions instead of cations. Additionally, several different fruit fly CTD 
constructs with varying degrees of truncation relative to the full length CTD protein were 
prepared in order to target specific regions of the CTD and thereby decrease the overall 
complexity in each LC-MS run. The sequences of the various CTD constructs are 
summarized in Table 5.1. CTD2 and CTD3 included the N-terminal region of the protein 
from heptad 1-16 and 1-25, respectively, whereas CTD4 included the C-terminal region 
from heptad 26-45. CTD5 covered an interior region of the protein spanning heptads 16-
24. In comparison to the full length fruit fly CTD, the majority of peptide identifications 
from the truncated constructs provided only redundant sequence and phosphorylation site 
information. CTD4 was the only exception yielding a single unique phosphopeptide, 
SPApSPKYSPTSPL, which was identified in both positive and negative modes.  
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Table 5.1 Full length fruit fly CTD and constructs CTD2, CTD3, CTD4, and CTD5. 
Each sequence includes the N-terminal GST-tag  
 
Positive mode UVPD analysis provided the best overall sequence coverage of the 
fruit fly CTD. Following treatment with Erk2, 22 phosphopeptides were identified 
accounting for 20 unique phosphosites from 20 individual heptads (Table 5.2A). 
Phosphorylation of two additional heptads was also detected but without confident 
localization to one specific serine, threonine, or tyrosine residue (Table 5.2B).  
Full length Drosophila GST-CTD
MHHHHHHSSMSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVK
LTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCH
KTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGG
GDHPPKSSSLEVLFQGPGSGMSPSYSPTSPNYTASSPGGASPNYSPSSPNYSPTSPLYASPRYASTTPNFNP
QSTGYSPSSSGYSPTSPVYSPTVQFQSSPSFAGSGSNIYSPGNAYSPSSSNYSPNSPSYSPTSPSYLPSSPSY
SPTSPCYSPTSPSYSPTSPNYTPVTPSYSPTSPNYSASPQYSPASPAYSQTGVKYSPTSPTYSPPSPSYDGSP
GSPQYTPGSPQYSPASPKYSPTSPLYSPSSPQHSPSNQYSPTGSTYSATSPRYSPNMSIYSPSSTKYSPTSPT
YTPTARNYSPTSPMYSPTAPSHYSPTSPAYSPSSPTFEESED
CTD2: Heptads 1-16
MHHHHHHSSMSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVK
LTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCH
KTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGG
GDHPPKSSSLEVLFQGPGSGMSPSYSPTSPNYTASSPGGASPNYSPSSPNYSPTSPLYASPRYASTTPNFNP
QSTGYSPSSSGYSPTSPVYSPTVQFQSSPSFAGSGSNIYSPGNAYSPSSSNY
CTD3: Heptads 1-25
MHHHHHHSSMSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVK
LTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCH
KTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGG
GDHPPKSSSLEVLFQGPGSGMSPSYSPTSPNYTASSPGGASPNYSPSSPNYSPTSPLYASPRYASTTPNFNP
QSTGYSPSSSGYSPTSPVYSPTVQFQSSPSFAGSGSNIYSPGNAYSPSSSNYSPNSPSYSPTSPSYSPSSPSY
SPTSPCYSPTSPSYSPTSPNYTPVTPSYSPTSPNYSASP
CTD4: Heptads 26-45 
MHHHHHHSSMSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVK
LTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCH
KTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGG
GDHPPKSSSLEVLFQGPGSGMQYSPASPAYSQTGVKYSPTSPTYSPPSPSYDGSPGSPQYTPGSPQYSPAS
PKYSPTSPLYSPSSPQHSPSNQYSPTGSTYSATSPRYSPNMSIYSPSSTKYSPTSPTYTPTARNYSPTSPMYS
PTAPSHYSPTSPAYSPSSPTFEESED
CTD5: Heptads 16-24
MHHHHHHSSMSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVK
LTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCH
KTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGG
GDHPPKSSSLEVLFQGPGSGMYSPSSSNYSPNSPSYSPTSPSYSPSSPSYSPTSPCYSPTSPSYSPTSPNYTP
VTPSYSPTSPN
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Table 5.2 Phosphopeptides with localized (A) and ambiguous (B) modification sites 
identified from Erk2 treated Drosophila CTD using positive mode UVPD. 
Phosphorylated residues are preceded by a lowercase “p” in the peptide 
sequence. The sites of localized phosphorylations are shown in red while 
ambiguous phosphorylations are shown in purple with all potential sites 
for a single phosphorylation to reside grouped together by parenthesis. 
The heptad number, phosphorylation site within each heptad, and the 
Drosophila CTD construct that each peptide was identified in are listed in 
columns to the right. Full indicates the full length Drosophila CTD, while  
CTD4 includes only heptads 26-45.  
 
Fewer overall phosphopeptides were identified using negative UVPD (Table 5.3A-B); 
however, one phosphosite from heptad 5 that could not be pinpointed by positive UVPD 
Table 2A: CTD peptides with localized phosphosites from positive mode UVPD analysis
Sequence Heptad #  (Phosphosite in Heptad) Construct
TASSPGGASPNYSPSSPNYSPTpSPLY 6 (S5) Full
YApSPRYASTTPNFNPQSTGY 7 (S5) Full
ASPRYASTpTPNFNPQSTGY 8 (T5) Full
SPTpSPVYpSPTVQF 11 (S5), 12 (S2) Full
QSpSPSFAGSGSNIY 13 (S5) Full
QSSPSFAGSGSNIYpSPGNAY 15 (S2) Full
SPGNAYpSPSSSNY 16 (S2) Full
SASPQYSPApSPAYSQTGVKY 26 (S5) Full
SPApSPAYSQTGVKY 26 (S5) Full
SPApSPKYSPTSPL 32 (S5) CTD4
YSPSSPQHSPSNQYpSPTGSTY 36 (S2) Full
SATpSPRYSPNMSIYSPSSTKY 37 (S5) Full
SATSPRYpSPNMSIY 38 (S2) Full, CTD4
pSPSSTKY 39 (S2) Full
SPTpSPTYpTPTARNY 40 (S5), 41 (T2) Full
SPTSPTYpTPTARNY 41 (T2) Full, CTD4
SPTpSPMYSPTAPSHY 42 (S5) Full, CTD4
SPTpSPMYpSPTAPSHY 42 (S5), 43 (S2) Full
SPTpSPAYSPSpSPTFEESED 44 (S5), 45 (S5) Full
Table 2B: CTD peptides with ambiguous phosphosites from positive mode UVPD analysis
Sequence Heptad #  (Phosphosite in Heptad) Construct
TASSPGGASPNYp(SPSS)PNYSPTpSPLY 5 (S2/S4/S5), 6 (S5) Full
p(SPTS)PTYSPPSPSY 28 (S2/T4/S5) CTD4
p(SPTS)PAYSPSSPTFEESED 44 (S2/T4/S5) Full, CTD4
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was confidently localized by negative UVPD analysis. All other site assignments agreed 
based on the UVPD spectra acquired for the protonated and deprotonated 
phosphopeptides, and the absence of more highly phosphorylated peptides in the negative 
mode UVPD dataset further supported the hypothesis that phosphorylation only occurs at 
one site per heptad.  
 
 
 
 
Table 5.3 Phosphopeptides with localized (A) and ambiguous (B) modification sites 
identified from Erk2 treated Drosophila CTD using negative mode UVPD. 
Phosphorylated residues are preceded by a lowercase “p” in the peptide 
sequence. The sites of localized phosphorylations are shown in red while 
ambiguous phosphorylations are shown in purple with all potential sites 
for a single phosphorylation to reside grouped together by parenthesis. 
The heptad number, phosphorylation site within each heptad, and the 
drosophila CTD construct that each peptide was identified in are listed in 
columns to the right. Full indicates the full length Drosophila CTD, while 
CTD4 includes only heptads 26-45.  
Table 3A: CTD Peptides with localized phosphosites from negative mode UVPD analysis
Sequence Heptad # (Phosphosite in Heptad) Construct
SPSpSPNYSPTpSPLY 5 (S5), 6 (S5) Full
SPSSPNYSPTpSPLY 6 (S5) Full
SPTpSPVYpSPTVQF 11 (S5), 12 (S2) Full
SPTSPVYpSPTVQF 12( S2) Full
QSpSPSFAGSGSNIY 13 (S5) Full
QSSPSFAGSGSNIYpSPGNAY 15 (S2) Full
SPApSPAYSQTGVKY 26 (S5) Full, CTD4
SPApSPKYSPTSPL 32 (S5) CTD4
SIYpSPSSTKY 39 (S2) CTD4
SPTSPMYpSPTAPSHY 43 (S2) Full, CTD4
SPTpSPAYSPSpSPTFEESED 44 (S5), 45 (S5) CTD4
SPTSPAYSPSpSPTFEESED 45 (S5) Full, CTD4
Table 3B: CTD Peptides with ambiguous phosphosites from negative mode UVPD analysis
Sequence Heptad # (Phosphosite in Heptad) Construct
ASp(TT)PNFNPQSTGY 8 (T4/T5) Full
SPp(TS)PVYSPTVQF 11 (T4/S5) Full
SAp(TS)PRYpSPNMSIY 37 (T4/S5), 38 (S2) CTD4
SPp(TS)PAYSPSSPTFEESED 44 (T4/S5) Full, CTD4
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Additional phosphorylation trends are revealed upon examination of all the 
phosphorylation sites in the context of the entire protein sequence as shown in Figure 
5.4A. Displaying the CTD as a series of vertically aligned heptads serves to further map 
the position of phosphorylation within each heptad while also efficiently showing the 
sites in each heptad that have deviated from the consensus sequence. Heptads shaded in 
grey, including heptads 17-24 and 30-31, were not detected by LC-MS in the positive or 
negative modes. The lack of sequence coverage in these regions was also observed prior 
to phosphorylation of CTD with Erk2, indicating that the result is more likely a function 
of the CTD protein structure and not due to the addition of phosphorylation. The 
remaining CTD heptads were effectively characterized by analysis of peptides created 
upon digestion with chymotrypsin, and heptads that lack any color coding distinctions 
were detected without phosphorylation. Single residues highlighted in green represent 
localized phosphorylation sites, while sets of residues highlighted in gold within the same 
heptad represent ambiguous phosphorylation where all putative sites for a single 
modification are highlighted. Based on the pattern of phosphorylation observed in the 
fruit fly CTD (Figure 5.4A), several rules governing phosphorylation by Erk2 are 
proposed. First, there is a clear preference for phosphorylation on Ser5 but only when 
followed directly by Pro in the six position. One of the many peptides exhibiting this 
trend is SPTpSPVYSPTVQ for which both positive (Figure 5.4B) and negative (Figure 
5.4C) UVPD mass spectra display extensive sequence coverage and confident phosphate 
localization. 
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Figure 5.4 Phosphorylations identified in Drosophila CTD following treatment with 
ERK2 (A), where sites highlighted in green and gold indicate localized 
and non-localized sites, respectively. Regions of the protein highlighted in 
grey were not detected in the Erk2 treated or control CTD samples. The 
phosphorylation map is the composite of sites identified using positive 
mode and negative mode LC UVPD-MS. Representative UVPD mass 
spectra from positive mode (B) and negative mode (C) analysis is shown 
for the chymotryptic peptide SPTpSPVYSPTVQF which covers heptads 
11 and 12. In both polarities, the doubly charged ions of m/z 745.3 and 
743.3  for positive and negative modes, respectively, were activated using 
2 pulses at 2 mJ. Ions that are detected following phosphate neutral loss 
are denoted by “-P”.  
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For heptads in which Ser5 is not conserved or is not followed by Pro, Ser2 may be 
phosphorylated provided that the Ser-Pro motif is satisfied. Additionally, if Thr takes the 
place of Ser in the two or five position beside a neighboring Pro, then phosphorylation 
may occur on Thr as demonstrated in heptads 8 and 41. The phosphorylation pattern does 
not appear to be influenced by the presence or absence of Thr4 and Ser7. The four and 
seven positions in the heptad both exhibit significant divergence from the consensus 
sequence and no correlation could be made between residue identity and the 
phosphorylation behavior of Erk2 within the corresponding heptad. Finally, the presence 
of an aromatic residue in the 1 position appeared to dictate phosphorylation, and no 
phosphorylation sites were detected in heptads that were not initiated by Tyr or Phe.  
 
5.4.3 Intact Mass Analysis of CTD5  
To further explore the significance of Tyr for kinase recognition, two position 1 
sequence variants were prepared from CTD5 and analyzed by western blot and top down 
mass spectrometry before and after reaction with Erk2. Results for the wild type CTD5 
are shown in Figure 5.5A, and phosphorylation is clearly observed following kinase 
treatment based on the appearance of characteristic mass shifts in both the western blot 
and mass spectrometry data. Up to two phosphoforms were detected, which are clearly 
identified by consecutive mass additions of ~80 Da in the deconvoluted mass spectrum. 
When each Tyr residue of CTD5 was mutated to Ala (Tyr to Ala), no mass shifts were 
observed between the control and Erk2-treated samples (Figure 5.5B), indicating a lack 
of kinase recognition in the absence of Tyr. In the second sequence variant Tyr was 
mutated to the more structurally similar Phe (Tyr to Phe), and in doing so an extensive 
array of mass-shifted bands appeared in the western blot after the reaction with Erk2 
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(Figure 5.5C). Although the quality of the corresponding mass spectrum of the intact 
protein(s) was marginal due to spectra complexity and no conclusions regarding the exact 
phosphorylation state could be made, a definite shift towards higher mass was observed 
for the Erk2-treated construct compared to the control. Clearly, Phe also plays a role in 
directing phosphorylation within the CTD, but more experiments are required to fully 
understand the evolutionary significance. 
 
 
Figure 5.5 Western blot and top down mass spectrometry results for CTD5 before 
and after treatment with Erk2. Three different constructs were analyzed 
including (A) wild type (WT) where Tyr was present at position one in 
each heptad , (B) Tyr to Ala where Tyr was mutated to Ala, and (C) Tyr to 
Phe where Tyr was mutated to Phe.  
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5.5 CONCLUSIONS 
Phosphate mapping in wild type yeast and fruit fly CTDs was successfully 
demonstrated using LC-MS and 193 nm UVPD. Alternative proteolysis was first 
established, using proteinase K for yeast CTD and chymotrypsin for fruit fly CTD, to 
generate suitably sized peptides for bottom-up analysis without the need for mutation 
within the CTD sequence. Erk2 and TFIIH were used to phosphorylate the yeast CTD, 
and both kinases modified the CTD at the same sites, Ser2 or Ser5, in the consensus 
heptad. Only one phosphorylation was observed per heptad which provides added 
evidence that phosphorylation in the CTD is non-saturating. In the fruit fly CTD, Erk2 
preferentially phosphorylated the same Ser2 and Ser5 marks, and again no instances of 
multiple phosphorylations within a single heptad were observed. The high degree of 
divergence in the fruit fly CTD was key for determining the influence of different amino 
acids for kinase recognition and phosphorylation. Notably, Tyr was needed in the 1 
position and Pro in the +1 position relative to Ser5 or Ser2 in order for phosphorylation to 
occur. Based on the detailed, residue resolved phosphorylation assignment afforded by 
UVPD-MS, this analytical strategy will likely be extended to future CTD studies.  
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Chapter 6 
Direct Identification of Tyrosine Sulfation by using Ultraviolet 
Photodissociation Mass Spectrometry2 
6.1 OVERVIEW 
Sulfation is a common post-translational modification of tyrosine residues in 
eukaryotes; however, detection using traditional liquid chromatography-mass 
spectrometry (LC-MS) methods is challenging based on poor ionization efficiency in the 
positive ion mode and facile neutral loss upon collisional activation. In the present study, 
193 nm ultraviolet photodissociation (UVPD) is applied to sulfopeptide anions to 
generate diagnostic sequence ions which do not undergo appreciable neutral loss of 
sulfate even using higher energy photoirradiation parameters. At the same time, neutral 
loss of sulfate is observed from the precursor and charge reduced precursor ions, a 
spectral feature that is useful for differentiating tyrosine sulfation from the nominally 
isobaric tyrosine phosphorylation. LC-MS detection limits for UVPD analysis in the 
negative mode were determined to be around 100 fmol for three sulfated peptides, 
caerulein, cionin, and leu-enkephalin. The LC-UVPD-MS method was applied for 
analysis of bovine fibrinogen, and its key sulfated peptide was confidently identified. 
 
 
                                                 
2 Robinson, M. R.; Moore, K. L.; Brodbelt, J. S. Direct Identification of Tyrosine Sulfation by using 
Ultraviolet Photodissociation Mass Spectrometry. Journal of the American Society for Mass Spectrometry. 
2014, 25, 1461–1471. 
KLM donated bovine fibrinogen and reviewed the manuscript prior to publication. JSB provided 
mentorship and reviewed the manuscript.  
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6.2 INTRODUCTION 
 The comprehensive identification of protein post-translational modifications 
(PTMs) continues to be an important goal of proteomics research in order to gain a better 
understanding of biological systems, especially in the context of how PTMs influence 
protein structure and function.
1
 Despite advancements in analytical technology, 
particularly in mass spectrometry (MS), PTM mapping remains a challenging task based 
on the diverse array of PTMs, their low abundance and lability, and their unique chemical 
properties, thus driving the development of new techniques to aid in characterization. O-
sulfation, first discovered in 1954 on bovine fibrinogen, is a primary modification of 
tyrosine with the potential for sulfate addition on up to an estimated 1% of all tyrosine 
residues of the total protein in an organism.
2–4
 Modification is limited to secretory and 
transmembrane proteins that have traversed the trans-Golgi network where two 
membrane-bound tyrosylprotein sulfotransferase enzymes (TPST1 and TPST2) catalyze 
the transfer of sulfate from adenosine 3’-phosphate 5’-phosphosulfate (PAPS) to the 
tyrosine phenol.
5–11
 The primary function of tyrosine sulfation is the modulation of 
protein-protein interactions in the extracellular region.
12–15
 More specifically, sulfation 
has been shown to play a profound role in numerous physiological and pathological 
processes, including hormonal regulation, hemostasis, inflammation and viral entry into 
host cells.
16,17
 However, other role(s) for tyrosine sulfation in protein function may exist. 
 Despite the biological significance of tyrosine sulfation, the sulfoproteome 
remains largely unexplored due to the analytical challenges associated with 
characterization using mass spectrometry. Several properties of sulfated peptides, 
including an often very acidic amino acid sequence and the labile sulfo-ester bond, 
present major handicaps for conventional positive mode MS analysis.
18,19
 Traditionally 
soft ionization techniques such as electrospray ionization (ESI) and matrix-assisted laser 
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desorption ionization (MALDI) result in partial or complete loss of the modification in 
the positive mode. Sulfopeptides that remain intact during ionization and the first stage of 
mass analysis undergo the predominant neutral loss of sulfate upon collisional induced 
dissociation (CID) and any product ions observed exhibit loss of modification.
20,21
 
Electron-based activation (ETD and ECD) also promote sulfate loss from product ions;
22
 
however, modification retention has been observed for highly basic sulfopeptides likely 
due to formation of a salt bridge between the acidic sulfo-moiety and arginine side 
chains.
23
 For more acidic peptides, gas-phase adduction using metal cations or 
guanidinium groups has been used to generate stabilizing salt bridges making sulfation 
site localization possible upon ECD.
24–26
 An alternative strategy for site localization in 
the positive mode takes advantage of the lability of sulfate in a subtractive-based 
identification method. In this method free tyrosine residues are acetylated prior to MS 
analysis so that any unmodified tyrosine residues detected must necessarily originate 
from sulfate loss in the mass spectrometer.
27,28
 While effective, these techniques rely on 
quantitative reaction of unmodified tyrosine and require more front-end sample 
processing. 
 Mass spectrometry analysis in the negative mode can provide a more direct approach 
for the detection of tyrosine sulfation based on the greater stability of sulfopeptides as 
gas-phase anions. The consistent detection of intact deprotonated sulfopeptides upon ESI 
is a significant advantage compared to the prevalent decomposition of protonated 
sulfopeptides during ESI; however, there remains a need for improved MS/MS 
characterization. The primary fragmentation pathway for CID of peptide anions is neutral 
loss of sulfate and while this information is useful for confirming the presence of 
sulfation, the lack of peptide backbone fragments is an impediment.
29–31
 Alternative 
activations methods including metastable atom-activated dissociation (MAD),
32
 which 
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uses a beam of high kinetic energy helium atoms for ion activation, and negative ion 
electron capture dissociation (niECD),
33
 have shown promise for tyrosine sulfation 
mapping.  Both techniques provide a high level of peptide sequence coverage without 
significant losses of the sulfate modifications. Specifically, MAD results in the formation 
of a diverse array of fragment ions, including a, b, c, x, y and z, and niECD favors 
formation of c and z fragment anions. Long activation times and/or extensive spectral 
averaging are required for optimal results for these two methods, limiting the 
compatibility of these methods with online LCMS methods.  
 Ultraviolet photodissociation (UVPD) at 193 nm is a fast activation method that has 
shown merits for peptide sequencing in both the positive and negative modes,
34–40
 
including analysis of peptides decorated with acidic PTMs.
38,41,42
 Upon UVPD activation, 
peptide anions dissociate into predominantly a and x type ions with other ion series 
including c, z, and y observed less frequently. The unique UVPD fragmentation behavior 
of peptide anions has been incorporated into a database search engine (MassMatrix) to 
effectively streamline data interpretation and make possible the analysis of more complex 
proteomic samples.
39
 Like electron based activation methods, UVPD is a fragmentation 
technique that does not promote neutral loss of post-translational modifications, one of 
the considerable disadvantages of CID. For example, in the UVPD analysis of 
deprotonated phosphorylated peptides, backbone cleavage remains the primary 
fragmentation pathway, thus allowing both the peptide sequence and the site of 
modification to be determined.
38,40
 Similar promising results have recently been obtained 
for a sulfated peptide derived from the Ax21 protein in the gram negative bacterium 
Xanthomonas oryzae pv. oryzae.
42
 This first successful identification of tyrosine sulfation 
using UVPD has prompted a more in-depth investigation of UVPD analysis of 
deprotonated sulfopeptides. In the present study, several figures of merit which are 
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relevant for sulfate mapping using UVPD are evaluated. These include: the overall 
peptide sequence coverage, changes in modification retention as a function of the laser 
settings, MS1 and MS2 sensitivity, and the compatibility with online LCMS analysis.  
 
6.3 EXPERIMENTAL 
6.3.1 Materials 
LCMS grade solvents and mobile phase additives were obtained from Fisher 
Scientific (Fairlawn, NJ). Other reagents were obtained from Sigma (St. Louis, Mo). 
Peptides GlpQDsYTGWMDF-NH2 (caerulein), RDsYTGWNleDF-NH2 (Thr28,Nle31-
cholecystokinin-33 sulfated), Ac-DpYVPML-NH2, RRLIEDAEpYAARG-NH2, Ac-
IpYGEF-NH2 (P60c-src Substrate II, phosphorylated), and TSTEPQpYQPGENL 
(Pp60c-src 521-553) were purchased from American Peptide Company (Sunnyvale, Ca); 
GDFEEIPEEsYLQ (hirudin fragment 54-65) and NsYsYGWMDF-NH2 (cionin) were 
purchased from Sigma; and sYGGFL  (leucine-enkephalin sulfated) was purchased from 
Phoenix Pharmaceuticals (Burlingame, Ca). Bovine fibrinogen was obtained from 
Calbiochem. The protein was reduced with 5 mM dithiothreitol (DTT) at 55 °C for 45 
minute. Iodoacetamide was then added to 15 mM, and alkylation proceeded for 45 
minutes in the dark. Additional DTT was added to quench the alkylation. Trypsin 
(Promega, Madison, WI) was added in a 1:20 enzyme: protein ratio, and digestion 
occurred overnight at 37 °C.  
 
6.3.2 MS, LC, and UVPD 
All experiments were conducted on a Thermo Fisher Scientific Orbitrap Elite 
mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) equipped with a 
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Coherent ExciStar XS excimer laser (Santa Clara, Ca) operated at 193 nm and 500 Hz as 
previously described.
43,44
 For direct infusion at 4 µL/min, 10 µM peptide solutions were 
prepared in water containing 25% methanol and either 0.1% formic acid, 0.1% 
ammonium hydroxide, or 5 mM ammonium acetate for analysis in the positive, negative, 
or both ion modes, respectively. For positive mode analysis, the ESI source was operated 
at 3.5 kV with a sheath gas flow of 4 units and auxiliary and sweep gases both zero. 
Orbitrap MS1 and MS2 automatic gain control (AGC) targets were 1,000,000 and 
50,000, respectively. For negative ion mode experiments, the heated ESI source (HESI) 
was used and the source parameters were tuned before each analysis in order to optimize 
the spray stability. Optimum HESI temperatures ranged from 40-60°C with source 
voltage 2.3-3 kV. A high sheath gas flow between 25-40 units improved desolvation, 
while lower amounts of auxiliary gas and sweep gas were needed (both were operated 
between 0-5 units). Orbitrap AGC targets were 1,000,000 for MS1 and 100,000 for MS2 
in negative mode. In both polarities CID and HCD were performed using 35% 
normalized collision energy with activation times of 10 and 0.1 ms, respectively. To 
optimize the UVPD conditions, a variety of energies including 1, 2, 3, 4, and 5 mJ were 
used with the number of laser pulses ranging from 1 to 6. Ultimately, 3 pulses at 2 mJ 
were selected for LCMS experiments. 
Liquid chromatography was performed on a Dionex Ultimate 3000 capillary LC 
operated at a flow rate of 4 µL/min. Mobile phase A was 5 mM ammonium acetate in 
water, and mobile phase B was 5 mM ammonium acetate in 90% methanol, 10% water. 
Peptide solutions were prepared in 100% mobile phase A for separation on a 3 x 150 mm 
Agilent Zorbax Extend-C18 column with 3.5 µm particle size (Santa Clara, CA). 
Separations of an equimolar mixture of caerulein, cionin, and leu-enkephalin were 
accomplished using a linear gradient that increased from 25% B to 60% B over 15 
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minutes. Doubly deprotonated caerulein (m/z 674.7162) and cionin (m/z 625.6651) and 
singly deprotonated leu-enkephalin (m/z 634.2178) were targeted for negative UVPD 
using a precursor mass list with associated 10 ppm m/z tolerance. Dynamic exclusion was 
disabled and MS1 (400-2000 m/z) and MS2 scans, both collected in the Orbitrap at 
resolution 15000, were alternated over the course of the LCMS run.  
For negative UVPD analysis of tryptic bovine fibrinogen, about 5 µg (≈14.7 
pmol) of protein digest was injected, and the percent B was increased linearly from 2% to 
35% over 45 minutes. A top ten data dependent scan program was used in which the first 
scan was a negative full FTMS survey scan over m/z 400-2000 at resolution 120,000 
followed by 10 UVPD events on the ten most abundant ions from scan event 1. Dynamic 
exclusion was enabled for 25 seconds with a single repeat count. For UVPD at 15000 
resolution, the isolation width was set to 3 Da, the HCD normalized collision energy was 
1% and the activation time was 6 ms in order to generate 3 laser pulses. After the initial 
analysis of fibrinogen, an additional segment from time 16.85-18.40 min was included to 
continually target a sulfated peptide of interest, GlpFPTDsYDEGQDDRPK 
(fibrinopeptide B), for UVPD. During this segment the m/z of interest, 935.35160, was 
isolated using an increased width of 6 Da and dissociated using 3 laser pulses each at 2 
mJ. 
 
6.3.3 Database Search 
Results from LCMS analysis of fibrinogen were interpreted using the MassMatrix 
database search algorithm 
45–48
. The experimental data was searched against the 
fibrinogen bovine FASTA and a reversed decoy database. Trypsin (no P rule) was 
specified for digestion while a maximum of 3 missed cleavages. The minimum peptide 
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length was 5 amino acids while the maximum length was 75 amino acids. The peptide 
mass tolerance was 20 ppm and the fragment mass tolerance was ±0.02 Da. MassMatrix 
uses three independent statistical scores including, pp, pp2, and pptag, to evaluate quality 
of peptide-spectrum matches, and the minimum output for each score was defined as 5.0, 
5.0, and 1.3 respectively.  Iodoacetamide derivatization of cysteine was a fixed 
modification, while sulfated tyrosine and pyroglutamate from glutamate were variable 
modifications. 
 
6.4 RESULTS AND DISCUSSION 
6.4.1 UVPD, CID, and HCD of Sulfopeptides   
Four singly sulfated peptides including caerulein (GlpQDsYTGWMDF-NH2), 
cholecystokinin (RDsYTGWLDF-NH2), hirudin (GDFEEIPEEsYLQ), and leu-
enkephalin (sYGGFL), and one doubly sulfated peptide, cionin (NsYsYGWMDF-NH2) 
were analyzed in both positive and negative modes and characterized using CID, HCD 
and UVPD. The spectral quality of MS survey scans in the positive mode was generally 
poor, even for cholecystokinin, the most basic of the five peptides analyzed and thus the 
most amenable to positive mode ionization. Figure 6.1A-B show full MS results for 
cholecystokinin electrosprayed in both acidic (0.1% formic acid containing) and neutral 
(5 mM ammonium acetate containing) solutions.  
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Figure 6.1 Positive mode ESI of 10 µM sulfated cholecystokinin, RDsYTGWNleDF-
NH2 in 25% methanol with the following solvent additives: 0.1% formic 
acid (A), 5mM ammonium acetate (B). Each spectrum is the average of 20 
FTMS scans. Cholecystokinin ions, M+H and M+2H, are annotated in 
green while various salt adducts of these ions are annotated in blue. Ions 
that exhibit neutral loss of SO3 are annotated in red.  
 
Under both conditions, singly protonated cholecystokinin was the most abundant charge 
state. A doubly protonated ion was also observed but in low abundance relative to an 
extensive array of sodium and potassium adducts. Further, spontaneous loss of SO3 was 
observed during ESI for all charge states, with neutral loss ions appearing about 40% 
abundant relative to 2+ sulfated precursor ions and about 3% abundant relative to 1+ 
sulfated precursor ions.  
Upon CID of 1+ cholecystokinin, loss of SO3 was the predominant product ion 
observed with b6 through b8 minus SO3 ions observed only after magnifying the spectrum 
50 times (Figure 6.2A). The higher energy deposition of HCD facilitated extensive 
backbone fragmentation of 1+ cholecystokinin (Figure 6.2B); however, all product ions 
lacked the sulfate modification. UVPD is an even higher energy process, with a single 
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193 nm photon having an energy of 6.4 eV. As a result, fragmentation can occur at each 
bond along the peptide backbone to generate a, b, c, x, y, and z ions. UVPD performed 
similarly to HCD (Figure 6.2C), producing an array of backbone fragments including a, 
b, and c ions, none of which retained the SO3 modification, allowing the amino acid 
sequence to be determined while the actual site of sulfation could not be pinpointed. 
  
 
 
Figure 6.2 MS/MS fragmentation behavior of 1+ cholecystokinin upon (A) CID, (B) 
HCD, each at 35% NCE, and (C) UVPD using three 2 mJ laser pulses 
Neutral loss of the entire sulfo-tyrosine side chain (CH2C6H4HSO4) was 
observed upon UVPD and annotated as “-sY”. In all spectra, neutral loss 
of SO3 or sY are annotated in red. Neutral loss of NH3 is indicated by an 
asterisk (*).
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Although doubly protonated cholecystokinin was also present in the MS1 spectrum, this 
charge state was more difficult to analyze based on instability during the ion isolation 
stage prior to MS/MS activation. Figure 6.3 shows a drastic decrease in ion abundance as 
well as a shift from the normal isotope distribution of 2+ cholecystokinin using an 
isolation width of 2 without applying normalized collision energy.  
 
 
 
Figure 6.3 FT isolation of 2+ sulfated cholecystokinin at various isolation widths  
 
Subsequent isolations at widths 4, 6, and 8 were performed while maintaining 0% 
normalized collision energy to determine the optimal isolation width. At isolation widths 
6 and 8, the isotope distribution returned to normal and the ion abundance was on scale 
with that observed in the full mass spectrum prior to isolation. Despite these 
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improvements at increased isolation widths, SO3 loss is observed following ion isolation 
further demonstrating the lability of the sulfoester bond. Activation using CID, HCD, and 
UVPD (Figure 6.4A-C) resulted in spectra similar to those obtained for 1+ 
cholecystokinin. Upon ETD (Figure 6.4D), three sulfated c ions, c6-c8, were generated 
accounting for 38% sequence coverage.  
 
 
 
Figure 6.4 MS/MS fragmentation behavior of 2+ cholecystokinin upon (A) CID, (B) 
HCD, each at 35% NCE, and (C) UVPD using three 2 mJ laser pulses, and 
(D) ETD using activation time 100 ms. Neutral losses of SO3 are 
annotated in red.  
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Under negative electrospray conditions, sulfopeptides ionized more readily and 
exhibited no loss of SO3. Figure 6.5 shows full MS results for cholecystokinin in pH 
neutral solution containing 5 mM ammonium acetate and basic solution containing 0.1% 
ammonium hydroxide. Electrospray using both solutions yielded an abundant 2- sulfated 
precursor ion with minimal salt adducts. 
 
  
 
Figure 6.5 Negative ESI of 10 µM sulfated cholecystokinin, RDsYTGWNleDF-NH2. 
in 25% methanol with the following solvent additives: 5 mM ammonium 
acetate (A), 0.1% ammonium hydroxide (B). Each spectrum is the average 
of 20 FTMS scans. Cholecystokinin M-2H ions are annotated in green. 
Sodium and potassium adducts to the precursor ion are annotated in blue.  
 
The CID spectrum for doubly deprotonated cholecystokinin (Figure 6.6A) was 
dominated by the neutral losses of H2O, CO2, and SO3, with water loss being the 
preferred fragmentation pathway. A few product ions were derived from cleavage of the 
peptide backbone, including a7 and c7. While these fragment ions retained the SO3 
modification, alone they did not provide sufficient information to sequence the peptide.  
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Figure 6.6 MS/MS for 2- cholecystokinin (RDsYTGWNleDF-NH2), m/z 624.24, 
using (A) CID at normalized collision energy (NCE) 35% and (B) UVPD 
using 3 pulses at 2 mJ. “-W” denotes side chain loss from tryptophan 
(C9H7N, 129 Da). Products ion that have lost SO3 are annotated in red 
font. UVPD data for the other model sulfopeptides is summarized in part 
(C) with sequence coverage listed for the most abundant charge state of 
each peptide. Product ions from which SO3 loss is observed are also listed. 
 
 
 
Figure 6.7 HCD fragmentation of doubly deprotonated cholecystokinin, 
RDsYTGWLDF-NH2(2-), m/z 624.24 using NCE 35% (top) and NCE 
55% (bottom). Sulfate loss ions are annotated in red. 
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HCD results for deprotonated cholecystokinin (Figure 6.7) mirrored those 
obtained using CID although more energy was required to obtain the same fragmentation 
results. In contrast, UVPD of deprotonated cholecystokinin (Figure 6.6B) provided 
nearly complete sequence coverage afforded by the broad series of a and x ions with only 
a single missed cleavage between the first and second amino acid residues (no a1 or x8 
ions). Also, significant SO3 loss was only observed for one product ion, a6, for which the 
analogous intact sulfated product ion was also observed and in greater abundance relative 
to the corresponding sulfate loss ion. Nearly full sequence coverage was likewise 
obtained upon UVPD of deprotonated caerulein, hirudin, and leu-enkephalin analyzed in 
3-, 4-, and 1- charge states, respectively. These results highlight the lack of charge state 
dependence on UVPD performance, thus making ion abundance the most important 
factor in choosing a particular charge state for dissociation. Some loss of SO3 from 
product ions was also observed for each peptide (listed in Figure 6.6C), but again the 
modified form of each ion was always detected. Interestingly, the UVPD results for di-
sulfated cionin were very different from the UVPD results for the singly sulfated 
peptides. While an extensive series of a ions was generated, each ion with the exception 
of a2 also underwent neutral loss of one out of the two SO3 modifications (Figure 6.8).  
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Figure 6.8 UVPD of doubly sulfated cionin in1- (A), 2- (B), and 3- (C) charge states. 
 
This result may be rationalized based on the side-by-side positioning of the sulfotyrosine 
residues in the peptide sequence and the ensuing instability caused by simultaneous 
deprotonation of both of the sulfate moieties, thus causing proton driven loss of one 
sulfate.
33,49
  
In addition to formation of diagnostic sequence ions, charge reduction of the 
deprotonated precursor ion via electron photodetachment 
50
 and concomitant loss of CO2 
and SO3 from these ions were also dominant fragmentation pathways upon UVPD. 
Several amino acid side chains also proved to be labile upon UVPD including the 
tryptophan side chains (C9H7N, 129 Da) and glutamic acid side chains (C3H4O2, 72 Da), 
which were observed as abundant neutral losses from the precursor and charge reduced 
radical ions. These side chain losses have also been reported previously following 
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negative electron transfer dissociation (NETD) and 266 nm UVPD of proton deficient 
radical cations.
51,52
 Combinations of CO2, SO3, and peptide side chain neutral losses were 
also commonly observed upon UVPD.  
 
6.4.2 Differentiating sY from pY 
After thorough analysis of UVPD fragmentation of deprotonated sulfated 
peptides, UVPD of deprotonated phospho-tyrosine containing peptides was examined to 
determine if the two modifications could be distinguished. Differentiating sulfotyrosine 
from phosphotyrosine is challenging based on the nearly isobaric nature of the 
modifications, with sulfation adding 79.956 Da and phosphorylation adding 79.966 Da. 
Other studies have approached the problem by exploiting differences in the neutral loss 
characteristics of phosphotyrosine- and sulfotyrosine-containing peptide anions upon 
CID.
30
 Based on the UVPD fragmentation behavior of four deprotonated 
phosphotyrosine-containing peptides including TSTEPQpYQPGENL, Ac-DpYVPML-
NH2, RRLIEDAEpYAARG, and Ac-IpYGEF-NH2, it appears that a similar method 
monitoring sulfo and phospho neutral losses can be used for UVPD. An example of the 
comparative UVPD spectra obtained for a deprotonated sulfopeptide and phosphopeptide 
is shown in Figure 6.9 (for sulfated leu-enkephalin and phosphorylated P60-src substrate 
IIAc-IpYGEF-NH2).   
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Figure 6.9 Negative UVPD mass spectra of singly deprotonated peptides: (A) 
sulfated leu-enkephalin  and (B) phosphorylated P60c-src substrate II Ac-
IpYGEF-NH2 using 3 laser pulses at 2 mJ. 
 
Table 6.1 displays the average relative percentage of loss of SO3 and PO3 from all the 
singly sulfated and phosphorylated peptides in the 1-, 2-, and 3- charge states (doubly 
sulfated cionin is excluded). For all phosphopeptides in all charge states, the percentage 
neutral loss was below 1%. The sulfopeptides, in contrast, showed a much greater extent 
of neutral loss with 23%, 27%, and 66% loss from 1-, 2-, and 3- precursor and charge-
reduced ions.  
 
                           
 
Table 6.1 Average percentage of the neutral loss product observed from the selected 
precursor and charge reduced precursor ions. Cionin is excluded from the 
sulfated peptide averages.  
 
For doubly and triply deprotonated precursor ions, the greatest neutral loss of the 
modification was observed from the 1- charge reduced ion derived from one electron 
photodetachment from 2- precursors and from two electron photodetachment products 
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detected in the UVPD mass spectra for deprotonated sulfotyrosine and phosphotyrosine 
peptides, corresponding to SO3
- 
and PO3
-
 ions, respectively. A one Dalton difference is 
easily distinguished using current mass spectrometry instrumentation; however, for 
detection in an Orbitrap mass analyzer (which UVPD necessitates since it is undertaken 
in the HCD cell of the instrument) the m/z of the precursor ion must be low enough such 
that the reporter ions fall within 1/20 of the precursor m/z. The UVPD spectra of 
deprotonated peptides sYGGFL (leu-enkephalin) and Ac-IpYGEF-NH2 in Figure 6.9 
showcase both the detection of low mass reporter ions and the significant difference in 
the degree of SO3 and PO3 neutral loss from the precursor ion, thus allowing 
phosphorylation and sulfation to be readily differentiated.  
 
6.4.3 Laser Parameter Optimization 
Photodissociation offers a high degree of tunability in terms of the laser energy 
and the number of pulses applied for MS/MS activation, enabling the selection of 
different UVPD parameters to suit particular applications. For sulfopeptide analysis, the 
optimal UVPD settings should maximize the abundance of sequence ions while 
minimizing the confounding neutral loss of SO3 from these ions. Also, the neutral loss of 
SO3 from the precursor ion and the charge-reduced precursor ion would ideally be 
prominent, as these ions provide further evidence for the presence of sulfation on the 
peptide and help to differentiate sulfotyrosine from phosphotyrosine. To establish the 
laser conditions that best meet these criteria, sulfopeptide analysis was undertaken using 
a matrix of 30 different laser parameters derived from combinations of 1, 2, 3, 4, 5, or 6 
pulses at energies of 1, 2, 3, 4, or 5 mJ.  
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Figure 6.10 Charge state distribution of sulfopeptides caerulein, cholecystokinin, 
cionin, hirudin, and leu-enkephalin in (A) basic (0.1% ammonium 
hydroxide) and (B) neutral (5mM ammonium acetate) solutions.  
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Various precursor charge states were accessed using ammonium hydroxide containing 
solutions (Figure 6.10A) including 1-, 2-, 3- for caerulein and hirudin and 1-, 2- for 
cholecystokinin and leu-enkephalin were analyzed in order to assess the impact of charge 
state on UVPD fragmentation. Hirudin, the most acidic peptide, was also observed in 4- 
and 5- charge states; however, UVPD data from these precursors was not included for the 
laser parameter optimization because of the lack of supporting data from other peptides 
that produce ions in charge states beyond 3-. Additionally, when peptides were analyzed 
in 5 mM ammonium acetate buffers which are more analogous to those used for LC-MS, 
charge states did not exceed 3- (Figure 6.10B). 
For each peptide, laser settings were evaluated based on the abundance of the 
neutral loss of sulfate from the precursor and/or charge-reduced precursor as well as the 
abundance of three singly deprotonated a or x products, all containing tyrosine to allow 
both sulfated and nonsulfated forms of each ion to be monitored. Specifically these were 
a4, a7, a8 (m/z 568.13, 912.28, 1043.32) from caerulein; a3, a6, a7 (m/z 485.15, 829.29, 
942.38) from cholecystokinin; a8, a9, a10 (m/z 1124.41, 1253.45, 1259.44) from hirudin; 
and a2, a3, a4 (m/z 271.04, 328.06, 475.13) from leu-enkephalin. To determine which 
laser conditions promoted the most efficient generation of informative sequence ions, the 
abundance of sulfated product ions were summed and charted as a function of laser 
conditions. Absolute abundances were then normalized to 100% for each peptide prior to 
averaging the values for all peptides of the same precursor charge state in order to avoid 
biasing the results towards the most abundant product ions arising from a single peptide. 
Figure 6.11A shows the results for 1-, 2-, and 3- peptides as heat maps in which the color 
red represents the greatest abundance of product ions and blue represents the lowest 
abundance of product ions.  
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Figure 6.11 Optimization of abundances of a/x ions and minimization of sulfate loss:  
For each peptide the abundances of three singly charged Y-containing a/x 
product ions were monitored in both their sulfated and non-sulfated forms. 
Specifically these were a4, a7, a8 from caerulein; a3, a6, a7 from 
cholecystokinin; x8, x9, a10 from hirudin; and a2, a3, a4 from leu-
enkephalin. (A) The summed abundances of sulfated product ions 
(normalized to 100%) is charted as a function of both laser energy (1-5 
mJ) and number of pulses (1-6). (B) Percent sulfate retention is 
determined for each set of laser conditions based on the total abundance of 
the sulfated products ions divided by the total abundance of both sulfated 
and non-sulfated (neutral loss) product ions. Heat maps for 1- and 2- 
precursor ions (left and middle, respectively) contain data from all four 
peptides, whereas heat maps for 3- precursor ions (right) contain data only 
from hirudin and caerulein. The deepest red shade indicates the most 
optimum outcome.  
 
While there is no single combination of laser energy and pulse number that 
outperformed all others, there is a clear trend of greater a/x ion abundance at lower 
energies and fewer laser pulses. This trend was consistent for 1-, 2-, and 3- precursor 
ions. These results align well with previous UVPD studies that favored the use of 
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minimal laser pulses and energy for fragmentation of deprotonated peptides.
38–40,42
 When 
the abundances of SO3 neutral loss ions from precursor and charge-reduced precursor 
ions were tabulated, normalized, and averaged across peptides (Figure 6.12), the results 
showed the same pattern that was observed for a/x sequence ions, with the SO3 neutral 
loss ions increasing in abundance as fewer laser pulses at lower energy were used for 
activation.  
   
 
 
Figure 6.12 Laser parameter optimization evaluated based on the degree of SO3 loss 
from the precursor or charge reduced precursor ions. The abundances of 
neutral loss ions were tracked across all laser conditions for each peptide 
and normalized to 100%, which is represented as the color red in the heat 
maps (0% is blue in color). Heat maps for 1- and 2- precursor ions (top 
and middle, respectively) contain data from all four peptides, whereas heat 
maps for 3- precursor ions (bottom) contain data only from hirudin and 
caerulein. The deepest red shade indicates the most optimum outcome.  
 
While the neutral loss of SO3 from precursor and charge-reduced precursor ions is a 
useful marker for peptide sulfation, loss of SO3 from product ions is an undesirable 
outcome of UVPD that can prevent localization of the sulfation sites. Thus, in addition to 
monitoring the sulfated product ion abundance, it is also critical to note the abundances 
of non-sulfated product ions so that laser conditions which promote this neutral loss can 
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be identified and avoided. Changes in sulfate retention are presented as percentages based 
on the abundance of the three sulfated a/x ions chosen for each peptide (listed above) and 
the abundance of the same a/x ions found 79 Da lower in mass after sulfate neutral loss 
using the following equation:  
 
               
                       
                                             
       
 
The percentage SO3 retention for peptides of the same charge state is averaged and 
displayed as heat maps in Figure 6.11B, with red representing 100% sulfate retention and 
blue 0%.  Interestingly, the decrease in the abundance of sulfated products observed at 
high energy using many pulses does not correspond with a significant increase in the 
abundance of non-sulfated, neutral loss ions. Instead the percentage of SO3 retention 
remains relatively constant across all laser conditions and only under the most energetic 
dissociation conditions (4-5 mJ, 5-6 pulse) does the extent of SO3 loss greatly increase, 
showing that UVPD is a robust method for sulfation mapping. Based on these analyses, 
the optimum UVPD parameters were 2-3 laser pulses at 2-3 mJ. 
 
6.4.4 MS1 and MS2 Limit of Detection 
Another important performance metric to consider for negative UVPD analysis of 
sulfopeptides is the absolute limit of detection because of the generally low abundance of 
modified peptides in biological samples. Detection limits are especially pertinent for 
negative mode LC-MS workflows because of the lower flux of precursor ions generated 
compared to using the positive ESI mode.
53–56
 Several LC mobile phase additives have 
been reported to improve ESI efficiency in the negative mode including acetic acid (pH 
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4) and ammonium hydroxide (pH 11);
57,58
 however, prolonged exposure to acidic 
solutions may result in hydrolysis of sulfate and thus should be avoided in favor of higher 
pH alternatives.
59
 At the same time, high pH solutions were damaging to the LC system 
and ultimately abandoned in favor of more robust separations at neutral pH using 5 mM 
ammonium acetate-containing mobile phases. Additionally methanol was used instead of 
acetonitrile as the organic mobile phase constituent to further boost the ESI efficiency.
57
  
 For the LOD determination, seven solutions containing 100, 250, 500, 750, 1000, 
1250, and 1500 femtomoles each of caerulein, cionin, and leu-enkephalin were analyzed 
by LCMS. A precursor mass list was used to target each peptide in its most abundant 
charge state (1- for leu-enkephalin and 2- for caerulein and cionin), and MS1 and MS2 
scans were alternated to ensure an even distribution of MS survey spectra and UVPD 
mass spectra across each eluting peak. MS extracted ion chromatograms (XIC) were 
generated for each peptide, and peak areas were plotted against the femtomole amount 
injected to create a linear calibration curve (Figure 6.13A-B). Each data point on the 
calibration curve has an associated error bar showing the standard deviation in the peak 
area for four replicate runs, with high reproducibility observed for measurements made at 
500 femtomoles and greater (≤3%RSD) and slightly lower reproducibility (≤20%RSD) at 
the most dilute concentrations. Assuming the limit of detection was equal to three times 
the standard deviation of the peak area, divided by the slope of the calibration curve, then 
the resulting MS1 LODs for caerulein, cionin, and leu-enkephalin were determined to be 
113 fmol, 182 fmol, and 96 fmol, respectively.  
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Figure 6.13 MS1 LOD for leu-enkephalin (1-), caerulein (2-), and cionin (2-) A) XIC 
for injections of 1500, 1250, 1000, 750, 500, and 250 fmol of peptide. B) 
The area under the curve was plotted as a function of femtomoles of 
peptide injected to generate a calibration curve for each peptide. C) MS1 
LOD was determined for each peptide using the calibration curve slope 
and the standard deviation of the average peak area. 
 
To evaluate the MS2 LODs, XICs were generated based on the sum of the three 
most abundant a-type product ions for each peptide including: a4, a7, a8 for caerulein; a2, 
a3, a4 for leu-enkephalin; and a2, a3-SO3, a5-SO3 for cionin. XICs and calibration curves 
for each peptide are displayed in Figure 6.14A-B. When the calibration curve was used 
to calculate MS2 LOD, the detection limits for each peptide were lower than those 
obtained for MS1, a result which is logically unsound because an ion cannot be selected 
for MS2 activation if it is not first detected by MS1.  
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Figure 6.14 MS2 LOD determined for leu-enkephalin (1-), caerulein (2-), and cionin 
(2-) using three 2 mJ pulses for photodissociation. (A) XIC representing 
the summed abundance of three product ions from each peptide were 
generated for each dilution and overlaid. (B) The area under the curve was 
plotted as a function of femtomoles of peptide injected to generate a 
calibration curve for each peptide. (C) Precursor ion peak area (MS1) was 
divided by product ion abundance (MS2) and plotted against the number 
of femtomoles injected.  
 
Following this result, a more empirical measure of MS2 LOD was employed 
based on the characteristic decrease in product ion abundance relative to precursor ion 
abundance upon UVPD. This was systematically accomplished using the MS1 peak areas 
from the XICs in Figure 6.13A and dividing each by the corresponding MS2 peak areas 
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from Figure 6.14A. Figure 6.14C shows the plot of MS1:MS2 ratio (factor decrease in 
abundance from MS1 to MS2) as a function of the number of femtomoles injected. In the 
range of 1500-250 fmol, the MS1:MS2 peak area ratio for each peptide is about 100 
which corresponds to a 2 order of magnitude difference in precursor and product ion 
abundance. For caerulein and cionin, an increase in the MS1:MS2 ratio is observed at 100 
femtomoles, indicating a larger than characteristic drop in the product ion abundance 
following UVPD and suggesting that the detection limit has been exceeded. Leu-
enkephalin did not exhibit the same increase and thus the limit of detection is expected to 
be lower than 100 fmol. Inspection of the MS/MS spectra at 250 and 100 femtomoles for 
each peptide (Supplemental figure 12) confirmed the LOD results of 250 fmol for 
caerulein and cionin and near 100 fmol for leu-enkephalin.  
Because molar detection limits will be specific for different peptides though, a 
more universal measure for the MS2 detection limit could be defined as the lowest 
precursor ion signal that can undergo UVPD and produce product ions which can be 
distinguished from background noise. Since, UVPD product ions are generally about two 
orders of magnitude lower in abundance compared to their precursor ion abundances, 
precursor ion abundances should be at least on the order of 10,000 units in order to detect 
the most abundant UVPD sequence ions and on the order of at least 100,000 units for the 
best quality UVPD data. Understanding the lower detection limits of UVPD can be useful 
for data dependent LCMS runs in which a threshold signal for MS2 can be defined, 
therefore making it possible to avoid activating ions that will not provide meaningful 
data. Also noteworthy is the abundance of the neutral loss of SO3 from precursor and 
charge reduced ions which is typically greater compared to the abundance of sequence 
ions. For 100 fmol injections of caerulein and cionin (Figure 6.15), the SO3 neutral loss 
ion was observed despite a lack of corresponding sequence ions. Detection of these 
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sulfate loss ions can provide evidence of peptide sulfation and enable specific ions to be 
targeted in subsequent analyses to obtain improved MS/MS results.   
The MS1 and MS2 detection limits reported for the LC-UVPD-MS strategy are 
suitable for the analysis of isolated sulfopeptides in which several micrograms of total 
digest are routinely injected for LC-MS analysis. For a complex biological sample, 
enrichment of sulfated peptides would be necessary based on their low stoichiometric 
abundances relative to unmodified proteins in the sample. Various enrichment methods 
have been reported including ones that utilize immobilized metal affinity 
chromatography, weak anion exchange, and anti-sulfotyrosine monoclonal antibodies and 
we are currently integrating a robust enrichment method with the sensitive UVPD-MS 
approach
60–62
. Additionally, the UVPD method is not designed for direct peptide 
quantification per se, although this could be achieved using peptide standards to generate 
a calibration curve or through the use of various label or label-free methods for relative 
quantification between samples. 
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Figure 6.15 UVPD for (A) leu-enkephalin, (B) caerulein, and (C) cionin in 100 and 
250 femtomole injections of the equimolar peptide mixture. In each set of 
spectra the three a ions used for MS2 LOD are highlighted in green, the 
precursor and charge reduced precursor and highlighted in blue, and the 
neutral loss of SO3 from the precursor is highlighted in red.   
 
6.4.5 Analysis of Bovine Fibrinogen 
Bovine fibrinogen is a heterohexameric protein containing two sets of three non-
identical alpha (615 residues, 67 kDa), beta (468 residues, 53 kDa), and gamma (444 
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residues, 50 kDa) chains. A single sulfo-modification is expected at tyrosine 6 on the beta 
chain. Trypsin-digested fibrinogen was analyzed by LCMS-UVPD in the negative mode 
using 3 pulses at 2 mJ based on the parameter optimization undertaken for the 
sulfopeptides. The base peak chromatogram is shown in red in Figure 6.16A with an XIC 
for the sulfopeptide of interest overlaid in green.  
 
 
 
Figure 6.16 (A) Base peak chromatogram of tryptic bovine fibrinogen (red) with 
extracted ion chromatogram for sulfopeptide GlpFPTDsYDEGQDDRPK 
(2-) from the fibrinogen beta chain (green) overlaid. B) Negative UVPD 
mass spectrum (three pulses at 2 mJ) of GlpFPTDsYDEGQDDRPK (2-) 
from the average of 18  MS/MS scans acquired over 12 seconds. 
 
The sequence coverage of the alpha, beta, and gamma chains obtained using 
UVPD was about 38%, 40%, and 19% respectively. The sulfated peptide, 
GlpFPTDsYDEGQDDRPK, was identified based on accurate precursor mass and the 
diagnostic 80 Da neutral loss ion; however, the quality of the MS/MS spectrum was poor 
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due to a low precursor ion signal (E4 range). To increase the abundance of the sulfated 
peptide, a greater amount of sample was injected and the isolation width was increased 
from 3 to 6. Additionally, the data dependent LCMS program was revised to include a 
targeted segment in which UVPD was performed on GlpFPTDsYDEGQDDRPK over the 
course of the peptide elution to allow MS/MS spectral averaging. The targeted run 
yielded an extensive series of a/x ions, including a6- a14 and x9 - x14, facilitated 
identification of the peptide. Because all of these product ions (with the exception of x9) 
contain the sulfation and there are cleavages at both the N-terminal and C-terminal sides 
of the sulfo-tyrosine, the site of sulfation was unambiguously assigned. 
 
6.5 CONCLUSION 
The present report demonstrates the suitability of 193 nm UVPD-MS for the 
analysis of sulfopeptide anions. For mono-sulfated peptides caerulein, cholecystokinin, 
leu-enkephalin, and hirudin, UVPD resulted in almost full sequence coverage across all 
charge states analyzed. Di-sulfated cionin also generated an extensive array of product 
ions; however, each ion only retained one of the two sulfate moieties. Systematic 
evaluation of laser parameters confirmed the stability of SO3 across various energies and 
numbers of pulses. This allowed the selection of laser parameters that maximized the 
abundance of sequence ions and SO3 loss ions which are useful for distinguishing 
between the nominally isobaric tyrosine sulfation and phosphorylation modifications. 
LC-UVPD-MS detection limits near 100 fmol were obtained for sulfated peptides, 
caerulein, cionin, and leu-enkephalin. The LC-UVPD-MS method was applied for 
analysis of bovine fibrinogen and the expected sulfated peptide, 
GlpFPTDsYDEGQDDRPK, was confidently identified. We anticipate that UVPD-LC-
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MS could be used for global sulfation analysis following enrichment of sulfated peptides 
from a biological sample.  
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Chapter 7 
Integrating Weak Anion Exchange and Ultraviolet Photodissociation 
Mass Spectrometry with Strategic Modulation of Peptide Basicity for 
the Enrichment of Sulfopeptides 
 
7.1 OVERVIEW 
Tyrosine sulfation is an important post-translational modification, but remains 
difficult to detect in biological samples because of the lack of effective enrichment 
methods. In the present study, weak anion exchange (WAX) is evaluated for the 
enrichment of model sulfopeptides that have been modified via carbamylation to convert 
all primary amines to less basic carbamates. Liquid chromatography tandem mass 
spectrometry (LC-MS/MS) in the negative ion mode was used to analyze the eluent from 
WAX, and ultraviolet photodissociation was applied for peptide sequencing. The 
decrease in basicity enhanced the binding of carbamylated sulfopeptides to WAX relative 
to a mixture of non-sulfated peptides from bovine serum albumin. The ultimate potential 
for sulfopeptide enrichment by two step wash and elute was evaluated, and three washes 
at 200 mM NH4Cl coupled with four elutions at 5 M NH4Cl was found to be most 
effective for isolating the sulfopeptides of interest. 
 
7.2 INTRODUCTION:  
Tyrosine sulfation is a post-translational modification (PTM) of secretory and 
transmembrane proteins that is responsible for modulating extracellular protein-protein 
interactions to initiate a variety of physiological and pathogenic responses.
1–3
 The 
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important role of tyrosine sulfation in the normal mammalian lifecycle has been 
showcased by studies of knockdown mice which suffer abnormalities in growth, 
development and fertility or premature death in the absence of one or both tyrosylprotein 
sulfotransferase enzymes (TPST-1 and TPST-2)  that are responsible for sulfation.
4–6
 A 
growing number of tyrosine-sulfated proteins have been identified, many of which are 
known to function as coagulation factors
7–10
, adhesion molecules
11
, or G-protein coupled 
receptors (GPCR).
12,13
 Because GPCRs and more specifically chemokine receptors play 
an important role in leukocyte recruitment and adhesion during the inflammatory 
response, these proteins represent potential therapeutic targets for the treatment of 
autoimmune disorders such as multiple sclerosis and rheumatoid arthreitis.
14
 Infectious 
diseases may also proceed through chemokine receptors as demonstrated by the  AIDs 
and malaria pathogens, HIV and p. vivax, which invade target cells through interaction 
with the sulfo-tyrosine containing portions of the chemokine receptors CCR5 and 
DARC.
15,16
 Clearly tyrosine sulfation is a critical modification of proteins, but additional 
effort is needed to determine the true scope of this PTM and further define its role in 
biological systems.  Attaining a broader understanding of sulfation has been impeded in 
part by inadequate methods to identify sulfoproteins.  
Liquid chromatography tandem mass spectrometry (LC-MS/MS) is the premier 
analytical technique for global PTM analysis based on the ability to accurately identify, 
localize, and quantify modifications in great detail without sacrificing throughput. Many 
PTMs such as phosphorylation,
17
 acetylation,
18
 and glycosylation,
19
 are routinely profiled 
in biological systems using LC-MS/MS, but to date no mass spectrometry-based global 
sulfation analysis has been reported due to a lack of appropriate methods for sulfopeptide 
characterization. The highly labile sulfo-ester bond and the acidic sequence motifs that 
often surround the site of sulfation present a mismatch for conventional methods that 
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employ positive mode ionization coupled with collision induced dissociation (CID).
20,21
  
Using these methods, sulfopeptides experience partial or complete modification loss 
during ionization and the first stage of mass analysis, and any remaining sulfated ions are 
effectively stripped of SO3 upon CID.
22,23
 Electron transfer and electron capture 
dissociation (ETD and ECD) also largely fail to maintain sulfations despite a proven 
record of preserving other labile PTMs, further underscoring the need for new LC-
MS/MS methodologies.
24
 One strategy for improved sulfopeptide analysis embraces the 
lability of sulfate in a subtractive-based identification scheme in which free tyrosine 
residues are acetylated prior to MS analysis so that any unmodified tyrosine residues 
detected must be derived from sulfate loss in the mass spectrometer.
25,26
 These techniques 
vastly improve sulfate site localization using conventional LC-MS/MS methods; 
however, incomplete reaction of unmodified tyrosine can lead to false positive 
sulfopeptide identifications. Direct identification of intact sulfo-tyrosine peptides is an 
attractive alternative but requires that the mass spectrometer be operated in negative ion 
mode to improve ionization and maximize modification stability. Because collision based 
activation methods are ineffective for sequencing peptide anions, a number of alternative 
activation techniques have been developed such as metastable atom-activated 
dissociation (MAD),
27
 negative ion electron capture dissociation (niECD),
28
 and 
ultraviolet photodissociation (UVPD).
29–31
 Each technique provides a high level of 
peptide sequence coverage, with diagnostic c/z backbone cleavage ions observed for 
NiECD and all ion series (a/x, b/y, c/z) observed for UVPD and MAD, without 
significant losses of the sulfate modifications. Both MAD and niECD have limited 
compatibility with online chromatography because long activation times and/or extensive 
spectral averaging is required to achieve optimal results. In contrast, UVPD is a fast 
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activation method that is routinely applied in LC-MS analysis, making it the best choice 
for larger scale applications that require front-end separations.
32–34
  
Although significant inroads have been made for improving the analysis of 
sulfopeptides using mass spectrometry, the potential for analysis on a global scale 
remains limited by the lack of effective methods for sulfopeptide enrichment from 
complex biological matrices.  Despite the chemical and structural similarities between 
sulfation and phosphorylation, the majority of enrichment techniques that have been 
developed for phosphopeptides are not directly applicable to sulfopeptides. These include 
strong cation exchange chromatography (SCX) in which peptides are separated by 
differences in net charge,
35–37
 immobilized metal affinity chromatography (IMAC) in 
which metal cations coordinate phosphate groups by affinity ,
38–40
 and titanium dioxide 
chromatography (TiO2) which proceeds through Lewis acid-base interactions.
41–43
 For 
optimal selectivity, each of the above methods must be carried out near pH 2 to ensure 
the protonation of carboxylic acids and thus reduce unwanted interactions between acidic 
unmodified peptides and the enrichment media. Since prolonged exposure to very acidic 
conditions has been shown to promote hydrolysis of sulfo-tyrosine, alternative 
enrichment strategies must be devised to specifically target sulfopeptides.
44
  
Ga(III)-IMAC enrichment was successfully applied at a more moderate pH of 3 
for the enrichment of sulfopeptides from a complex peptide mixture isolated from the 
skin secretions of the P. dacnicolor frog.
45
 Four sulfopeptides were structurally 
characterized for the first time, however several other non-sulfated peptides were co-
enriched indicating a lack of specificity. Greater specificity for sulfopeptide enrichment is 
possible using novel anti-sulfotyrosine antibodies developed using phage display 
technology.
46,47
 The PSG2 antibody in particular binds with high affinity and incredible 
specificity to sulfotyrosine resides, even discriminating against phosphotyrosine residues 
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and sulfated glycans.
47
 Binding occurs independently of sequence context, making the 
anti-sulfotyrosine antibodies widely applicable for the enrichment of sulfopeptides from 
complex biological samples. Despite these superior performance metrics, antibodies have 
not been broadly adopted for sulfopeptide enrichment likely due to their high cost and 
susceptibility to denaturation. Molecularly imprinted polymers (MIPs) are a class of 
synthetic polymer receptors that combine the specificity of antibodies with the high 
thermal, chemical, and stress tolerance of polymers to offer a robust, reproducible, and 
low cost alternative to biological receptors such as antibodies.
48–50
 By designing MIPs 
with arrangements of urea based hydrogen-bond donors to complement the desired sulfo-
tyrosine acceptors, specificity was achieved for tyrosine sulfated peptides.
50
 For a simple 
three peptide mixture, efficient separation of unmodified, phosphorylated, and sulfated 
peptides was demonstrated using MIPs, but this technique has yet to be evaluated on a 
larger scale. 
Weak anion exchange chromatography exploits the strong affinity of sulfate for 
anion exchange relative to other peptide anion moieties such as carboxylates without the 
need for acidic solutions. Upon removal of basic C-terminal lysine and arginine residues 
in tryptic peptides using carboxypeptidase B, sulfopeptide binding to WAX was further 
enhanced.
51
 WAX enrichment has also been demonstrated for carboxypeptidase B treated 
sulfated glycopeptides as well as heparin sulfate molecules.
52–54
 Chemical derivatization 
is another option for modulating peptide charge and the carbamylation reaction provides 
an efficient means for neutralizing positive charges on primary amines.
55–57
 In the present 
study, weak anion exchange chromatography is applied to sulfopeptides that have been 
modified to convert primary amines to less basic carbamates for improved enrichment 
prior to MS/MS using ultraviolet photodissociation. 
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7.3 EXPERIMENTAL 
7.3.1 Materials 
Sulfated peptides GlpQDsYTGWMDF-NH2 (caerulein) and RDsYTGWNleDF-
NH2 (Thr28,Nle31-cholecystokinin-33 sulfated) were purchased from American Peptide 
Company (Sunnyvale, CA); GDFEEIPEEsYLQ (hirudin fragment 54-65) and 
NsYsYGWMDF-NH2 (cionin) were purchased from Sigma; and sYGGFL  (leucine-
enkephalin sulfated) was purchased from Phoenix Pharmaceuticals (Burlingame, CA). 
LCMS grade solvents were obtained from EMD Millipore (Temecula, CA), and mobile 
phase additives and other reagents were also obtained from either Sigma or Fisher 
Scientific (Fairlawn, NJ).  
 
7.3.2 Protein digestion, carbamylation, and weak anion exchange 
Bovine serum albumin (BSA) was reduced with 5 mM dithiothreitol (DTT) at 55 
°C for 30 minutes followed by alkylation with 15 mM iodoacetamide (IAM) proceeding 
for 30 min at room temperature in the dark. An additional aliquot of 5 mM DTT was 
added to quench the alkylation reaction. MS grade trypsin (Thermo Fisher Scientific, 
Grand Island, NY)) was added in a 1:50 enzyme to protein ratio, and digestion occurred 
overnight at 37 °C. After proteolysis, model sulfopeptides were spiked into solution with 
the BSA peptides and the resulting mixture was immediately subject to either weak anion 
exchange chromatography (WAX) or carbamylation reaction. For carbamylation, urea 
was added directly to digest solutions to a concentration of ~8 M and the samples were 
incubated at 80 °C for 4 hours. Both unmodified and carbamylated peptide mixtures were 
diluted to 500 µL in 50 mM ammonium chloride in preparation for weak anion exchange.  
 165 
Weak anion exchange (WAX) columns for offline fractionation and enrichment of 
sulfopeptides were prepared as follows. A 50 mg/mL slurry of Diethylaminoethyl 
(DEAE)-Sephadex A-25 (Sigma, St. Louis, MO) resin was prepared in 50 mM 
ammonium acetate and allowed to swell overnight at room temperature. Fritted columns 
were loaded with 400 µL of the slurry accounting for 20 µg of DEAE-Sephadex, and the 
resin bed was secured by placement of a second frit on top. Flow through the WAX 
columns was driven by gravity. Columns were conditioned with several milliliters of 50 
mM ammonium chloride loading buffer. Samples were loaded in 50 mM ammonium 
chloride and the flow-through, unbound fraction was saved. For fractionation 500 µL 
aliquots of increasing ammonium chloride concentration (200 mM, 400 mM, 600 mM, 
800 mM, 1 M, 2 M, and 4 M) were passed through the WAX column in succession and 
collected separately. For the enrichment of sulfopeptides, washing and elution steps were 
evaluated using various volumes of different salt concentrations to determine the optimal 
conditions for maximum specificity. Prior to LC-MS analysis, all WAX fractions were 
desalted using C18 stage tips that were fabricated using Empore C18 extraction disks 
(3M, Minneapolis, MN) according to published protocols.
58
  
 
7.3.3 LC, MS, and UVPD 
Liquid chromatography was performed on a Dionex Ultimate 3000 capillary LC 
system operated at a flow rate of 4 µL/min. Mobile phase A was 5 mM ammonium 
acetate in water that was adjusted to pH ~8 using ammonium hydroxide. Mobile phase B 
was 5 mM ammonium acetate in 85% acetonitrile with an equal volume of ammonium 
hydroxide relative to mobile phase A. WAX fractions were reconstituted in 95% mobile 
phase A to match starting gradient conditions. Separations of were carried on a 3 x 150 
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mm Agilent Zorbax Extend-C18 column with 3.5 µm particle size (Santa Clara, CA) 
using a linear gradient in which the percentage of mobile phase B was increased from 5-
45% over 45 min.  
Mass spectrometry analysis was carried out using a Velos Pro dual linear ion trap 
mass spectrometer (Thermo Scientific, San Jose, CA) equipped for photodissociation at 
193 nm as previously described.
59
 All experiments were conducted in the negative ion 
mode using a spray voltage of 4 kV. For negative UVPD analysis of unmodified and 
carbamylated WAX fractions, a top eight data dependent scan program was used in 
which the first scan was a negative full MS survey scan over m/z 400-2000, followed by 
eight UVPD events on the eight most abundant ions from scan event 1. Dynamic 
exclusion was enabled for 10 seconds with a single repeat count. For UVPD, the CID 
normalized collision energy was set to zero, the activation q was decreased to 0.1, the 
isolation width was 3 Da, and the activation time was 4 ms (allowing 2 laser pulses per 
scan). AGC targets for MS1 and MS2 were 30000 ions and 10000 ions, respectively.  
 
7.4 RESULTS AND DISCUSSION 
7.4.1 Carbamylation of Sulfopeptides 
 
With the establishment of appropriate MS/MS tools for sulfopeptide 
characterization, the next step towards global sulfation analysis is the development of 
effective enrichment methodologies. Weak anion exchange (WAX) was targeted to meet this 
aim because it can be performed under conditions of neutral or basic pH to preserve sulfate 
modifications without compromising the overall selectivity for sulfopeptides. The selectivity 
of ion exchange is derived from various factors that modulate Coulombin interactions 
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including the number and location of charges on the molecule and the ion exchanger as well 
as the charge density. Ions with a higher charge and smaller solvated radius bind more 
strongly, and it has been shown that sulfate has the strongest affinity for WAX followed by 
chloride, phosphate, acetate, and hyrdoxide.
60
 This general trend of affinity is expected to shift 
in the context of peptides for which multiple charged moieties contribute to the overall 
binding characteristics in anion exchange. In sulfopeptides the presence of multiple negatively 
charged (deprotonated) aspartate and glutamate residues can further influence binding relative 
to nonsulfated peptides which typically do not exhibit the same acidic sequence motifs. At the 
same time, positively charged (protonated) lysine and arginine residues diminish the binding 
affinity through repulsive interactions with like positive charges on the anion exchanger.
61
 For 
the present study, in order to enhance the interaction between sulfopeptides and the WAX 
resin, carbamylation was used to convert the highly basic lysine residues and N-termini 
primary amines to less basic carbamates, thus effectively removing those ionizable sites from 
interaction with the WAX resin. The carbamylation reaction is an incredibly simple, efficient, 
and cost effective method for the derivatization of primary amines but commonly is 
performed at high temperatures over an extended period of time (80°C for 4 hrs) to proceed to 
completion.
55
 To ensure that these rather harsh reaction conditions would not promote 
hydrolysis of the labile sulfate modification, carbamylation was first applied to several model 
sulfopeptides including doubly sulfated cionin and singly sulfated cholecystokinin, Leu-
enkephalin, and hirudin. Each of these peptides contains one N-terminal primary amine that is 
expected to undergo carbamylation. LC-MS/MS in the negative ion mode using 193 nm 
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UVPD was used to confirm the integrity of the sulfopeptides following carbamylation and 
also evaluate the reaction efficiency (Figure 7.1A-D).  
 
                       
 
Figure 7.1 Carbamylation of sulfopeptides (A) hirudin, (B) leu-enkephalin , (C) 
cionin, and (D) cholecystokinin demonstrated in base peak LC-MS 
chromatograms and negative ESI spectra 
 
For each peptide, a single dominant peak was observed in the LC-MS chromatogram (Figure 
7.1, left panel) which was identified by mass spectrometry as the fully carbamylated peptide 
with retention of sulfation (Figure 7.1, right panel). Some evidence for desulfation was 
observed by monitoring the m/z values of the corresponding non-sulfated peptides, but these 
species were several orders of magnitude lower in abundance compared to the sulfated 
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carbamylation reaction products, as shown in Figure 7.2 showing the base peak MS1 
extracted ion chromatograms for sulfated and desulfated leu-enkephalin.  
 
                
 
Figure 7.2 Extracted ion chromatograms showing carbamylated leu-enkephalin with (A) 
retained sulfate and (B) following sulfate loss. 
 
A small amount of unreacted (i.e. non-carbamylated) peptide was detected for doubly 
sulfated cionin (Figure 7.1C), whereas all singly sulfated peptides (Figure 7.1A-B, D) 
were fully carbamylated. Incomplete carbamylation of cionin may be attributed to an 
increased probability of salt bridge formation between the positively charged peptide N-
terminus and one of the two available negatively charged sulfates, thus blocking the α-
amine and impeding carbamylation.
62
 Carbamylation did not have a profound effect on 
the ionization efficiency of the sulfopeptides in the negative mode; however, the charge 
state distribution was shifted towards more negatively charged ions following reaction as 
shown in Figure 7.3. The UVPD fragmentation was not adversely affected by 
carbamylation because a mobile proton, as typically required for fragmentation of 
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protonated peptides upon collisional activation, is not required for dissociation of 
peptides energized by absorption of UV photons. 
              
 
 
 
Figure 7.3  Negative ESI mass spectra for sulfopeptides before and after 
carbamylation 
 
Figure 7.3 shows the UVPD spectra for doubly deprotonated hirudin acquired before and 
after carbamylation. The same fragmentation pattern, composed of mostly a and x type 
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ions, was observed for both peptides with the exception of product ions containing the 
site of carbamylation which were mass shifted by 43 Da in the spectrum of the modified 
peptide.  
 
 
               
 
 
Figure 7.4 UVPD using 2 pulses at 2 mJ for (A) non-carbamylated and (B) 
carbamylated cholecystokinin in the 2- charge state at m/z 772.8 and 794.3, 
respectively.  The carbamylation site is designated as +43 at the N-terminus 
of the peptide sequence.  
 
7.4.2 Weak Anion Exchanges of Sulfopeptides 
 
To determine the impact of carbamylation on enhancing sulfopeptide binding in 
weak anion exchange, a mixture of non-carbamylated sulfopeptides was first fractionated by 
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WAX to provide a baseline for subsequent comparisons. A mixture of cionin, cholecystokinin, 
Leu-enkephalin, hirudin, and caerulein (a mono-sulfated peptide that does not contain any 
primary amines) was loaded onto a WAX column and eluted by sequential salt steps of 
increasing ammonium acetate concentration ranging from 50 mM up to 4 M. LC-MS/MS was 
used to track the sulfopeptides in the resulting WAX fractions, and elution profiles were 
constructed based on chromatographic peak areas for each peptide detected in each fraction. 
No sulfopeptides were collected in the unbound fraction and each mono-sulfated peptide was 
observed in multiple subsequent WAX fractions to yield a Gaussian-like elution profile 
(Figure 7.5).  
 
 
Figure 7.5 WAX elution profile of sulfopeptides using ammonium acetate eluents 
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the WAX resin. To improve the recovery of cionin and preemptively account for peptides in 
even higher sulfation states which may be present in biological samples, ammonium chloride 
(NH4Cl) was used in place of ammonium acetate to introduce a stronger competing anion (Cl
-
). Doing so greatly improved the recovery of cionin without the need to increase the salt 
concentration beyond 4 M, and thus NH4Cl was used for all subsequent experiments.  
 With general conditions established for sulfopeptide elution from WAX, the five 
sulfated peptides were spiked into a mixture of tryptic peptides from BSA and fractionated by 
WAX both before and after carbamylation to evaluate (1) the shift in sulfopeptide retention 
after the neutralization of primary amines, and (2) the potential for sulfopeptide separation 
from a complex matrix of unmodified peptides. Including the 0.05 M NH4Cl unbound 
fractions, seven additional WAX fractions were collected for each run by elution with 0.2 M, 
0.4 M, 0.6 M, 0.8 M, 1 M, 2 M, and 4 M salt solutions. LC-MS analysis of the WAX fractions 
collected prior to carbamylation revealed differences in the elution profiles for each 
sulfopeptide that appeared to be linked to variations in the number of sulfate modifications as 
well as the number of basic sites (Figure 7.6A-E, blue bars). The elution order, in which Leu-
enkephalin elutes first (Figure 7.6A) followed by cholecystokinin (Figure 7.6B), hirudin 
(Figure 7.6C), caerulein (Figure 7.6E), and lastly cionin (Figure 7.6D), was governed by a 
combination of attractive and repulsive interactions occurring between the WAX anion 
exchanger and the acidic and basic sites of the peptides, respectively, with more influence 
attributed to the overall peptide basicity.  
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Figure 7.6 Sulfopeptide elution profiles from WAX using ammonium chloride 
eluents  before and after carbamylation 
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a greater number of acidic residues lead to longer WAX retention. As expected, sulfo-tyrosine 
residues were more effective than glutamate or aspartate for strengthening the overall peptide 
binding to WAX, and the retention of doubly sulfated cionin exceeded the retention of singly 
sulfated hirudin despite hirudin having seven acidic sites compared to only four in cionin.  
When the carbamylated sulfopeptide mixture was fractionated by WAX, the desired 
shift to greater retention was observed for all peptides (Figure 7.6A-D, red bars). Doubly 
sulfated cionin remained the most highly retained peptide, and the elution order of the mono-
sulfated peptides was dictated by the number of acidic sites. Carbamylated hirudin replaced 
caerulein as the most strongly retained mono-sulfated peptide due to the greater number of 
aspartic and glutamic acid residues compared to caerulein. Cholecystokinin was the only 
peptide that retained basic sites after carbamylation, and thus was expected to take the place of 
Leu-enkephalin as the first peptide to elute. While the switch in elution order was not 
pronounced, the salt concentrations required for the elution of cholecystokinin and leu-
enkephalin were essentially the same within the precision of the measurement, so the general 
trend of decreasing sulfopeptide retention as a function of basicity seems to hold true. The 
order of elution otherwise remained unchanged between underivatized and carbamylated 
sulfopeptides.. To further quantify the increase in WAX retention following carbamylation, 
the average salt concentration required for peptide elution before and after derivatization was 
determined by weighted average based on peptide peak areas across the WAX fractions 
(Table 7.1). 
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Table 7.1 Average NH4Cl concentration for sulfopeptides elution from WAX 
 
Comparing the average NH4Cl concentrations required for peptide elution revealed absolute 
molar increases of 0.44 M, 0.27 M, 0.16 M, and 0.70 M after carbamylation for Leu-
enkephalin, cholecystokinin, hirudin, and cionin, respectively. In terms of the percent increase 
in salt concentration required for elution of the carbamylated peptides relative to elution of the 
underivatized peptides, the greatest shifts in WAX retention were observed for Leu-
enkephalin, at 173%, and cholecystokinin, at 62%. Leu-enkephalin is the smallest of all the 
sulfopeptides with just five amino acids in its sequence, and thus single residue changes have 
a greater impact on the overall peptide retention characteristics on WAX. Carbamylation of 
Leu-enkephalin resulted in a complete loss of basicity which likely explains the very large 
shift in retention relative to underivatized Leu-enkephalin. All basic sites on hirudin and 
cionin were similarly converted to non-ionizable sites upon carbamylation, but these peptides 
experienced much lower percent increases in NH4Cl concentration required for elution, likely 
owing to the significant acidity of these peptides which translated to fairly strong retention on 
WAX prior to carbamylation.  
Average NH4Cl concentration for elution (M)
Peptide Non-carbamylated Carbamylated Delta
Leu-enkephalin 0.26 (±0.03) 0.71 (±0.05) 0.44
Cholecystokinin 0.45 (±0.02) 0.73 (±0.05) 0.27
Hirudin 0.78 (±0.01) 0.94 (±0.04) 0.16
Cionin 2.14 (±0.13) 2.84 (±0.08) 0.70
 177 
The efficiency of weak anion exchange for separating sulfopeptides from non-sulfated 
BSA peptides was next evaluated before and after carbamylation reaction. To visualize the 
separation, extracted ion chromatograms (XIC) showing the sulfopeptides of interest (red) 
were overlaid on the base peak MS1 chromatogram (blue) for each WAX fraction, as shown 
in Figure 7.7. For the non-carbamylated sample (Figure 7.7, left panel), the bulk of the BSA 
peptides eluted in the 0.05 M unbound and 0.2 M NH4Cl fractions. Nearly all of the Leu-
enkephalin loaded onto the WAX column co-eluted with the unmodified peptides in the 0.2 M 
fraction, and a significant amount of cholecystokinin also eluted in this fraction. Hirudin, 
caerulein, and cionin were effectively isolated in later fractions. After carbamylation, all 
peptides, including the non-sulfated BSA peptides which also underwent carbamylation at 
lysine residues and N-termini, were retained more strongly on the WAX column (Figure 7.7, 
right panel). Importantly, Leu-enkephalin and cholecystokinin which were both poorly 
separated from the unmodified peptides prior to carbamylation were much more effectively 
separated after reaction.  
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Figure 7.7 Base peak full MS chromatograms (blue) showing WAX fractions collected 
for a mixture of tryptic BSA and model sulfopeptides before (left) and after 
(right) carbamylation. XICs for sulfopeptides (red) are overlaid in each 
chromatogram. 
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7.4.3 Washing and Elution Optimization 
 
To streamline the carbamylation/WAX strategy for the enrichment of sulfopeptides, 
washing and elution conditions were optimized. Ideally, washes would be performed using a 
single solution of NH4Cl at a concentration which allows retention of carbamylated 
sulfopeptides while removing carbamylated non-sulfated peptides from the WAX column. For 
elution, conditions must be established that maximize sulfopeptide recovery. Initially, three 
500 µL washes using 400 mM NH4Cl and three 500 µL elutions using 4 M NH4Cl were tested 
to separate sulfated and BSA peptides. Each wash and elution solution was collected 
separately and analyzed by LC-MS to evaluate each phase of washing and elution, with the 
ultimate goal of pooling all elution fractions together to maximize the signal in LC-MS. The 
chromatographic peak area of each sulfopeptide was tracked and then summed across all 
washes and all elutions to determine the percentage that was detected in the wash (blue bars) 
or elution (red bars) steps as shown in Figure 7.8A. Despite choosing a concentration of 
NH4Cl that was well below the average NH4Cl concentration required for the elution of each 
carbamylated sulfopeptide (Table 7.1), greater than 80% of cholecystokinin and Leu-
enkephalin and about 50% of caerulein was prematurely eluted from WAX in the washing 
steps. The elution was also found to be sub-optimal based on the significant percentage of 
cionin and hirudin that was detected in the final elution relative to the first and second elutions 
which suggested that more peptides remained on the WAX column (Figure 7.8B). Two 
additional sets of conditions were tested which decreased the concentration of NH4Cl used in 
the washes and increased the amount of NH4Cl used for elution. Figure 7.8C-D shows the 
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results obtained using three washes with 300 mM NH4Cl combined with four elutions using 5 
M NH4Cl. Figure 7.8E-F shows the results from three washes with 200 mM NH4Cl and four 
elutions using 4 M NH4Cl.  
 
 
 
 
Figure 7.8 Wash and elution optimization for sulfopeptide enrichment using WAX. 
E1, E2, E3, and E4 refer to sequential elutions, where E1 is the first 
elution step. 
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By washing with 200 mM NH4Cl, the best retention of carbamylated sulfopeptides was 
achieved while still removing the majority of the BSA background peptides. Four elutions 
using 5 M NH4Cl appeared to optimize the peptide recovery based on the low percentage of 
each peptide in the final elution relative to the total peptide recovered in all elutions. In 
comparison to the initial results from WAX fractionation, the increase in NH4Cl concentration 
required for the final elution was expected given the non-Gaussian elution profile of cionin in 
the WAX fractions in which the maximum peak area was detected in the final, 4 M NH4Cl 
fraction (Figure 7.6D). The lower than expected retention of sulfopeptides during the wash 
optimization is more difficult to rationalize. Perhaps when multiple washes are incorporated, 
the elution effect is additive which requires the use of lower overall salt concentration to 
retain the sulfopeptides of interest.    
7.5 CONCLUSION 
 
The enrichment of model sulfopeptides by weak anion exchange following 
carbamylation reaction was demonstrated. Carbamylation efficiently converted all primary 
amines to less basic carbamates without promoting loss of the labile sulfate moiety or altering 
the UVPD fragmentation efficiency. In WAX fractionation using NH4Cl as the eluent, 
sulfopeptide binding was enhanced following carbamylation. Carbamylated peptides eluted at 
an average concentration of NH4Cl ranging from 0.7 M for the weakest retained peptide, leu-
enkephalin, to 2.8 M for the most strongly retained and most highly sulfated peptide, cionin. 
Non-sulfated, carbamylated BSA peptides eluted in earlier WAX fractions, thus 
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demonstrating the potential of the WAX/carbamylation strategy for sulfopeptide enrichment. 
Multiple washes and elutions at static salt thresholds were evaluated for sulfopeptides 
enrichment from BSA in place of stepwise fractionation by increasing salt concentration. 
Sulfopeptides were optimally isolated using three washes at 200 mM NH4Cl together with 
four elutions at 5 M NH4Cl. These results provide a basis for sulfopeptide enrichment using 
carbamylation and WAX which may be applied for larger scale analysis of sulfo-tyrosine 
modifications in biological samples.  
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Chapter 8 
Conclusions 
Significant advances have been made in the field of proteomics, yet the analysis 
of post-translational modifications remains a challenging task. Hundreds of PTMs exist 
that are responsible for maintaining normal cellular health and function; thus effective 
PTM characterization is necessary to attain a comprehensive view of the proteome. 
Abnormalities in PTM expression have been linked to a number of diseases, including 
cancer and autoimmune disorders, which has spurred the development of methods for 
increasingly deeper PTM profiling to aid in the discovery of potentially useful 
biomarkers or therapeutic targets. The low abundance and often transient lifetime of 
PTMs in biological systems present a significant analytical challenge. Advancements in 
sample handling and enrichment methods have helped to mitigate these problems. In 
contrast to the myriad of PTM specific techniques used for protein processing prior to 
mass spectrometry analysis, tandem MS is still largely restricted to conventional collision 
induced dissociation methods. This one-size-fits-all approach to peptide sequencing is 
problematic for PTM analysis based on the labile chemistries of many important PTMs, 
including phosphorylation and sulfation. The research in this dissertation sought to 
address the need for alternative activation methods by developing ultraviolet 
photodissociation for the characterization of PTMs.  
In chapter 3, a de novo sequencing method was developed which biased 
fragmentation for the generation of N-terminal ions. This was accomplished by applying 
Lys-N proteolysis and imidazolinylation of the resulting N-terminal lysine ε-amine prior 
to LC-MS-UVPD. The resulting mass spectra were composed primarily of a, b, and c 
“golden triplet” ions while C-terminal ions were much sparser owing to the effective 
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capture of protons at the N-terminus. For cleavage at the same residue position, the mass 
shift between a, b, and c ions is static, and thus these ions can be easily distinguished and 
used for de novo sequencing.  
De novo sequencing methods offer significant flexibility for PTM discovery but 
lack the sensitivity of more focused analysis that is directed towards a single or small 
number of PTMs. Chapters 4-7 sought to develop UVPD-MS methods specifically for the 
analysis of two labile PTMs, phosphorylation and sulfation.     
 In chapter 4 UVPD was applied for the analysis of phosphopeptides, and its utility 
for the analysis of peptide anions as well as cations was explored. Negative mode 
provided superior characterization of highly phosphorylated peptides from alpha and beta 
casein and also exhibited the greatest phosphate retention on product ions, but the overall 
sensitivity was low. Positive mode UVPD provided much greater sensitivity compared to 
negative mode for peptides in lower phosphorylation states, and phosphate neutral loss 
was lessened but not entirely eliminated. For phosphoproteomic analysis of HeLa and 
HCC70 cell lysates in positive ion mode, more peptides and proteins were identified 
using HCD compared to UVPD, but phosphate was better retained on UVPD product 
ions, suggesting that UVPD can be applied to improve phospho-site localization.   
 Following the success of photodissociation for large scale phosphopeptide 
analysis is chapter 4, UVPD was next applied in chapter 5 to more specifically map 
phosphorylation sites within the C-terminal domain (CTD) of RNA polymerase II. 
Because phosphorylation extends along the entire length of the CTD, very high sequence 
coverage at the protein level from bottom-up LC-MS/MS is required for complete 
characterization of all phosphorylation sites. To this end, alternative proteolysis using 
proteinase K or chymotrypsin was used to effectively digest the unconventional CTD, 
which consists of a species specific number of repeats of the consensus amino acid 
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sequence YSPTSPS. UVPD analysis of the resulting CTD peptides provided ample 
peptide level sequence coverage to allow phosphate localization despite the presence of 
many phosphate accepting sites within each heptad. Phosphorylation on Ser2 and Ser5 
was favored in CTDs from two different species, yeast and fruit fly, and using two 
different kinases, TFIIH and ERK2. 
 UVPD was next evaluated for the analysis of tyrosine sulfation in chapter 6. 
Unlike phosphorylation, which may be characterized reasonably well using conventional 
methods such as CID and HCD, sulfation cannot be directly identified using these 
methods based on the extreme lability of the sulfo-ester. In fact, analysis in the negative 
ion mode is required to stabilize sulfate PTMs. For this reason, UVPD was a natural fit 
based on superior sequencing capabilities for peptide anions. Upon negative UVPD 
analysis, a rich array of sulfate retaining a and x type ions was produced which allowed 
peptide sequencing as well as sulfate localization. As further proof of concept, the 
negative mode LC-UVPD-MS strategy was successfully applied to identify the sulfated 
peptide of interest from bovine fibrinogen, a large 340 kDa heterohexamer plasma 
protein.  
 No mass spectrometry based global sulfation analysis has been reported primarily 
due to the lack of effective MS based characterization tools. Following the successful 
application of negative mode UVPD-MS for sulfopeptide analysis in chapter 6,  efforts 
were next aimed at extending the method for sulfopeptide characterization on a more 
global scale in chapter 7. To do this, an enrichment method was devised which used weak 
anion exchange chromatography (WAX) and strategic modulation of peptide basicity. 
Carbamylation was used to neutralize all primary amines to less basic carbamates in 
sulfopeptides without knocking off the labile sulfate modification. Doing so improved 
sulfopeptide retention on WAX by the removal of interfering positive charges. The shift 
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to longer retention was more significant for sulfopeptides compared to carbamylated non-
sulfated peptides which allowed their separation from a complex background of BSA.  
While the research presented in this dissertation showcases the utility of UVPD 
for PTM analysis, several avenues for continued development remain. Although UVPD 
provides richer fragmentation in both the positive and negative ion modes, the 
fragmentation efficiency is lower compared to CID and HCD. Thus sensitivity is a 
significant limitation, especially for the analysis of PTMs which are already present in 
low abundance in biological samples. This problem may be addressed in a number of 
different ways. The attachment of aromatic chromophores has been demonstrated for 
improving the UVPD efficiency in positive mode, and applying similar derivatization to 
peptides carrying PTMs might provide the needed boost in sensitivity.
1
 Alternatively, as 
UVPD becomes more widely adopted, new developments in instrument design will 
almost certainly improve UVPD performance for peptide sequencing.  
In negative ion mode, the sensitivity problem is further exacerbated by low 
ionization efficiencies especially during the high aqueous phase of gradient LC 
separations. While a variety of different mobile phase systems were tested over the 
course of this dissertation, other alternative mobile phase additives may prove more 
effective for improving ionization. Chemical modification is another option, and 
carbamylation has been used to neutralize peptide positive charges and improve the 
ionization of peptide anions.
2
 Aside from modifying the LC mobile phases or the analyte 
of interest, changes to the ionization source and other front end components of the mass 
spectrometer may be used to improve ionization efficiency.
3
 Improvements in sensitivity 
would be invaluable for improving global PTM analysis in the negative mode, and will 
be necessary in order to scale up the WAX sulfopeptide enrichment method described in 
chapter 7 to a biologically relevant sample. 
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Finally, although the research presented in this dissertation was directed for the 
analysis of phosphorylation and sulfation, it is conceivable that UVPD-MS may be 
applied for the analysis of other PTMs with the greatest advantage expected for those that 
are labile and thus poorly characterized using conventional methods. Examples of other 
labile PTMs include s-nitrosylation,
4
 arginine phosphorylation,
5
 and histidine 
phosphorylation,
6
 among others, which provides a rich landscape for the continued 
development of UVPD-MS.   
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